Search Result
Results for "
human monoclonal antibody
" in MedChemExpress (MCE) Product Catalog:
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P99246
-
-
-
- HY-P9938
-
|
|
CGRP Receptor
|
Others
|
|
Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene–related peptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine .
|
-
-
- HY-P99514
-
|
AGEN1884
|
CTLA-4
|
Cancer
|
|
Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling .
|
-
-
- HY-P99631
-
|
CSL312
|
Factor Xa
|
Cardiovascular Disease
|
|
Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research .
|
-
-
- HY-P9916
-
|
Anti-human IL6Rα, human antibody
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Sarilumab (Anti-Human IL6Rα, Human Antibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a interleukin-6 (IL-6) receptor antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6, resulting in reduced inflammation. Sarilumab can be used for the research of Rheumatoid arthritis .
|
-
-
- HY-P99632
-
|
REGN 2477
|
TGF-β Receptor
|
Inflammation/Immunology
|
|
Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research .
|
-
-
- HY-P99040
-
|
JNJ-61610588; CI-8993; VSTB112
|
VISTA
|
Cancer
|
|
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab can be used in colorectal cancer research .
|
-
-
- HY-P9967
-
|
BIIB037
|
Amyloid-β
|
Neurological Disease
|
|
Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research .
|
-
-
- HY-P99039
-
|
MEDI9447
|
CD73
|
Cancer
|
|
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity .
|
-
-
- HY-P99474
-
|
CAT 213; iCo-008
|
CCR
|
Inflammation/Immunology
|
|
Bertilimumab (CAT 213; iCo-008) is a human monoclonal antibody targeting eotaxin-1 (CCL11). Bertilimumab has the potential for allergic disorders research .
|
-
-
- HY-P99424
-
|
RG 7624; RO 5553110; NI-1401
|
Interleukin Related
|
Inflammation/Immunology
|
|
Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities .
|
-
-
- HY-108810
-
|
Ilaris; ACZ 885
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin .
|
-
-
- HY-P9974
-
|
OMP-18R5
|
Wnt
|
Cancer
|
|
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .
|
-
-
- HY-P99041
-
|
ABX-EGF
|
EGFR
|
Cancer
|
|
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer .
|
-
-
- HY-P99041B
-
|
ABX-EGF (powder)
|
EGFR
|
Cancer
|
|
Panitumumab (ABX-EGF) (powder) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (powder) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (powder) can be used in the research of cancers, such as colon cancer .
|
-
-
- HY-P99184
-
|
|
Integrin
|
Infection
Inflammation/Immunology
Cancer
|
|
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .
|
-
-
- HY-P99041A
-
|
|
EGFR
|
Cancer
|
|
Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer .
|
-
-
- HY-P9957
-
|
ABthrax
|
Bacterial
|
Infection
|
|
Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research .
|
-
-
- HY-P99232
-
|
5F9 monoclonal antibody
|
Guanylate Cyclase
|
Cancer
|
|
Indusatumab (5F9 Monoclonal antibody) is an anti-human GUCY2C (Guanylate cyclase 2C) monoclonal antibody .
|
-
-
- HY-P99509
-
-
-
- HY-P991451
-
|
SGN-ALPV antibody
|
Phosphatase
|
Cancer
|
|
Anti-ALPP Antibody (SGN-ALPV antibody) is a human monoclonal antibody (mAb) targeting ALPP. Anti-ALPP Antibody can be used in solid tumors research .
|
-
-
- HY-P99324
-
|
Anti-human EGFR Recombinant antibody
|
EGFR
Apoptosis
|
Cancer
|
|
Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonal antibody against EGFR. Tomuzotuximab has anticancer effects .
|
-
-
- HY-P99271
-
|
Anti-human F3 Recombinant antibody
|
ADC Antibody
|
Cancer
|
|
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab targets tissue factor (TF). Tisotumab can be used for the research of solid tumors .
|
-
-
- HY-P99526
-
-
-
- HY-P99447
-
|
|
Bacterial
|
Infection
|
|
Atidortoxumab is a human IgG1κ monoclonal antibody that targets Staph aureus alpha toxin .
|
-
-
- HY-P9908
-
-
-
- HY-P991120
-
|
|
TNF Receptor
|
Cancer
|
|
Balertatug is a human IgG1K antibody targeting CD70. The corresponding isotype control is: Human lgG1 kappa, lsotype Control (HY-P99001) .
|
-
-
- HY-P991486
-
-
-
- HY-P99304
-
|
Anti-human ERBB3 Recombinant antibody
|
EGFR
|
Cancer
|
|
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody that can be used for the research of cancer .
|
-
-
- HY-P990727
-
-
-
- HY-P991379
-
-
-
- HY-P99457
-
-
-
- HY-P991191
-
-
-
- HY-P99453
-
|
|
ADC Antibody
|
Cancer
|
|
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .
|
-
-
- HY-P9909
-
-
-
- HY-P991299
-
|
|
LAG-3
|
Cancer
|
|
ENUM006 is a human monoclonal antibody (mAb) targeting CD223/LAG3 .
|
-
-
- HY-P99347
-
-
-
- HY-P991298
-
|
|
LAG-3
|
Cancer
|
|
DNV-3 is a human monoclonal antibody (mAb) targeting CD223/LAG3 .
|
-
-
- HY-P99867
-
|
MEDI 573
|
IGF-1R
|
Others
|
|
Dusigitumab (MEDI 573) is a human IgG2λ monoclonal antibody that specifically targets IGF2 and IGF1 .
|
-
-
- HY-P991360
-
|
MLN2704 antibody
|
PSMA
|
Cancer
|
|
MLN 591 is a human monoclonal antibody (mAb) targeting PSMA. MLN 591 can be used in Prostate cancer research .
|
-
-
- HY-P991343
-
|
ALD309
|
PCSK9
|
Endocrinology
|
|
ALD306 is a human monoclonal antibody (mAb) targeting PCSK9. ALD306 can be used in Hypercholesterolaemia research .
|
-
-
- HY-P99211
-
|
ChAglyCD3; TRX 4
|
CD3
|
Metabolic Disease
|
|
Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes .
|
-
-
- HY-P99200
-
-
-
- HY-108730A
-
-
-
- HY-P991204
-
|
ARX517 antibody
|
PSMA
|
Cancer
|
|
Anti-PSMA Antibody is a humanized IgG1 monoclonal antibody that targets PSMA. Anti-PSMA Antibody is the antibody part of the ADC molecule ARX517. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
-
- HY-P9981
-
|
XmAb5574; MOR00208; Tafasitamab-cxix; MOR-208
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19 .
|
-
-
- HY-P991386
-
-
-
- HY-P990753
-
-
-
- HY-P991383
-
-
-
- HY-P99616
-
|
MOR-202
|
CD38
|
Cancer
|
|
Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research .
|
-
- HY-P99305
-
-
- HY-P9964
-
|
|
EGFR
|
Cancer
|
|
Necitumumab is a human IgG monoclonal antibody directed against EGFR. Necitumumab can be used for research of NSCLC, colorectal cancer, etc .
|
-
- HY-P991325
-
-
- HY-P990047
-
|
AMG133 antibody
|
GLP Receptor
|
Metabolic Disease
|
|
Maridebart is a human immunoglobulin G1-kappa, anti-GIPR (gastric inhibitory polypeptide receptor) monoclonal antibody .
|
-
- HY-P99785
-
|
HLX20
|
PD-1/PD-L1
|
Cancer
|
|
Opucolimab is an anti-PD-L1 recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors .
|
-
- HY-P99604
-
|
AZD-1061; COV2-2130
|
SARS-CoV
|
Infection
|
|
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .
|
-
- HY-P991177
-
|
|
c-Met/HGFR
|
Cancer
|
|
Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonal antibody that targets c-Met. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991295
-
-
- HY-P991390
-
-
- HY-P99408
-
-
- HY-P990074
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Enlonstobart is a human immunoglobulin G4-kappa, anti-PDCD1 monoclonal antibody. Enlonstobart is an immunostimulant and antineoplastic .
|
-
- HY-P991389
-
-
- HY-P991429
-
|
|
VEGFR
|
Metabolic Disease
|
|
THR-317 is a human monoclonal antibody (mAb) targeting PLGF. THR-317 can be used in Diabetic retinopathy research .
|
-
- HY-P991312
-
-
- HY-P991163
-
|
|
CD3
Claudin
|
Cancer
|
|
Tixentamig is a bispecific monoclonal antibody targeting human CD3 ε and CLDN18 (claudin 18). Tixentamig is promising for research of cancers .
|
-
- HY-P99017
-
-
- HY-P991371
-
|
PF-06664178 antibody; RN926
|
TROP2
|
Cancer
|
|
PF-06478924 (PF-06664178 antibody; RN926) is a human monoclonal antibody (mAb) targeting TROP2. PF-06478924 can be used in the study of advanced and metastatic solid tumors .
|
-
- HY-P991165
-
|
|
Fc Receptor (FcR)
|
Others
|
|
Trovostobart is an anti-VSIR human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990734
-
-
- HY-P99195
-
|
|
Trk Receptor
|
Inflammation/Immunology
|
|
Fasinumab (Anti-Human NGF) is a human IgG4 monoclonal antibody to nerve growth factor (NGF). Fasinumab can be used in acute sciatica and knee osteoarthritis (OA) studies .
|
-
- HY-P990746
-
-
- HY-P990754
-
|
|
c-Kit
|
Inflammation/Immunology
|
|
Opelkibart is an anti-KIT human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990749
-
-
- HY-P991405
-
|
|
TNF Receptor
|
Cancer
|
|
EU-102 is a human monoclonal antibody (mAb) targeting TNFSF18. EU-102 can be used in solid tumors research .
|
-
- HY-P991339
-
-
- HY-P99356
-
|
BIIB054; Anti-Alpha-synuclein Reference antibody (cinpanemab)
|
α-synuclein
|
Neurological Disease
|
|
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease .
|
-
- HY-P99533
-
|
SRF-231; SRF231
|
CD47
Interleukin Related
|
Cancer
|
|
Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction .
|
-
- HY-P99393
-
|
MEDI 0562; Tavolimab
|
TNF Receptor
|
Cancer
|
|
Tavolixizumab (MEDI 0562; Tavolimab) is a human monoclonal antibody to TNFRSF4 (TNF receptor superfamily member 4) for use in cancer immunology research .
|
-
- HY-P991418
-
|
|
VEGFR
|
Others
|
|
MW02 is a human monoclonal antibody (mAb) targeting VEGFA. MW02 can be used in Wet age-related macular degeneration research .
|
-
- HY-P991361
-
-
- HY-P991410
-
|
MEDI0641 antibody
|
Wnt
|
Cancer
|
|
5T4_0108 (MEDI0641 antibody) is a human monoclonal antibody (mAb) targeting TPBG. 5T4_0108 can be used in breast and prostate cancer research .
|
-
- HY-P991182
-
|
|
CCR
|
Inflammation/Immunology
|
|
Anti-CCR8 Antibody (10A11) is a humanized IgG1 monoclonal antibody that targets CCR8. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99214
-
|
KBPA101
|
Bacterial
|
Infection
|
|
Panobacumab (KBPA101) is a fully human IgM/κ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of P. aeruginosa .
|
-
- HY-P99515
-
-
- HY-P991375
-
|
|
Tau Protein
|
Neurological Disease
|
|
E2814 is a human monoclonal antibody (mAb) targeting MAPT/Tau. E2814 can be used for passive immunity research in Alzheimer's disease (AD) .
|
-
- HY-P99160
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy .
|
-
- HY-P991288
-
-
- HY-P991376
-
|
|
Tau Protein
|
Neurological Disease
|
|
BIIB076 is a human monoclonal antibody (mAb) targeting PHF-tau. BIIB076 can be used for passive immunity research in Alzheimer's disease (AD) .
|
-
- HY-P991488
-
-
- HY-P99617
-
|
REGN3767
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity .
|
-
- HY-P990080
-
|
|
CTLA-4
|
Cancer
|
|
Sovipostobart is an immunoglobulin G1-kappa, anti-CTLA-4 human monoclonal antibody with cleavable prodomain. Sovipostobart is an immunostimulant and antineoplastic .
|
-
- HY-P991409
-
-
- HY-P991290
-
-
- HY-P991435
-
-
- HY-P991387
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
AGEN1307 is a human monoclonal antibody (mAb) targeting TIGIT. AGEN1307 has an active FcγR binding region and enhances antibody-dependent cellular cytotoxicity (ADCC). AGEN1307 can be used in cancer research .
|
-
- HY-P991042
-
|
|
IGF-1R
|
Cancer
|
|
Anti-IGFBP2 Antibody (M14) is an human anti-IGFBP2 monoclonal inhibitory antibody, which binds IGFBP2 with high affinity and blocks its binding with IGF1. Anti-IGFBP2 Antibody (M14) inhibits human endothelial cell recruitment, thus blocks the tumor progression of human metastatic cancer .
|
-
- HY-P990781
-
|
SM03
|
CD22
|
Inflammation/Immunology
|
|
Suciraslimab is an anti-CD22 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990774
-
-
- HY-P990686
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ispectamab is an anti-TNFRSF17 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990697
-
|
ARX-788
|
EGFR
|
Inflammation/Immunology
|
|
Anvatabart is an anti-ERBB2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990728
-
|
|
CD74
|
Inflammation/Immunology
|
|
Bezetabart is an anti-CD74 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990729
-
|
|
CD19
|
Inflammation/Immunology
|
|
Budoprutug is an anti-CD19 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990764
-
|
SGN-B6A antibody
|
Integrin
|
Inflammation/Immunology
|
|
Sigvotatug is an anti-ITGB6 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991340
-
|
|
PAI-1
|
Cardiovascular Disease
|
|
CT140 is a human IgG4 monoclonal antibody (mAb) targeting PAI-1. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990747
-
|
|
CD38
|
Inflammation/Immunology
|
|
Lumrotatug is an anti-CD38 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990739
-
|
|
CTLA-4
|
Inflammation/Immunology
|
|
Evalstotug is an anti-CTLA4 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991166
-
|
|
Mucin
|
Others
|
|
Ubletamig is an anti-MUC16 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991115
-
|
|
Trk Receptor
|
Others
|
|
Amdokitug is an anti-MUSK human IgG1 λ monoclonal antibody. Recommend Isotype Controls: Human IgG1 Lambda2, Isotype Control (HY-P990096) .
|
-
- HY-P990767
-
-
- HY-P991117
-
|
|
Factor Xa
|
Cardiovascular Disease
|
|
Amrecibart is an anti-coagulation factor 11 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990712
-
|
RZ-358; XOMA 358
|
Insulin Receptor
|
Inflammation/Immunology
|
|
Ersodetug is an anti-INSR (insulin receptor) human IgG2 κ monoclonal antibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P991164
-
|
|
Antifolate
|
Inflammation/Immunology
|
|
Torvutatug is an anti-FOLR1 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990775
-
|
|
CTLA-4
|
Inflammation/Immunology
|
|
Vilastobart is an anti-CTLA4 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99274
-
|
BI 836845; Anti-human IGF1 and IGF2 Recombinant antibody
|
IGF-1R
|
Cancer
|
|
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation .
|
-
- HY-P991175
-
-
- HY-P99332
-
|
Anti-human CD3E Recombinant antibody; HuM291
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .
|
-
- HY-P991480
-
-
- HY-P99646
-
|
MEDI6570
|
LOX-1
|
Metabolic Disease
|
|
Golocdacimab (MEDI6570) is a fully human anti-LOX-1 monoclonal antibody. Golocdacimab (MEDI6570) has the potential for the research of type 2 diabetes .
|
-
- HY-P991412
-
-
- HY-P991437
-
-
- HY-P9927A
-
-
- HY-P99199
-
|
NI-0401
|
CD3
|
Inflammation/Immunology
|
|
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .
|
-
- HY-P991196
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-CD24 Antibody (SWA11) is a human IgG1 monoclonal antibody (mAb) targeting CD24. Anti-CD24 Antibody (SWA11) has anticancer effects, such as lung cancer and ovarian cancer. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991169
-
|
|
Factor Xa
|
Cardiovascular Disease
|
|
Zemocimig is an anti-coagulation factor F9 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990758
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
Reflocibart is an anti-VEGFB human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P990737
-
|
LY-3041658
|
CXCR
|
Inflammation/Immunology
|
|
Eltrekibart is an anti-CXCL human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P990768
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Timcevibart is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99034
-
-
- HY-P990725
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Nisfevitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991116
-
-
- HY-P990705
-
|
REGN-15160
|
SARS-CoV
|
Inflammation/Immunology
|
|
Gorivitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990713
-
-
- HY-P990773
-
|
LY-3361237
|
CD28
|
Inflammation/Immunology
|
|
Venanprubart is an anti-BTLA human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P99266
-
|
Anti-human CD4 Recombinant antibody
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma .
|
-
- HY-P991202
-
|
|
TSH Receptor
|
Endocrinology
|
|
Anti-TSHR Antibody (M22) is a humanized IgG1 monoclonal antibody that targets thyrotropin receptor (TSHR). Anti-TSHR Antibody (M22) inhibits the binding of TSH and TSHR. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991185
-
|
|
c-Met/HGFR
|
Cancer
|
|
Anti-MST1R Antibody (MOR07692) is a humanized IgG1 monoclonal antibody that targets MST1R. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99328
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule .
|
-
- HY-P991197
-
|
|
CD3
|
Cancer
|
|
Anti-GPRC5D Antibody is a humanized IgG1 monoclonal antibody that targets GPRC5D. Anti-GPRC5D Antibody is the antibody part of the ADC molecule LM-305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990068
-
|
SRF617
|
NTPDase
|
Cancer
|
|
Perenostobart is a human immunoglobulin G4-kappa, anti-ENTPD1/CD39 monoclonal antibody. Perenostobart is an immunostimulant and antineoplastic .
|
-
- HY-P9929
-
|
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
Bezlotoxumab is a human monoclonal antibody directed against C. difficile toxin B. Bezlotoxumab binds to C. difficile toxin B preventing intestinal epithelial damage and colitis .
|
-
- HY-P9918
-
|
Ticilimumab; CP-675206
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research .
|
-
- HY-P991398
-
|
|
Toll-like Receptor (TLR)
|
Cancer
|
|
IPH33 is a human monoclonal antibody (mAb) targeting TLR3/CD283. IPH33 can be used in Cancer and Inflammation research .
|
-
- HY-P991428
-
|
|
HIV
|
Infection
|
|
DIACC-1010 is a human monoclonal antibody (mAb) targeting PLA2G1B. DIACC-1010 can be used in HIV infections research .
|
-
- HY-P991296
-
-
- HY-P99642
-
-
- HY-P991416
-
|
|
VEGFR
|
Others
|
|
BAT5906 is a human monoclonal antibody (mAb) targeting VEGFA. BAT5906 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .
|
-
- HY-P991498
-
|
|
Influenza Virus
|
Infection
|
|
CAL-203 is a human monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. CAL-203 can be used in respiratory tract infections research.
|
-
- HY-P991377
-
|
|
Tau Protein
|
Neurological Disease
|
|
TBL-100 is a human monoclonal antibody (mAb) targeting Tau. TBL-100 can be used in Alzheimer's disease (AD) and Progressive supranuclear palsy research .
|
-
- HY-P3203
-
-
- HY-P991417
-
|
|
VEGFR
|
Cancer
|
|
LYN00101 is a human monoclonal antibody (mAb) targeting VEGFA. LYN00101 can be used in Cervical cancer, Colorectal cancer, Gastric cancer and Ovarian cancer research .
|
-
- HY-P991407
-
-
- HY-P99205
-
|
|
ADC Antibody
|
Cancer
|
|
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .
|
-
- HY-P99355
-
|
Anti-ACVR2B Reference antibody; BYM338
|
TGF-β Receptor
|
Metabolic Disease
|
|
Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness .
|
-
- HY-P991170
-
|
|
SARS-CoV
|
Infection
|
|
Ibramvibart is an anti-SARS-CoV-2 Spike human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990771
-
|
|
CD73
|
Inflammation/Immunology
|
|
Uprevstobart is an anti-NT5E human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990704
-
|
AZD-2936
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Rilvegostomig is an anti-PDCD1/TIGIT human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990755
-
|
|
EGFR
|
Inflammation/Immunology
|
|
Pamvatamig is an anti-EGFR/MET human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P991171
-
-
- HY-P991485
-
-
- HY-P991297
-
|
|
|
Cancer
|
|
AM0003 is a human monoclonal antibody (mAb) targeting CD223/LAG3. AM0003 can be used in the study of advanced solid tumors .
|
-
- HY-P991331
-
|
|
CD73
|
Cancer
|
|
BC-010 is a human monoclonal antibody (mAb) targeting NT5E/CD73. BC-010 can be used in the study of tumors.
|
-
- HY-P99318
-
|
LT 1009; Anti-human S1P Recombinant antibody
|
LPL Receptor
|
Cancer
|
|
Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC) .
|
-
- HY-P991293
-
|
|
c-Kit
|
Metabolic Disease
|
|
NN-2101 is a human monoclonal antibody (mAb) targeting c-Kit/CD117. NN-2101 is used in the research of retinal disorders and diabetic macular edema.
|
-
- HY-P99357
-
|
REGN1193; Anti-GCGR Reference antibody (crotedumab)
|
GCGR
|
Metabolic Disease
|
|
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes .
|
-
- HY-P991327
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
PAT-LM1 is a human monoclonal antibody (mAb) targeting NRB54/NONO. PAT-LM1 can be used in haematological malignancies research.
|
-
- HY-P3203A
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
DSTYSLSSTLTLSK TFA is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
|
-
- HY-P99586
-
|
REGN2222
|
RSV
|
Infection
|
|
Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection .
|
-
- HY-P991306
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
ATG-032 is a human monoclonal antibody (mAb) targeting LILRB2/ILT4. ATG-032 can be used in haematological malignancies research.
|
-
- HY-P99286
-
|
PRO 95780; rhuMAb-DR 5; Anti-human DR5 Recombinant antibody
|
Apoptosis
|
Cancer
|
|
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma .
|
-
- HY-P99703
-
|
17.1.41
|
HBV
|
Infection
|
|
Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .
|
-
- HY-108852
-
|
CHI 621
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation .
|
-
- HY-P99057A
-
|
CDX-1127 (anti-CD27)
|
TNF Receptor
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Varlilumab (CDX-1127) (anti-CD27) is an agonist anti-CD27 monoclonal antibody. Varlilumab (anti-CD27) can promote T cell expansion and activate the immune response. Varlilumab (anti-CD27) has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors .
|
-
- HY-P99057
-
|
CDX-1127
|
TNF Receptor
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Varlilumab (CDX-1127) is an agonist anti-CD27 monoclonal antibody. Varlilumab can promote T cell expansion and activate the immune response. Varlilumab has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors .
|
-
- HY-P991174
-
|
|
TREM receptor
|
Inflammation/Immunology
|
|
Anti-TREM2 Antibody (AL2p-58) is a humanized IgG1 monoclonal antibody that targets TREM2. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991075
-
|
|
NAMPT
|
Inflammation/Immunology
|
|
ALT-100 (Human IgG1) is a humanized IgG1 monoclonal antibody that targets NAMPT. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990726
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Abiprubart is an anti-CD40 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P990702
-
|
LVGN-3616
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Pradusinstobart is an anti-PDCD1 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P990750
-
|
|
LAG-3
|
Inflammation/Immunology
|
|
Negalstobart is an anti-LAG3 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P99668
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research .
|
-
- HY-P991453
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Cancer
|
|
Anti-CD371/CLEC12A Antibody (H6e7) is a human monoclonal antibody (mAb) targeting CD371/CLEC12A. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99335
-
|
Anti-human IL17A Recombinant antibody
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis .
|
-
- HY-P991072
-
|
MAPP-66
|
HIV
HSV
|
Infection
|
|
MB-66 (MAPP-66) is a fully human IgG1 antibody that targets HSV and HIV. MB-66 is a monoclonal antibody film for vaginal application. The isotype control for MB-66 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-164153
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
ADC Control Human IgG1-vcMMAE is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
|
-
- HY-P99209
-
|
MEDI-524
|
RSV
|
Infection
|
|
Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research .
|
-
- HY-P99323
-
|
BTT 1023; Anti-human AOC3 Recombinant antibody
|
VAP-1
|
Inflammation/Immunology
|
|
Timolumab (BTT1023 ), a recombinant fully human monoclonal antibody that specifically binds VAP-1. Timolumab (BTT1023 ) could be used in the study of chronic inflammatory diseases .
|
-
- HY-P9905
-
Cetuximab
Maximum Cited Publications
39 Publications Verification
C225
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
|
Cancer
|
|
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
|
-
- HY-P991368
-
-
- HY-P991291
-
|
|
Insulin Receptor
|
Endocrinology
|
|
XOMA 129 is a human monoclonal antibody targeting INSR. XOMA 129 is an insulin receptor (IR) antagonist that inhibits the drop in blood glucose. XOMA 129 can be used in the study of hypoglycemia .
|
-
- HY-P99473
-
|
BI-505
|
Integrin
|
Cancer
|
|
Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects .
|
-
- HY-P991385
-
|
|
Tie
|
Neurological Disease
Metabolic Disease
|
|
UBX2050 is a human monoclonal antibody (mAb) targeting TIE2. UBX2050 can be used in Age-related macular degeneration, Diabetic macular oedema and Diabetic retinopathy research .
|
-
- HY-P991303
-
|
Sym022; S 95017
|
|
Cancer
|
|
TQB-2223 is a human monoclonal antibody (mAb) targeting CD223/LAG3. TQB-2223 can be used in the study of Hodgkin lymphoma .
|
-
- HY-P99465
-
-
- HY-P991494
-
|
|
RSV
|
Infection
|
|
IN-002 is a human monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. IN-002 can be used in respiratory syncytial virus (RSV) infections research.
|
-
- HY-P99832
-
|
c13C6-FR1
|
Filovirus
|
Infection
|
|
Cosfroviximab (c13C6-FR1) is a mouse/human chimeric monoclonal antibody against Ebola virus glycoprotein (EBOV-GP) .
|
-
- HY-P990690
-
|
MEDI-5752
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Volrustomig is an anti-CTLA4/PDCD1 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990761
-
-
- HY-P99485
-
|
AMG 139; MEDI2070
|
Interleukin Related
|
Inflammation/Immunology
|
|
Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease .
|
-
- HY-P990700
-
|
RO-7247669; RG-6139
|
PD-1/PD-L1
LAG-3
|
Inflammation/Immunology
|
|
Tobemstomig is an anti-PDCD1/LAG3 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990694
-
|
TG-1801
|
CD19
CD47
|
Inflammation/Immunology
|
|
Zeripatamig is an anti-CD19/CD47 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990701
-
|
RO-7121661
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Lomvastomig is an anti-PDCD1/HAVCR2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P99364
-
|
Anti-VEGFR1/FLT1 Reference antibody; IMC-18F1
|
VEGFR
|
Cancer
|
|
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a human Anti-VEGFR-1 IgG1 monoclonal antibody. Icrucumab has the potential for the research of advanced solid tumors .
|
-
- HY-P991106
-
|
LY-3076226 antibody
|
FGFR
|
Cancer
|
|
IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody against FGFR3. IMC-D11 can be used for the antibody part of LY3076226. IMC-D11 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P9950
-
|
Olizumab; rhuMab-E25
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research .
|
-
- HY-P99353
-
|
Anti-ACVRL1 / ALK-1 Reference antibody (ascrinvacumab); PF-03446962
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) .
|
-
- HY-P990756
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Pemivibart is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
-
- HY-P990777
-
-
- HY-P990766
-
|
AZD3152
|
SARS-CoV
|
Inflammation/Immunology
|
|
Sipavibart is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
-
- HY-P990751
-
-
- HY-P991341
-
|
|
Cadherin
|
Inflammation/Immunology
|
|
FF-21101 is a human IgG1 monoclonal antibody (mAb) targeting CDH3/P-cadherin. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990711
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Canrivitug is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
-
- HY-P99307
-
|
AMG-203; Anti-human CSF2 Recombinant antibody
|
c-Fms
|
Inflammation/Immunology
|
|
Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis .
|
-
- HY-P991326
-
|
EDP-10; JHL-1311
|
Interleukin Related
|
Endocrinology
|
|
BL-9020 is a human monoclonal antibody (mAb) targeting NKp46/NCR1. BL-9020 can be used in type 1 diabetes mellitus research.
|
-
- HY-P991347
-
|
|
PD-1/PD-L1
|
Cancer
|
|
AM0001 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. AM0001 can be used in cancer research .
|
-
- HY-P991420
-
|
|
VEGFR
|
Cancer
|
|
UB-925 is a human monoclonal antibody (mAb) targeting VEGFR2/KDR/CD309. UB-925 can be used in Gastric cancer research .
|
-
- HY-P991439
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
BIIB023 is a human monoclonal antibody (mAb) targeting TNFRSF12A/TWEAKR/CD266. BIIB023 can be used in lupus nephritis and rheumatoid arthritis research .
|
-
- HY-P99760
-
|
BCD-145
|
CTLA-4
|
Cancer
|
|
Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma .
|
-
- HY-P991499
-
|
|
RSV
|
Infection
|
|
EVO-46120 is a human monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. EVO-46120 can be used in respiratory syncytial virus (RSV) and metapneumovirus infections research.
|
-
- HY-P99807
-
|
BCD-100
|
PD-1/PD-L1
|
Cancer
|
|
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma .
|
-
- HY-P99262
-
|
BAX69; Anti-human MIF Recombinant antibody
|
Macrophage migration inhibitory factor (MIF)
|
Cancer
|
|
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer .
|
-
- HY-P99484
-
|
AGEN 1181
|
CTLA-4
|
Cancer
|
|
Botensilimab (AGEN 1181), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer .
|
-
- HY-P99320
-
|
OMP 59R5; Anti-human NOTCH2 Recombinant antibody
|
Notch
|
Cancer
|
|
Tarextumab (OMP-59R5) is an anti-Notch2/3 fully human IgG2 monoclonal antibody. Tarextumab shows anti-tumor activity .
|
-
- HY-P991140
-
|
|
Claudin
|
Cancer
|
|
Garetatug is a humanized monoclonal antibody targeting human CLDN18 (claudin-18). Garetatug specifically binds to CLDN18, interfering with relevant cell signaling pathways and exerting antitumor activity .
|
-
- HY-P9925
-
|
AMG 827; KHK4827
|
Interleukin Related
|
Inflammation/Immunology
|
|
Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis .
|
-
- HY-P991414
-
|
|
HIV
|
Infection
Cancer
|
|
FGI-1011A6 is a human monoclonal antibody (mAb) targeting TSG101. FGI-1011A6 can be used in Prostate cancer and Viral infections research .
|
-
- HY-P991187
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-TM4SF1 Antibody (AGX-A07) is a humanized IgG1 monoclonal antibody that targets TM4SF1. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P9985
-
|
RC48
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity .
|
-
- HY-P99014
-
|
ARGX-110
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML) .
|
-
- HY-P99354
-
|
Anti-human CTLA4xLAG3
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .
|
-
- HY-P991304
-
|
|
MMP
|
Cancer
|
|
IO-106 is a human IgG1 monoclonal antibody (mAb) targeting LAIR1/CD305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991302
-
|
|
LAG-3
|
Cancer
|
|
KL-A289 is a human monoclonal antibody (mAb) targeting CD223/LAG3. KL-A289 can be used in the study of metastatic GC .
|
-
- HY-P99337
-
|
Ansuvimab-zyk; mAb114
|
Filovirus
|
Infection
|
|
Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells .
|
-
- HY-P99695
-
|
CAT-152
|
TGF-beta/Smad
|
Neurological Disease
|
|
Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research .
|
-
- HY-P99857
-
|
PF-06252616
|
TGF-beta/Smad
|
Metabolic Disease
|
|
Domagrozumab is an anti-myostatin humanized monoclonal antibody with a KD value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD) .
|
-
- HY-P991309
-
-
- HY-P99423
-
|
ADG 20
|
SARS-CoV
|
Infection
|
|
Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .
|
-
- HY-P99168
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research .
|
-
- HY-P991434
-
|
|
Integrin
|
Inflammation/Immunology
|
|
SAN-300 is a human IgG1 monoclonal antibody (mAb) targeting ITGA1/VLA-1. SAN-300 can be used in Rheumatoid arthritis research .
|
-
- HY-P99375
-
|
IMC-RON8; LY3012219; Anti-MSPR/RON/CD136 Reference antibody (narnatumab)
|
Tyrosinase
c-Met/HGFR
|
Cancer
|
|
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer .
|
-
- HY-P9979
-
|
UCB7665
|
TNF Receptor
|
Inflammation/Immunology
|
|
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .
|
-
- HY-P990876
-
|
PF-06480605; RVT-3101
|
TNF Receptor
|
Inflammation/Immunology
|
|
Afimkibart (PF-06480605) is a human IgG1 monoclonal antibody targeting tumor necrosis factor-like ligand 1A (TL1A). Afimkibart can be used in the research of inflammatory bowel disease .
|
-
- HY-P99607
-
|
IDEC-151
|
HIV
|
Inflammation/Immunology
|
|
Clenoliximab (IDEC-151) is a macaque-human chimeric monoclonal antibody (immunoglobulin G4) specific for the CD4 molecule on the surface of T lymphocytes. Clenoliximab can be used for the research of rheumatoid arthritis .
|
-
- HY-P99889
-
|
BRII-198
|
SARS-CoV
|
Infection
|
|
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
|
-
- HY-P9S0008
-
|
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
|
Cancer
|
|
Cetuximab (PBS) is a human IgG1 monoclonal antibody that can inhibit EGFR. The SPR method measured the Kd value of Cetuximab for EGFR to be 0.201 nM; Cetuximab has a highly effective anti-tumor effect .
|
-
- HY-P991384
-
|
|
Tie
|
Cancer
|
|
DX-2240 is a human monoclonal antibody (mAb) targeting TIE1. DX-2240 inhibits tumor growth and sensitizes tumor vasculature to anti-angiogenic agents (VEGF pathway inhibitors) .
|
-
- HY-P9966
-
|
MGA271
|
CD276/B7-H3
|
Cancer
|
|
Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators .
|
-
- HY-P99366A
-
|
AMG 157 (anti-TSLP); MEDI 19929 (anti-TSLP); Tezepelumab-ekko (anti-TSLP)
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tezepelumab (anti-TSLP) is human monoclonal antibody (IgG2λ) that binds specifically to TSLP, blocking it from interacting with its heterodimeric receptor. Tezepelumab can be used for the research of severe, uncontrolled asthma .
|
-
- HY-P991082
-
|
SAR-428926 antibody
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-LAMP1/CD107a Antibody (SAR-428926 antibody) is an anti-LAMP1 humanized monoclonal antibody. Anti-LAMP1/CD107a Antibody can be used for the antibody part of SAR-428926. Antibody Anti-LAMP1/CD107a Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990752
-
|
REGN-5678
|
CD28
|
Inflammation/Immunology
|
|
Nezastomig is an anti-FOLH1/CD28 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P991333
-
-
- HY-P99900
-
|
MSL-109
|
CMV
|
Infection
|
|
Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL .
|
-
- HY-P991399
-
-
- HY-P991392
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
TGTB227 is a human monoclonal antibody (mAb) targeting TIGIT. TGTB227 inhibits the immunosuppressive function of Tregs by reducing the expression of Foxp3 in Tregs. TGTB227 can be used in tumor immunity research .
|
-
- HY-P99411
-
|
SHP647
|
Integrin
|
Inflammation/Immunology
|
|
Ontamalimab (SHP647) is a fully-human IgG2 monoclonal antibody targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Ontamalimab can be used for the research of Crohn's disease .
|
-
- HY-P991126
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy .
|
-
- HY-P991139
-
|
|
CTLA-4
|
Cancer
|
|
Futermestotug is a humanized immunoglobulin G1-κ monoclonal antibody targeting human cytotoxic T-lymphocyte associated protein 4 (CTLA4). Futermestotug is promising for research of various malignant tumors .
|
-
- HY-P99207
-
|
KB 003
|
SARS-CoV
|
Cancer
|
|
Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies .
|
-
- HY-P99461
-
|
ISU-104
|
EGFR
|
Cancer
|
|
Barecetamab (ISU-104) is a fully human anti-ErbB3 monoclonal antibody. Barecetamab can be used for the research of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) .
|
-
- HY-P9922
-
|
IMC-3G3; LY3012207
|
PDGFR
|
Cancer
|
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .
|
-
- HY-P991436
-
|
BMS-986415
|
Interleukin Related
IFNAR
|
Cancer
|
|
DF6002 (BMS-986415) is a human monoclonal antibody (mAb) targeting IL-12. DF6002 increases IFN-γ levels. DF6002 can be used in solid tumors research .
|
-
- HY-P991152
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Oturkibart is a humanized immunoglobulin G4-κ monoclonal antibody targeting the human interleukin 4 receptor (IL4R). Oturkibart is promising for research of inflammatory diseases, such as asthma and atopic dermatitis .
|
-
- HY-164152
-
|
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
|
Cancer
|
|
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
-
- HY-164152A
-
|
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
|
Cancer
|
|
ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
-
- HY-164154
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
|
-
- HY-P990745
-
-
- HY-P990691
-
-
- HY-P99909
-
|
PF-06863135
|
TNF Receptor
|
Inflammation/Immunology
|
|
Elranatamab (PF-06863135) is an anti-CD3E/TNFRSF17 human IgG2κ monoclonal antibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P990692
-
|
|
CD3
|
Inflammation/Immunology
|
|
Ciduvectamig is an anti-CD3E/TMEFF2 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P99263
-
|
Anti-human selectin P Recombinant antibody
|
P-selectin
|
Cardiovascular Disease
|
|
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion .
|
-
- HY-P9991
-
|
TST001
|
Gap Junction Protein
|
Cancer
|
|
Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
|
-
- HY-P991404
-
|
|
TNF Receptor
|
Cancer
|
|
AMG-228 is a human IgG1 monoclonal antibody (mAb) targeting TNFRSF18/GITR/CD357. AMG-228 can be used in advanced solid tumors research .
|
-
- HY-P990021
-
|
|
Bacterial
|
Others
|
|
Calpurbatug is an immunoglobulin G1 antibody. Calpurbatug has activity with anti-bacterial DNA-binding protein DNABII family and anti-human monoclonal TRL1068 γ1-chain .
|
-
- HY-P991150
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ompekimig is a humanized immunoglobulin monoclonal antibody targeting human interleukin 4 (IL-4) and interleukin 13 (IL-13). Ompekimig is promising for research of immune-mediated inflammatory diseases, such as asthma and atopic dermatitis .
|
-
- HY-P991396
-
|
|
Tim3
|
Cancer
|
|
LY-3321367 is a human monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. LY-3321367 can be used in solid tumors research .
|
-
- HY-P99550
-
|
MEDI-3506
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease .
|
-
- HY-P99955
-
-
- HY-P99442
-
|
Hu1D10
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro .
|
-
- HY-P991313
-
|
|
c-Fms
|
Inflammation/Immunology
|
|
PD-360324 is a human monoclonal antibody (mAb) targeting CSF1/M-CSF. PD-360324 can be used in cutaneous lupus erythematosus, pulmonary sarcoidosis and rheumatoid arthritis research .
|
-
- HY-P991308
-
-
- HY-P991349
-
|
|
PD-1/PD-L1
|
Cancer
|
|
GNR-051 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. GNR-051 can be used in Solid tumours research .
|
-
- HY-P991252
-
|
AIMab-7195
|
Histamine Receptor
|
Inflammation/Immunology
|
|
XmAb-7195 (AIMab-7195) is a human monoclonal antibody (mAb) targeting IGHE. XmAb-7195 can be used in Food hypersensitivity, Allergic asthma, Allergic rhinitis, Atopic dermatitis and Conjunctivitis research .
|
-
- HY-P991433
-
|
|
TNF Receptor
|
Cancer
|
|
BIIB036 is a human IgG1 monoclonal antibody (mAb) targeting TNFRSF12A/Fn14. BIIB036 inhibits the growth of patient-derived primary colorectal tumors in SCID mice .
|
-
- HY-P99792
-
|
NM57; rhRIG
|
RABV
|
Infection
|
|
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .
|
-
- HY-P99895
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .
|
-
- HY-P991336
-
-
- HY-P99530
-
|
AGT-181; HIRMAb-IDUA
|
Insulin Receptor
|
Metabolic Disease
|
|
Valanafusp alfa (AGT-181) is a chimeric monoclonal antibody that fuses human α-L-iduronidase (IDUA) and targets the human insulin receptor (HIR). Valanafusp alfa has brain penetrating properties, making it useful for research on mucopolysaccharidosis type I (MPS I) .
|
-
- HY-P991305
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
AGEN-1571 is a human IgG1 monoclonal antibody (mAb) targeting ILT2. AGEN-1571 promotes adaptive and innate immune responses. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001)
|
-
- HY-P991314
-
|
|
MDM-2/p53
|
Cancer
|
|
NMC-001 is a human IgG1 monoclonal antibody (mAb) targeting MDM2. NMC-001 can be used in pancreatic cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99234
-
|
|
Interleukin Related
ADC Antibody
|
Cancer
|
|
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .
|
-
- HY-P991342
-
|
PCA062 antibody
|
Cadherin
|
Cancer
|
|
CQY684 (PCA062 antibody) is a human monoclonal antibody (mAb) targeting CDH3/P-cadherin. CQY684 stabilizes the X-dimer of P-cadherin, promoting its endocytosis and directing it to lysosomal degradation. CQY684 can be used in Breast, esophageal, and head and neck cancers research .
|
-
- HY-P99013
-
|
GC33; RO5137382
|
Glycoprotein VI
|
Cancer
|
|
Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .
|
-
- HY-P99280
-
|
Anti-human IL17A/IL-17F Recombinant antibody
|
Interleukin Related
|
Inflammation/Immunology
|
|
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation .
|
-
- HY-P991362
-
|
|
TNF Receptor
|
Cancer
|
|
GB-223 is a human monoclonal antibody (mAb) targeting TNFSF11/RANKL/CD254. GB-223 can be used in Giant cell tumour of bone and Postmenopausal osteoporosis research .
|
-
- HY-P991320
-
|
|
PD-1/PD-L1
|
Cancer
|
|
BAT-1308 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. BAT-1308 can be used in cervical cancer and endometrial cancer research.
|
-
- HY-P99036
-
-
- HY-P991135
-
|
|
CCR
|
Cancer
|
|
Enzelkitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the human C-C motif chemokine receptor 8 (CCR8). Enzelkitug is promising for research of various solid tumors and hematological malignancies .
|
-
- HY-P99365
-
|
ALXN1210
|
Complement System
|
Metabolic Disease
|
|
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .
|
-
- HY-P99764
-
|
REGN-3471
|
Filovirus
|
Infection
|
|
Odesivimab is a human monoclonal antibody, targeting Ebola virus glycoprotein with a KD value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein. Odesivimab can be used in research of Ebola virus infection .
|
-
- HY-P9901
-
|
MDX-010; BMS-734016
|
CTLA-4
|
Cancer
|
|
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies .
|
-
- HY-P991323
-
-
- HY-P99795
-
|
GSK 3196165; MOR103
|
c-Fms
|
Inflammation/Immunology
|
|
Otilimab (GSK 3196165) is an anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) human monoclonal antibody. Otilimab neutralises the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor .
|
-
- HY-P991334
-
|
|
Orexin Receptor (OX Receptor)
|
Cancer
|
|
INCAGN1949 is a human IgG1 monoclonal antibody (mAb) targeting TNFRSF4/OX40/CD134. INCAGN1949 selectively deplete intratumoral regulatory T cells .
|
-
- HY-P99196
-
|
|
c-Met/HGFR
|
Cancer
|
|
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion .
|
-
- HY-P991162
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tilrekimig is a monoclonal antibody targeting human interleukin 4 (IL-4), interleukin 13 (IL-13), and TSLP (thymic stromal lymphopoietin). Tilrekimig is promising for research of allergic and inflammatory diseases, such as asthma and atopic dermatitis .
|
-
- HY-P991143
-
|
|
Claudin
|
Cancer
|
|
Ixotatug is a monoclonal antibody targeting human CLDN6 (claudin-6). Ixotatug specifically binds to CLDN6, interfering with relevant signaling pathways in tumor cells and exerting antitumor activity. Ixotatug is promising for research of cancers .
|
-
- HY-P991195
-
|
|
TNF Receptor
|
Cancer
|
|
SIM-0235 is humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets and inhibits TNFR2, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
|
-
- HY-P991124
-
|
|
Factor XI
|
Cardiovascular Disease
|
|
Cenvacibart is a monoclonal antibody with anticoagulant activity, targeting human coagulation factor XI (F11). Cenvacibart blocks the role of coagulation factor XI in the coagulation cascade, reducing thrombus formation. Cenvacibart is promising for research of thrombotic diseases .
|
-
- HY-P9915
-
|
Anti-human CD38, human antibody
|
CD38
ADC Antibody
|
Inflammation/Immunology
Cancer
|
|
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
|
-
- HY-P991460
-
|
|
TNF Receptor
|
Cancer
|
|
Sym029 is a human IgG monoclonal antibody (mAb) targeting TNFRSF5/CD40. Sym029 can be used in cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991145
-
|
|
SLC39 (Zinc Transporter)
|
Cancer
|
|
Laventatug is a humanized monoclonal antibody targeting human SLC39A6. Laventatug specifically binds to SLC39A6, interfering with the intracellular zinc ion transport process and thus exerting antitumor activity. Laventatug is promising for research of cancers .
|
-
- HY-P991137
-
|
|
Ser/Thr Protease
|
Metabolic Disease
|
|
Exerenibart is an immunoglobulin G4-κ monoclonal antibody targeting human transmembrane serine protease 6 (TMPRSS6). Exerenibart is promising for research of diseases associated with iron metabolism disorders, such as iron overload or iron deficiency .
|
-
- HY-P99222
-
|
MGA-031; PRV-031
|
CD3
|
Metabolic Disease
|
|
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .
|
-
- HY-P99648
-
|
BMS-986168; IPN007; BIIB092
|
Tau Protein
|
Neurological Disease
|
|
Gosuranemab (BMS-986168) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab binds to human N-terminal tau residues 15-22. Gosuranemab has the potential for the research of alzheimer’s disease (AD) .
|
-
- HY-P991203
-
|
|
Guanylate Cyclase
|
Cancer
|
|
PF-07062119 is humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets and inhibits GUCY2C, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
|
-
- HY-P991355
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PDL-GEX is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. PDL-GEX can be used in cancer research .
|
-
- HY-P991348
-
|
|
PD-1/PD-L1
|
Cancer
|
|
BAT-1306 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. BAT-1306 can be used in Colorectal cancer and Solid tumours research .
|
-
- HY-P99010A
-
|
|
Interleukin Related
FGFR
|
Cancer
|
|
Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa .
|
-
- HY-P99656
-
|
MCDS0593A
|
ADC Antibody
|
Cancer
|
|
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .
|
-
- HY-P99813
-
|
HER3-DXd; U3-1402
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .
|
-
- HY-141604
-
|
CDX-011; CR011-vcMMAE
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Glembatumumab vedotin (CDX-011) is an ADC (antibody-drug conjugates (ADCs)) comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects .
|
-
- HY-P991484
-
|
|
Influenza Virus
|
Infection
|
|
ADI-65534 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-65534 can be used in Hantavirus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991450
-
|
ADI-15742; MBP-134 AF
|
Filovirus
|
Infection
|
|
ADI-15878 is a human IgG monoclonal antibody (mAb) targeting Envelope glycoprotein, GP2. ADI-15878 can be used in Ebola virus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991489
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
ENx-108A is a human IgG4 monoclonal antibody (mAb) targeting IL-11. BI-765423 can be used in fibrotic diseases research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991483
-
|
|
Influenza Virus
|
Infection
|
|
ADI-65533 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-65533 can be used in Hantavirus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99971
-
|
|
ADC Antibody
Transmembrane Glycoprotein
|
Cancer
|
|
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991301
-
|
|
LAG-3
|
Cancer
|
|
IMP-761 is a human IgG4 monoclonal antibody (mAb) targeting CD223/LAG3. IMP-761 binds to D1 of human LAG32. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991335
-
|
|
Orexin Receptor (OX Receptor)
|
Cancer
|
|
BAT6026 is a human monoclonal antibody (mAb) targeting TNFRSF4/OX40/CD134. BAT6026 significantly reduces Treg cells and increased CD8+ T cells in tumor .
|
-
- HY-P99945
-
-
- HY-P990014
-
|
IMC-001; STI-3031
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic .
|
-
- HY-P99007
-
|
BAY 1179470
|
FGFR
|
Cancer
|
|
Aprutumab (BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research .
|
-
- HY-P99936
-
|
LJM716
|
EGFR
|
Cancer
|
|
Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential .
|
-
- HY-P99652
-
|
AK 111
|
Interleukin Related
|
Inflammation/Immunology
|
|
Gumokimab (AK 111) is a monoclonal antibody targeting IL-17A, which can be used in the study of psoriasis, ankylosing spondylitis. Gumokimab competitively blocks the binding of human IL-17A to IL-17R.
|
-
- HY-P991394
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
SEA-TGT is a human monoclonal antibody (mAb) targeting TIGIT. SEA-TGT enhances binding to the activating FcγRIIIA while reducing binding to the inhibitory FcγRIIb. SEA-TGT can be used in advanced solid tumors and Lymphoma research .
|
-
- HY-P9801
-
|
SARS-CoV-2 (2019-nCoV) Spike RBD antibody
|
SARS-CoV
|
Infection
|
|
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .
|
-
- HY-P991369
-
|
|
Sialyltransferase
|
Cancer
|
|
EBU-141 is a human monoclonal antibody (mAb) targeting CD75/ST6GAL1. EBU-141 can be used in B-cell lymphoma and multiple myeloma research .
|
-
- HY-P4025
-
|
|
HIV
|
Others
|
|
ELDKWA is the highly conserved amino acids on the ecto-domain of gp41. ELDKWA acts as the epitope of a neutralizing monoclonal antibody 2F5 (mAb 2F5) directed against human immunodeficiency virus type 1 .
|
-
- HY-P991300
-
|
|
LAG-3
|
Cancer
|
|
GSK2831781 is a human IgG1 monoclonal antibody (mAb) targeting CD223/LAG3. GSK2831781 can be used in the study of ulcerative colitis Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991282
-
|
|
Interleukin Related
|
Cancer
|
|
KHK2823 is a humanized monoclonal anti-human CD123/IL3RA antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001). KHK2823 can be used in research related to leukemia .
|
-
- HY-P991446
-
|
|
Influenza Virus
|
|
|
MEDI-8852 is a human IgG1 monoclonal antibody (mAb) targeting influenza A virus hemagglutinin HA. MEDI-8852 can be used in influenza A virus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P9914
-
|
Anti-human C5, humanized antibody
|
Complement System
|
Cardiovascular Disease
Neurological Disease
|
|
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies .
|
-
- HY-P990043
-
|
|
Ser/Thr Kinase
TREM receptor
|
Inflammation/Immunology
|
|
Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP) .
|
-
- HY-P99313
-
|
Anti-human IGHE Recombinant antibody
|
Apoptosis
|
Inflammation/Immunology
|
|
Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research .
|
-
- HY-P99230
-
|
|
Integrin
CD22
|
Cancer
|
|
Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99194
-
|
REGN1500
|
ANGPTL
|
Cardiovascular Disease
Metabolic Disease
|
|
Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia .
|
-
- HY-P991374
-
|
|
Tau Protein
|
Neurological Disease
|
|
PNT001 is a human IgG1 monoclonal antibody (mAb) targeting cis-pT231 Tau. PNT001 can be used in Neurodegenerative disorders and Traumatic brain injuries research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P9915A
-
|
Anti-human CD38, human antibody (PBS)
|
ADC Antibody
CD38
|
Cancer
|
|
Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
|
-
- HY-P991442
-
|
TAK-920
|
TREM receptor
|
Neurological Disease
|
|
DNL-919 (TAK-920) is a human IgG1 monoclonal antibody (mAb) targeting TREM-2. DNL-919 can be used in Alzheimer's disease research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99257
-
|
ASKP 1240
|
TNF Receptor
|
Inflammation/Immunology
|
|
Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (Kd: 0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection .
|
-
- HY-P991278
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
ABM-125 is a human IgG anti-IL-25 monoclonal antibody. The isotype control of ABM-125 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). ABM-125 can be used in research related to viral asthma .
|
-
- HY-P99178
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
CTX-471 is a fully human monoclonal antibody of CD137. CTX-471 has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with Kd values of 50 nM, 61 nM and 748 nM, respectively. CTX-471 can be used for the research of immunomodulation and cancer .
|
-
- HY-P991421
-
|
|
VISTA
|
Cancer
|
|
W0180 is a human IgG1 monoclonal antibody (mAb) targeting VISTA/B7-H5. W0180 has the potential to activate T cells. W0180 can be used in solid tumors research .
|
-
- HY-P991130
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Dalidnetug is a humanized monoclonal antibody targeting human amyloid-beta precursor protein (APP). Dalidnetug specifically binds to APP to reduce the production of amyloid-beta (Aβ), thus exerting the activity of clearing amyloid-beta. Dalidnetug is promising for research of Alzheimer's disease .
|
-
- HY-P99197
-
|
CP-751871
|
IGF-1R
|
Cancer
|
|
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM .
|
-
- HY-P99346
-
|
CT-P59
|
SARS-CoV
Angiotensin-converting Enzyme (ACE)
|
Infection
|
|
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .
|
-
- HY-P99833
-
|
CK-301; TG-1501
|
PD-1/PD-L1
|
Cancer
|
|
Cosibelimab (CK-301) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab exhibits antitumor efficacy .
|
-
- HY-P991125
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy .
|
-
- HY-P991337
-
-
- HY-P991192
-
|
|
TNF Receptor
|
Cancer
|
|
BI-1808 is a human IgG1 monoclonal antibody that targets TNFR2by blocking interaction of TNFR2 with ligand TNF-α, confers FcγR-dependent depletion of Treg and mediates expansion of intratumoral CD8 + T cells .
|
-
- HY-P991155
-
|
|
CD3
TNF Receptor
|
Cancer
|
|
Ramantamig is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (tumor necrosis factor receptor superfamily member 17)。Ramantamig is promising for research of cancers, especially hematological malignancies such as multiple myeloma .
|
-
- HY-P9934
-
|
C7E3
|
Integrin
|
Cardiovascular Disease
|
|
Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .
|
-
- HY-P991156
-
|
|
Ras
|
Inflammation/Immunology
|
|
Rapaprutug is a monoclonal antibody targeting human KARS1 (lysyl-tRNA synthetase 1). Rapaprutug blocks the relevant inflammatory signaling pathways in which KARS1 is involved, reducing the production and release of inflammatory factors. Rapaprutug is promising for research of inflammatory diseases .
|
-
- HY-P991321
-
|
|
Trk Receptor
|
Inflammation/Immunology
|
|
ABT-110 is a human monoclonal antibody (mAb) targeting NGF/bNGF. ABT-110 reduces established thermal and mechanical hypersensitivity in the CFA rat model. ABT-110 can be used in persistent/chronic inflammatory pain research .
|
-
- HY-P9807
-
|
SARS-CR3022; SARS-CoV-2 antibody-CR3022
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .
|
-
- HY-P991127
-
|
|
Complement System
|
Inflammation/Immunology
|
|
Claseprubart is a monoclonal antibody targeting human complement C1s. Claseprubart specifically binds to complement C1s to inhibit the activation of the complement system, exerting immunosuppressive activity. Claseprubart is promising for research of autoimmune diseases and inflammation-related diseases .
|
-
- HY-P991332
-
|
|
CD73
|
Cancer
|
|
JAB-BX102 is a human monoclonal antibody (mAb) targeting NT5E/CD73. JAB-BX102 can be used in the study of cancers such as breast cancer, pancreatic cancer, and prostate cancer .
|
-
- HY-P991168
-
|
|
Amyloid-β
CCR
|
Neurological Disease
Inflammation/Immunology
|
|
Velaprumig is a monoclonal antibody targeting human CD99, CCL25, and anti-human Aβ (Aβ-47F). Velaprumig regulates immune cell migration and reduces β-amyloid-related pathological processes, exerting immunomodulatory and potential anti - Alzheimer's disease activities .
|
-
- HY-145622
-
|
BA3011; CAB-Axl-ADC; CAB-anti-Axl-ADC
|
TAM Receptor
|
Cancer
|
|
Mecbotamab vedotin (BA301) is an IgG1 antibody inhibitor of anti-(human tyrosine kinase receptor AXL) (human-Mus musculus monoclonal BA301 γ1-chain). Mecbotamab vedotin can be used to make immunoconjugates for Methods of Axl-expressing cancers research .
|
-
- HY-P991351
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
RTX-002 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. RTX-002 can be used to study autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis .
|
-
- HY-P991317
-
|
|
Mucin
|
Cancer
|
|
BTH1704 is a human monoclonal antibody (mAb) targeting MUC1. BTH1704 enables PGG-primed leukocytes to kill iC3b-opsonized tumor cells. BTH1704 can be used in pancreatic and breast cancer research .
|
-
- HY-P99768
-
|
TTAC-0001
|
VEGFR
|
Cancer
|
|
Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer .
|
-
- HY-P991147
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Ledostomig is an immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human netrin-5 (NTS5) and programmed death-1 (PD-1). Ledostomig is promising for research of various cancers .
|
-
- HY-P991254
-
|
|
Integrin
TGF-β Receptor
|
Metabolic Disease
|
|
VPI-2690B is a human monoclonal antibody (mAb) targeting Integrin aVb3. VPI-2690B inhibits TGF-β signaling. VPI-2690B can be used in Diabetic nephropathies research .
|
-
- HY-P991363
-
|
|
Myosin
|
Inflammation/Immunology
|
|
AX-202 is a human monoclonal antibody (mAb) targeting S100A4. AX-202 has antifibrotic effects in the mouse Tsk-1 model. AX-202 can be used in Plaque psoriasis and Systemic scleroderma research .
|
-
- HY-P991357
-
|
|
PD-1/PD-L1
|
Cancer
|
|
STT-001 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. STT-001 can be used in Solid tumours research .
|
-
- HY-P9927
-
|
AIN457
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .
|
-
- HY-P991411
-
|
ALXN2220
|
Transthyretin (TTR)
|
Cardiovascular Disease
Neurological Disease
|
|
NI-006 (ALXN2220) is a human monoclonal antibody (mAb) targeting Transthyretin/TTR. NI-006 stimulates macrophage-mediated phagocytosis of deposited amyloid fibrils. NI-006 can be used in Cardiomyopathies and Familial amyloid neuropathy research .
|
-
- HY-P99415
-
|
MAA868
|
Factor Xa
|
Cardiovascular Disease
|
|
Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies .
|
-
- HY-P991373
-
|
|
Tau Protein
|
Neurological Disease
|
|
APNmAb005 is a human monoclonal antibody (mAb) targeting MAPT/Tau/PHF-tau. APNmAb005 blocks tau seeding in vitro and rescues neuronal loss in rTG4510 mice. APNmAb005 can be used in Alzheimer’s disease (AD) research .
|
-
- HY-P99770
-
|
514-G3
|
Bacterial
|
Infection
|
|
Omodenbamab is an anti-SpA (Staphylococcal protein A) human monoclonal antibody with a KD value of 0.0467 nM. Omodenbamab circumvents a key S. aureus evasion mechanism by targeting the cell wall moiety Protein A (SpA). Omodenbamab can be used in research of S. aureus bloodstream infection .
|
-
- HY-P99858
-
|
AB154
|
Transmembrane Glycoprotein
|
Cancer
|
|
Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used for studies of non-small cell lung cancer and esophageal cancer .
|
-
- HY-P991128
-
|
|
Transthyretin (TTR)
|
Cardiovascular Disease
Neurological Disease
|
|
Cliramitug is a monoclonal antibody targeting human transthyretin (TTR). Cliramitug binds to TTR to inhibit its amyloid-forming process, exerting activity against amyloid protein formation. Cliramitug is promising for research of diseases related to transthyretin amyloidosis, such as certain neurological and cardiovascular diseases .
|
-
- HY-P99710
-
|
BI 767551; DZIF-10c
|
SARS-CoV
|
Infection
|
|
Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .
|
-
- HY-P991123
-
|
|
Adenylate Cyclase
|
Inflammation/Immunology
|
|
Bocunebart is a humanized monoclonal antibody targeting human adenylate cyclase-activating polypeptide (ADCYAP1). Bocunebart exerts anti-inflammatory activity by specifically binding to ADCYAP1 and inhibiting related inflammatory signaling pathways. Bocunebart is promising for research of inflammation-related diseases .
|
-
- HY-P991426
-
|
|
Transmembrane Glycoprotein
IFNAR
TNF Receptor
|
Cancer
|
|
MB-314 is a human IgG1 monoclonal antibody (mAb) targeting Lewis Y. MB-314 induces enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MB-314 increases the release of IFN-γ, TNF-α, MCP-1, and IL-6. MB-314 can be used in cancer research .
|
-
- HY-P99167
-
|
HCD122
|
TNF Receptor
|
Cancer
|
|
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .
|
-
- HY-P99622
-
|
IMC-20D7S
|
Tyrosinase
|
Cancer
|
|
Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance .
|
-
- HY-P991495
-
|
|
RSV
|
Infection
|
|
VIR-8190 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. VIR-8190 can be used in respiratory syncytial virus (RSV) and metapneumovirus infections research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991346
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
CC-90006 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. CC-90006 can be used in psoriasis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99260
-
|
AMG 655; TRAIL-R2 mAb; human Anti-TNFRSF10B Recombinant antibody
|
TNF Receptor
|
Cancer
|
|
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers.
.
|
-
- HY-P991138
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Firsekibart is an immunoglobulin G4-λ2 monoclonal antibody targeting human interleukin 1β (IL-1β). Firsekibart is promising for research of inflammation-related diseases, such as rheumatoid arthritis and inflammatory bowel disease .
|
-
- HY-P99056
-
|
PF 05082566
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20 + non-Hodgkin lymphomas .
|
-
- HY-P99846
-
|
QAX576
|
Interleukin Related
|
Inflammation/Immunology
|
|
Dectrekumab (QAX576) is a human monoclonal antibody that targets IL-13. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research .
|
-
- HY-P99519
-
|
KPL-716
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) receptor β subunit monoclonal antibody. Vixarelimab inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash .
|
-
- HY-P991161
-
|
|
Complement System
|
Inflammation/Immunology
|
|
Tanruprubart is a monoclonal antibody targeting human complement C1q. Tanruprubart specifically binds to complement C1q, inhibiting the initiation of the classical complement activation pathway and exerting immunosuppressive activity. Tanruprubart is promising for research of autoimmune diseases and inflammation-related diseases .
|
-
- HY-P991367
-
|
|
CD47
|
Cancer
|
|
ES004 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a. ES004 enhances macrophage phagocytosis and induces potent T cell responses to promote tumor killing. ES004 can be used in Solid tumours research .
|
-
- HY-P99399
-
|
RG 6100; RO7105705; MTAU-9937A
|
Tau Protein
|
Neurological Disease
|
|
Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .
|
-
- HY-P99786
-
|
REGN3918
|
Complement System
|
Metabolic Disease
|
|
Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .
|
-
- HY-P99322
-
|
LFG316; Anti-human C5 Recombinant antibody
|
Complement System
|
Inflammation/Immunology
|
|
Tesidolumab (LFG316) is a fully-human IgG1/λ anti-C5 monoclonal antibody of 143 kDa (without glycosylation). Tesidolumab (LFG316) blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex .
|
-
- HY-P99110
-
|
SHP643; DX-2930
|
Kallikrein
|
Inflammation/Immunology
|
|
Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema .
|
-
- HY-P991141
-
|
|
VEGFR
|
Cancer
|
|
Inlecitug is a chimeric monoclonal antibody targeting human KDR (kinase insert domain receptor). Inlecitug specifically binds to KDR, blocking the binding of vascular endothelial growth factor (VEGF) to KDR and inhibiting angiogenesis, thus exerting antitumor activity. Inlecitug is promising for research of cancers .
|
-
- HY-P99156
-
|
BMS-986016
|
LAG-3
|
Cancer
|
|
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer .
|
-
- HY-P99151
-
|
|
ADC Antibody
TNF Receptor
|
Cancer
|
|
Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC50 of 10 nM against human CD30+ cancer cells .
|
-
- HY-P99275
-
|
human Anti-ERBB3 Recombinant antibody
|
EGFR
Akt
ERK
PARP
Survivin
|
Cancer
|
|
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
|
-
- HY-P99114
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .
|
-
- HY-P990764B
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Sigvotatug (Biotinylated) is a biotinylated derivative of Sigvotatug (HY-P990764). Sigvotatug (Biotinylated) is a humanized IgG1 κ monoclonal antibody inhibitor against ITGB6. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991251
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
QX006N is a humanized monoclonal antibody inhibitor targeting human interferon α/β receptor 1 (IFNAR1). QX006N is promising for research of systemic lupus erythematosus (SLE) and other IFNAR1-related autoimmune diseases .
|
-
- HY-P991378
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
MORAb-066 is a human monoclonal antibody (mAb) targeting CD142/F3/TF. MORAb-066 can be used in Breast cancer, Colorectal cancer, Non-small cell lung cancer and Pancreatic cancer research .
|
-
- HY-P991134
-
|
|
IGF-1R
|
Inflammation/Immunology
|
|
Elegrobart is an immunoglobulin G1-κ monoclonal antibody targeting the human insulin-like growth factor 1 receptor (IGF1R). Elegrobart is promising for research of diseases associated with abnormal IGF1R signaling, especially thyroid eye disease .
|
-
- HY-P99450
-
|
IPH 5401; Anti-C5aR1 mAb
|
Complement System
|
Inflammation/Immunology
Cancer
|
|
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .
|
-
- HY-P991352
-
|
|
PD-1/PD-L1
|
Cancer
|
|
SG-001 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. SG-001 can be used in Cervical cancer, Colorectal cancer, Solid tumours and Biliary cancer research .
|
-
- HY-P99556
-
|
AZD8895
|
SARS-CoV
|
Infection
|
|
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .
|
-
- HY-P99376
-
|
OMS 721; Anti-MASP2 Reference antibody (narsoplimab)
|
SARS-CoV
|
Infection
|
|
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 .
|
-
- HY-P991280
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
BMS-981164 is a human IgG1-kappa anti-IL31 monoclonal antibody. The isotype control of BMS-981164 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). BMS-981164 can be used in research related to atopic dermatitis .
|
-
- HY-P991482
-
|
|
Influenza Virus
|
Infection
|
|
ADI-42898 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-42898 binds to the Gn/Gc complex and blocks the cell entry of seven HCPS- and HFRS-associated hantaviruses. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99389
-
|
JNJ-64304500; IPH-2301; NN-8555
|
C-type Lectin-like Receptors (CTLRs)
|
Inflammation/Immunology
|
|
Tesnatilimab (JNJ-64304500) is a human IgG4 monoclonal antibody targeting NKG2D. Tesnatilimab can be studied in research for diseases such as Crohn’s disease (CD) and Inflammatory Bowel Disease (IBD). Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991338
-
|
|
Orexin Receptor (OX Receptor)
|
Cancer
|
|
MEDI-6469 is a human monoclonal antibody (mAb) targeting TNFRSF4/OX40/CD134. MEDI-6469 targets the OX40 receptor on activated T cells to enhance the immune response against cancer cells. .
|
-
- HY-P99754
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Netakimab is an anti-IL-17 IgG1 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99220
-
|
LY2127399
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .
|
-
- HY-P99336
-
|
BI-RR 0001; Anti-human IL6 Recombinant antibody
|
Integrin
|
Neurological Disease
Inflammation/Immunology
|
|
Enlimomab (BI-RR 0001), a murine IgG2a monoclonal antibody to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. Enlimomab has anti-inflammatory effects, and can be used for stroke research .
|
-
- HY-P990033
-
|
CC-95251; BMS-986351
|
CD47
|
Cancer
|
|
Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPα antibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research .
|
-
- HY-152963
-
|
|
Antibody-Drug Conjugates (ADCs)
|
Inflammation/Immunology
Cancer
|
|
Tisotumab vedotin is an antibody drug conjugate (ADC) targeting tissue factor (TF), formed by covalently linking a fully human monoclonal antibody (TF-011) against TF with the microtubule disruptor Monomethyll Auristatin E (MMAE) (HY-15162). Tisotumab vedotin has immunomodulatory and anti-tumor activities, and can be used in the study of advanced or metastatic solid tumors such as cervical cancer .
|
-
- HY-P990031
-
|
M-6223
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function .
|
-
- HY-P991393
-
|
|
Transmembrane Glycoprotein
IFNAR
TNF Receptor
|
Cancer
|
|
ASP8374 is a human IgG4 monoclonal antibody (mAb) targeting TIGIT. ASP8374 increases IL-2 production in Jurkat cells and IFN-γ and TNF-α production in human PBMCs. ASP8374 can be used in advanced solid tumors research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991445
-
|
|
SARS-CoV
|
Infection
|
|
REGN3051 is a human IgG1 monoclonal antibody (mAb) targeting MERS CoV. REGN3051 reduces viral titers in the lungs of mice expressing human DPP4. REGN3051 decreases lung disease severity and viral replication in marmosets inoculated with MERS-CoV. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991458
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
hu3S193 is a human IgG monoclonal antibody (mAb) targeting Lewis Y. hu3S193 has excellent immune effector function (complement-dependent cytotoxicity) (IC50: 1.0 μg/ml) and antibody-dependent cellular cytotoxicity (IC50: 5.0 μg/ml). hu3S193 can be used in small cell lung cancer (SCLC) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991255
-
|
|
IGF-1R
|
Inflammation/Immunology
|
|
VRDN-002 is a human monoclonal antibody (mAb) targeting IGF1R/CD221. VRDN-002 reduces inflammation and proptosis in thyroid eye disease (TED). VPI-2690B can be used in Graves ophthalmopathy research .
|
-
- HY-P99669
-
|
MDX-060
|
TNF Receptor
|
Cancer
|
|
Iratumumab (MDX-060) a human anti-CD30 IgG1κ monoclonal antibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) .
|
-
- HY-P9919
-
|
MEDI 4736
|
PD-1/PD-L1
|
Cancer
|
|
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
|
-
- HY-P991391
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
COM902 is a human IgG4 monoclonal antibody (mAb) targeting TIGIT. COM902 enhances anti-tumor immune responses. COM902 can be used in Multiple myeloma, Solid tumours and Colorectal cancer research. Recommended isotype control: IgG4-lambda .
|
-
- HY-P99541
-
|
anti-hepatitis B; OST 577; SDZ-OST 577
|
HBV
|
Infection
|
|
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research .
|
-
- HY-P991345
-
|
AMP-514
|
PD-1/PD-L1
|
Cancer
|
|
MEDI-0680 (AMP-514) is a human IgG4 monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. MEDI-0680 can be used in Diffuse Large B-Cell Lymphoma (DLBCL) research .
|
-
- HY-P991292
-
|
|
ADC Antibody
|
Cancer
|
|
AB-3A4 is a human IgG1 monoclonal antibody (mAb) targeting KAAG1. AB-3A4 can be used in the study of ovarian cancer, triple-negative breast cancer, and prostate cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991448
-
|
|
Glycoprotein VI
|
Cancer
|
|
MDX-1414 is a human IgG1 monoclonal antibody (mAb) targeting GPC3. MDX-1414 has antitumor activity in the HepG2 xenograft model. MDX-1414 can be used in liver cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991422
-
|
DS9231; TS-23; CSL-301
|
PAI-1
|
Cardiovascular Disease
|
|
Stromab (DS9231; TS-23; CSL-301) is a human IgG1 monoclonal antibody (mAb) targeting Serpin F2. Stromab can be used in schaemic stroke, Pulmonary embolism, Myocardial infarction and Thrombosis research. Recommended isotype control: Human IgG1 lambda, Isotype Control (HY-P99992) .
|
-
- HY-P9920A
-
|
|
VEGFR
|
Cancer
|
|
Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .
|
-
- HY-P991225
-
|
|
Fc Receptor (FcR)
CD20
|
Inflammation/Immunology
Cancer
|
|
BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) .
|
-
- HY-P9933
-
|
APN-311
|
Apoptosis
PERK
mTOR
|
Cancer
|
|
Dinutuximab (APN-311) is a chimeric human-mouse anti-GD2 monoclonal antibody. Dinutuximab can bind to GD2 on the cell surface, triggering antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and promoting tumor regression. Dinutuximab can inhibit the growth, invasion, and migration and induce apoptosis of tumor cells. Dinutuximab can be used in the research of tumors such as neuroblastoma and breast cancer .
|
-
- HY-P99756
-
|
MEDI8897
|
RSV
|
Infection
|
|
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
|
-
- HY-P99191
-
|
NI-0501
|
IFNAR
|
Inflammation/Immunology
|
|
Emapalumab (NI-0501) is a human monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH) .
|
-
- HY-P991413
-
|
|
Trk Receptor
|
Neurological Disease
|
|
ZEB85 is a human monoclonal antibody (mAb) targeting TrkB. ZEB85 activates TrkB and its downstream signaling cascades and increases neuronal activity. ZEB85 prevents β-amyloid toxicity in cultured hippocampal neurons. ZEB85 can be used in Alzheimer's disease (AD) research .
|
-
- HY-P99299
-
|
HGS-ETR 2; ETR2-ST01
|
Apoptosis
|
Cancer
|
|
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .
|
-
- HY-P991329
-
|
|
Complement System
|
Cancer
|
|
ASP-1948 is a human monoclonal antibody (mAb) targeting NRP1/VEGF165R/CD34. ASP-1948 reverses the suppressive effects of regulatory T cells. ASP-1948 can be used in solid tumors research .
|
-
- HY-P99486
-
|
ABT-874
|
Interleukin Related
|
Inflammation/Immunology
|
|
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .
|
-
- HY-P991401
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
GSK2862277 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK2862277 increases neutrophil extracellular trap formation and alveolar macrophage phagocytosis. GSK2862277 can be used in Acute lung injury and Acute Respiratory Distress Syndrome (ARDS) research. Recommended isotype control: VHH-hFc .
|
-
- HY-P99680
-
|
SB-210396; IDEC CE9.1
|
Interleukin Related
|
Cancer
|
|
Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research .
|
-
- HY-P991403
-
|
|
TNF Receptor
|
Cancer
|
|
BC011 is a human monoclonal antibody (mAb) targeting TNFRSF1B. BC011 promotes CD8+T cell proliferation and depletes Treg cells, thereby increasing the proportion of effector T cells in the tumor microenvironment. BC011 can be used in tumor Immunity research.
|
-
- HY-P991330
-
|
|
CD73
|
Cancer
|
|
BMS-986179 is a human monoclonal antibody (mAb) targeting NT5E/CD73. BMS-986179 inhibits CD73 enzymatic activity in tumor vasculature and tumor cells. BMS-986179 can be used in advanced solid tumors research .
|
-
- HY-P99643
-
|
UCB6114
|
Dan family
|
Cancer
|
|
Ginisortamab (UCB6114) is a fully human IgG4P anti Gremlin-1 monoclonal antibody, with mean IC50 values of 8.2 nM and 9 nM against human and mouse gremlin-1, respectivly. Ginisortamab inhibits gremlin-1 antagonism of BMP signaling pathways. Ginisortamab has the potential for the research of gastrointestinal (GI) tumors .
|
-
- HY-P991311
-
|
|
LPL Receptor
Wnt
|
Cancer
|
|
GSK3178022 is a human IgG1 monoclonal antibody (mAb) targeting LRP6. GSK3178022 inhibits the expression of WNT target genes SP5 and AXIN2. GSK3178022 has antitumor activity in the RSPO fusion model of colorectal cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991247
-
|
|
MHC
|
Cancer
|
|
Anti-HLA-A2 (Hu8F4) is a human monoclonal antibody (mAb) targeting HLA-A2. Anti-HLA-A2 (Hu8F4) can be used in Acute myeloid leukaemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99294
-
|
AMG 479; human Anti-IGF1R Recombinant antibody
|
IGF-1R
|
Cancer
|
|
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer .
|
-
- HY-P991144
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lasrekibart is a humanized monoclonal antibody targeting human interleukin 5 (IL-5). Lasrekibart specifically binds to IL-5, blocking the interaction between IL-5 and its receptor, thus exerting immunosuppressive and anti-inflammatory activities. Lasrekibart is promising for research of allergic and inflammatory diseases, such as asthma .
|
-
- HY-P99162
-
|
CIM331
|
Interleukin Related
|
Inflammation/Immunology
|
|
Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD) .
|
-
- HY-P991129
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Crusekitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A). Crusekitug specifically binds to IL-17A, blocking its signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Crusekitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
|
-
- HY-P991397
-
|
|
Tim3
|
Cancer
|
|
Sym023 is a human monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. Sym023 enhances immunostimulatory and anti-tumor activities. Sym023 can be used in Non-small cell lung cancer, Solid tumors and Lymphoma research .
|
-
- HY-P99688
-
|
AL001
|
Neurotensin Receptor
|
Cancer
|
|
Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research .
|
-
- HY-P99913
-
|
|
c-Fms
|
Inflammation/Immunology
Cancer
|
|
Eflapegrastim is a human IgG4 monoclonal antibody, is also a granulocyte colony-stimulating factor (G-CSF). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia .
|
-
- HY-171191
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
c-Met/HGFR
|
Cancer
|
|
REGN5093-M114 is a bispecific antibody-drug conjugate (ADC) that targets two epitopes of the MET receptor tyrosine kinase inhibits the proliferation of NSCLC cells, exhibits antitumor efficacy in mouse models. REGN5093-M114 is composed of the human monoclonal anti-MET antibody Davutamig (HY-P990073) and the tubulin-inhibiting linker-payload (HY-148528) .
|
-
- HY-P99252
-
|
Anti-human CD6 Recombinant antibody
|
CD6
|
Infection
Inflammation/Immunology
|
|
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .
|
-
- HY-P991452
-
|
|
Orexin Receptor (OX Receptor)
|
Cancer
|
|
Anti-CD200R1/OX2R Antibody (I-4P) is a human monoclonal antibody (mAb) targeting CD200R1/OX2R. Anti-CD200R1/OX2R Antibody (I-4P) can be used in solid tumors research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991425
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
AT-1413 is a human monoclonal antibody (mAb) targeting CD43. AT-1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) in melanoma cell lines and acute myeloid leukemia (AML) cells. AT-1413 has antitumor activity in AML mouse models. AT-1413 can be used in Acute myeloid leukaemia, Breast cancer, Malignant melanoma and Myelodysplastic syndromes research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99384
-
|
B-701; MFGR-1877S; RG-7444
|
FGFR
|
Cancer
|
|
Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991142
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
Isuventatug is a monoclonal antibody targeting human MICA (MHC class I chain-related molecule A) and MICB (MHC class I chain-related molecule B). Isuventatug binds to MICA and MICB to regulate the interaction between immune cells and tumor cells, exerting antitumor activity. Isuventatug is promising for research of cancer immunotherapy .
|
-
- HY-P9803
-
|
SARS-80R; SARS antibody-80R
|
SARS-CoV
|
Infection
|
|
Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells .
|
-
- HY-P991395
-
|
|
Tim3
|
Cancer
|
|
TQB2618 is a human IgG4 monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. TQB2618 activates immune cell function and induces significant anti-tumor activity when used in combination with anti-PD-1 agents .
|
-
- HY-P991319
-
|
|
Mucin
|
Cancer
|
|
TAB-004 is a human monoclonal antibody (mAb) targeting MUC1. TAB-004 specifically recognizes tMUC1 in all major subtypes of breast cancer without affecting normal breast epithelial cells. TAB-004 can be used in triple-negative breast cancer (TNBC) research .
|
-
- HY-P99637
-
|
MHAA4549A; RG7745
|
Influenza Virus
|
Infection
|
|
Gedivumab (MHAA4549A; RG7745) is a human monoclonal antibody that targets influenza A virus (IAV) with high specificity and binds to the highly conserved stem region of the IAV haemagglutinin protein, thereby preventing haemagglutinin maturation and blocking haemagglutinin-mediated membrane fusion in the intranucleosome. Gedivumab can be used in IAV infection disease studies .
|
-
- HY-P9805
-
|
MERS-3A1; MERS antibody-3A1
|
SARS-CoV
|
Infection
|
|
Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells.
Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor .
|
-
- HY-P991382
-
|
|
TGF-β Receptor
|
Cancer
|
|
SAR-439459 is a human monoclonal antibody (mAb) targeting TGFB1/TGFβ-1. SAR-439459 blocks TGFβ-mediated pSMAD signaling, and suppression of T cells and NK cells. SAR-439459 has anti-tumor activity .
|
-
- HY-P991201
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
REGN-7257 is a humanized monoclonal antibody targeting IL2RG that effectively blocks signaling of all γ-c cytokines. REGN-7257 can be used in the study of aplastic anemia. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-P99342
-
|
REGN10987
|
SARS-CoV
|
Infection
|
|
Imdevimab (REGN10987) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Imdevimab lacks efficacy against COVID-19 variants. Imdevimab can be used in combination with Casirivimab (HY-P99341), it reduces viral load and improves diseases .
|
-
- HY-P991402
-
|
|
TNF Receptor
|
Cancer
|
|
BI-1910 is a human monoclonal antibody (mAb) targeting TNFRSF1B. BI-1910 enhances T cell activation and induces CD8 T cell-dependent anti-tumor effects. BI-1910 can be used in solid tumors research. Recommended isotype control: Human IgG1 lambda, Isotype Control (HY-P99992) .
|
-
- HY-P9931
-
|
CNTO 1959
|
Interleukin Related
|
Inflammation/Immunology
|
|
Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research .
|
-
- HY-P99385
-
|
ALX-0061
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis .
|
-
- HY-P991114
-
|
|
FLT3
|
Inflammation/Immunology
|
|
Adezkibart is a human monoclonal antibody immunosuppressant targeting the human FMS-like tyrosine kinase 3 ligand (FLT3LG). Adezkibart is found in the Chinese hamster ovary cell line CHO-K1, which binds to FLT3LG to block the relevant signaling pathway, inhibits the immune response, and exerts immunosuppressive activity. Adezkibart is promising for research of immune-related diseases .
|
-
- HY-P991493
-
|
|
RSV
|
Infection
|
|
AR-201 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. AR-201 has anti-respiratory syncytial virus (RSV) activity. AR-201 can be used in lower respiratory tract illness (LRTI) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P991279
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Mik-Beta-1 is a human IgG1-kappa anti-IL2RB monoclonal antibody. The isotype control of Mik-Beta-1 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). Mik-Beta-1 can be used in research related to the prevention of allograft rejection .
|
-
- HY-P990094
-
|
CSL311
|
c-Fms
|
Inflammation/Immunology
|
|
Trabikibart (CSL311), a βc (CSF2RB)-specific, fully human monoclonal antibody, binds to a unique epitope that is specific to the cytokine-binding site of the human βc receptor. Trabikibart has picomolar binding affinity for the human βc receptor. Trabikibart is a potent inhibitor of the combined effects of IL-3, GM-CSF and IL-5 on the survival of eosinophils. Trabikibart has the potential for chronic inflammatory diseases research .
|
-
- HY-P991052
-
|
|
TNF Receptor
|
Cancer
|
|
GSK-3174998 is a humanized IgG1 OX40/TNFRSF4 agonistic monoclonal antibody. GSK-3174998 has the potential for the study of advanced solid tumors. The isotype control for GSK-3174998 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991406
-
|
|
TNF Receptor
|
Cancer
|
|
MK-1248 is a human IgG4 monoclonal antibody (mAb) targeting TNFSF18. MK-1248 enhances the proliferative response of tumor-infiltrating lymphocytes to anti-CD3 stimulation and promotes the production of anti-tumor-associated regulatory cytokines. MK-1248 can be used in solid tumors research .
|
-
- HY-P99344
-
|
Anti-human SARS-CoV-2
|
SARS-CoV
|
Infection
|
|
Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab .
|
-
- HY-P99268
-
|
SAR 256212; MM 121; Anti-human ERBB3/ErbB 3 Recombinant antibody
|
EGFR
Apoptosis
|
Cancer
|
|
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .
|
-
- HY-P991283
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
AMG 317 is a humanized monoclonal anti-CD124/IL4R/IL-4Rα antibody. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002). AMG 317 can be used in research related to asthma .
|
-
- HY-P991256
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
FB-825 is a human monoclonal antibody (mAb) targeting IGHE. FB-825 targets the CεmX domain of membrane IgE (mIgE), resulting in the downregulation of mIgE-positive B cells and the production of IgE. FB-825 can be used in Allergic asthma, Atopic dermatitis, Job syndrome and Allergic rhinitis research .
|
-
- HY-P991400
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
GSK1995057 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK1995057 attenuates pulmonary neutrophilia, inflammatory cytokine release and signs of endothelial injury in bronchoalveolar lavage and serum samples. GSK1995057 can be used in Acute lung injury and Adult respiratory distress syndrome research. Recommended isotype control: dAb (VHH-His) .
|
-
- HY-P991066
-
|
|
nAChR
|
Neurological Disease
|
|
ARGX-119 is a first-in-class humanized agonist monoclonal antibody specific for muscle-specific kinase (MuSK). ARGX-119 can be used for the study of neuromuscular diseases. The isotype control for ARGX-119 can refer to Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
-
- HY-P99345
-
|
TSR-042
|
PD-1/PD-L1
|
Cancer
|
|
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively .
|
-
- HY-P99233
-
|
HuMax-TAC
|
ADC Antibody
Transmembrane Glycoprotein
Interleukin Related
|
Cancer
|
|
Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonal antibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991457
-
|
|
IGF-1R
|
Cancer
|
|
AVE1642 is a human IgG monoclonal antibody (mAb) targeting CD221/IGF1R. AVE1642 delays growth of tumour xenografts and prolongs the survival of tumour-bearing nude mice. AVE1642 can be used in advanced solid tumours research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991149
-
|
|
TNF Receptor
|
Cancer
|
|
Nesfrotamig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2) and human tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Nesfrotamig is promising for research of cancers, especially in ERBB2-positive related tumor diseases, such as breast cancer and gastric cancer .
|
-
- HY-P991492
-
|
|
RSV
|
Infection
|
|
RSM-01 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. RSM-01 has anti-respiratory syncytial virus (RSV) activity. VIR-7229 can be used in lower respiratory tract illness (LRTI) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990015
-
|
VIR-3434
|
HBV
|
Infection
|
|
Tobevibart (VIR-3434) is a human IgG1 lambda monoclonal antibody against hepatitis B virus (HBV) surface antigen (HBsAg). Tobevibart shows potent neutralization against HBsAg from all HBV genotypes in vitro and inhibits viral entry of HBV and hepatitis delta virus (HDV). Recommend Isotype Controls: Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
-
- HY-P9958
-
|
AMG-162
|
NF-κB
Caspase
Apoptosis
RANKL/RANK
|
Endocrinology
Cancer
|
|
Denosumab is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .
|
-
- HY-P991370
-
|
|
STAT
|
Cancer
|
|
SBT-100 is a human monoclonal antibody (mAb) targeting STAT3. SBT-100 inhibits IL-6-mediated P-STAT3 nuclear translocation in HEp-2 and PANC-1 cells. SBT-100 has tumor growth inhibitory effects on MDA-MB-231 .
|
-
- HY-P991151
-
|
|
PD-1/PD-L1
TNF Receptor
|
Cancer
|
|
Opamtistomig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human programmed death ligand 1 (PD-L1), CD274 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Opamtistomig is promising for research of various solid tumors and hematological malignancies .
|
-
- HY-P990078
-
|
LY3372993
|
Amyloid-β
|
Neurological Disease
|
|
Remternetug is a human immunoglobulin G1-kappa, anti-APP (amyloid beta A4 precursor protein) Aβ42 N3pGlu peptide monoclonal antibody. Remternetug recognizes a pyroglutamated form of Aβ. Remternetug results in rapid and robust amyloid plaque reduction. Remternetug can be used for Alzheimer's disease research .
|
-
- HY-P99203
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .
|
-
- HY-P991173
-
|
|
Notch
|
Cancer
|
|
AMG-119 is a humanized IgG1 monoclonal antibody that targets delta-like ligand 3 (DLL3). AMG-119 can be used for the study of relapsed/refractory (R/R) small cell lung cancer (SCLC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99293
-
|
IDEC 114; Anti-human CD80 Recombinant antibody
|
CD28
|
Cancer
|
|
Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen and blocks CD80–CD28 binding. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma .
|
-
- HY-P991380
-
|
|
Transferrin Receptor
|
Neurological Disease
|
|
TXB4 is a brain-permeable human monoclonal antibody (mAb) targeting CD71. TXB4 prevents 6-OHDA-induced death of TH-positive neurons in the SNc in a 6-OHDA mouse model of Parkinson's disease (PD). TXB4 can be used in neurodegenerative diseases, acute brain and spinal cord injury, and depression research .
|
-
- HY-P99552
-
|
IBI-306
|
PCSK9
|
Cardiovascular Disease
|
|
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .
|
-
- HY-P9806
-
|
MERS-D12; MERS antibody-D12
|
SARS-CoV
|
Infection
|
|
Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding .
|
-
- HY-P991464
-
|
|
TNF Receptor
|
Cancer
|
|
IBI37G5 is a human monoclonal antibody (mAb) targeting TNFRSF18/GITR/CD357. IBI37G5 has anti-tumor activity in MC38 and B16F10 mouse tumor models. IBI37G5 can be used in the study of cancer immunity .
|
-
- HY-P99493
-
|
IMGN242; huC242-DM4
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (DM4 (HY-12454)). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
|
-
- HY-P99163
-
|
ABBV-8E12; C2N-8E12
|
Tau Protein
|
Neurological Disease
|
|
Tilavonemab (ABBV-8E12) is a humanized anti-tau monoclonal antibody that binds to amino acids 25-30 near the N-terminus of the tau protein. Tilavonemab can block the ability of human and mouse neurons to uptake tau aggregates. Tilavonemab can be used for research on Alzheimer’s disease and other tauopathies .
|
-
- HY-P991366
-
|
AL008
|
CD47
|
Cancer
|
|
IBI-397 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a . IBI-397 promotes human monocyte-derived dendritic cell-mediated T cell proliferation and increases the expression of CD86 and HLA-DR. IBI-397 has antitumor activity in the mouse MDA-MB-231 tumor model. IBI-397 can be used in Myeloma research .
|
-
- HY-P990093
-
|
CM310
|
Interleukin Related
|
Inflammation/Immunology
|
|
Stapokibart (CM310) is a humanised monoclonal antibody targeting IL-4Rα and efficiently blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart has the capacity to interact with IL-4Rα in humans, cynomolgus monkeys, and rats .
|
-
- HY-P99155
-
|
|
EGFR
|
Cancer
|
|
Zalutumumab is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer .
|
-
- HY-P99962
-
|
BGB-A425
|
Mucin
|
Cancer
|
|
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (KD=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .
|
-
- HY-P99325
-
|
IDEC-131; Anti-human CD40 ligand Recombinant antibody
|
TNF Receptor
|
Inflammation/Immunology
|
|
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease .
|
-
- HY-P99020
-
|
GC1008
|
TGF-beta/Smad
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab improves Bleomycin (HY-108345)-induced acute lung injury. Fresolimumab radiolabeled with 89Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease .
|
-
- HY-P99970
-
|
|
ADC Antibody
|
Cancer
|
|
Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-141600
-
|
BAY 1187982
|
Antibody-Drug Conjugates (ADCs)
FGFR
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer .
|
-
- HY-P991253
-
|
|
IGF-1R
|
Cancer
|
|
BIIB022 is a human IgG4 monoclonal antibody (mAb) targeting IGF1R/CD221. BIIB022 blocks IGF-1 and IGF-2-induced phosphorylation of IGF-1R and downstream substrates. BIIB022 can be used in lung, pancreatic, and colon cancer research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991487
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
LASN01 is a human IgG1 monoclonal antibody (mAb) targeting IL-11RA. LASN01 inhibits IGF-1 and IL-11-induced hyaluronic acid (HA) release and TGFβ-stimulated procollagen in orbital fibroblasts. LASN01 can be used in thyroid eye disease (TED) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991430
-
|
TB-403
|
VEGFR
|
Cancer
|
|
RO5323441 (TB-403) is a human IgG1 monoclonal antibody (mAb) targeting PLGF. RO5323441 inhibits the binding of human PlGF-1 or PlGF-2 to VEGFR-1 (IC50 values are 0.1 and 0.2 nM, respectively). RO5323441 blocks PlGF-induced VEGFR-1 phosphorylation in Flt-1-transfected HEK293 cells. RO5323441 has antitumor activity .
|
-
- HY-P991443
-
|
|
CD73
|
Cancer
|
|
IPH5301 is a human IgG1 monoclonal antibody (mAb) targeting NT5E/CD73. IPH5301 has a functionally silent Fc domain, specifically inhibits soluble and membrane CD73 enzyme activity, and restores the proliferation of immune T cells. IPH5301 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991491
-
|
|
SARS-CoV
Influenza Virus
|
Infection
|
|
VIR-7229 is a human IgG1 monoclonal antibody (mAb) targeting Receptor-Binding Domain, RBD, Spike glycoprotein. VIR-7229 exerts antiviral activity by competing with ACE2 for binding and inducing S1 protein shedding. VIR-7229 can be used in SARS-CoV-2 infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991455
-
|
|
TNF Receptor
|
Cancer
|
|
PTX-35 is a human IgG monoclonal antibody (mAb) targeting TNFRSF25. PTX-35 reduces the suppressive activity of regulatory T cells and enhances CD4+ T cell effector responses in a mouse melanoma model. PTX-35 can be used in Islet cell transplant rejection and Solid tumours research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991481
-
|
|
CCR
|
Cancer
|
|
S-531011 is a human IgG1 monoclonal antibody (mAb) targeting CCR8. S-531011 reduces tumor-infiltrating CCR8+ Tregs and has anti-tumor activity in CT26.WT and EMT6 tumor-bearing mouse tumor models. S-531011 can be used in the study of cancer immunity. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P9958A
-
|
|
RANKL/RANK
Apoptosis
NF-κB
|
Neurological Disease
Endocrinology
Cancer
|
|
Denosumab (anti-TNFSF11) is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .
|
-
- HY-P991427
-
|
|
Apoptosis
|
Cancer
|
|
NP137 is a human IgG1 monoclonal antibody (mAb) targeting Netrin-1. NP137 inhibits the binding of netrin-1 to its receptor UNC5H2 (IC50: 0.5 nM). NP137 activates caspase 3 to induce apoptosis. NP137 can be used in solid tumors and hematologic malignancies research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991070
-
|
|
TNF Receptor
|
Cancer
|
|
ADG-106 is a fully human agonistic monoclonal IgG4 antibody against CD137 (4-1BB). ADG-106 has the mechanism to activate CD137 via strong FcγRIIB-mediated crosslinking while antagonizing CD137 ligands. The isotype control for ADG-106 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991365
-
|
|
Transmembrane Glycoprotein
|
Endocrinology
|
|
DS-1501 is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. DS-1501 inhibits osteoclastogenesis. DS-1501 suppresses the decrease of lumbar spine bone mineral density (BMD) in ovariectomized (OVX) rats. DS-1501 can be used in Osteoporosis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991444
-
|
|
NTPDase
|
Cancer
|
|
IPH5201 is a human IgG1 monoclonal antibody (mAb) targeting ENTPD1/CD39. IPH5201 accumulates immunostimulatory ATP released by tumor cells treated with combination chemotherapy (CT) and reduces immunosuppressive Ado levels in the tumor microenvironment (TME). IPH5201 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99229
-
|
|
ADC Antibody
|
Cancer
|
|
Upifitamab is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC). Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) .
|
-
- HY-164957
-
|
|
Antibody-Drug Conjugates (ADCs)
Integrin
|
Cancer
|
|
SGN-B6A is an ADC, which targets integrin beta-6 (ITGB6) through human IgG1 monoclonal antibody Sigvotatug (HY-P990764), and exhibits cytotoxicity against multiple integrin beta-6-positive cancer cell through mitotic inhibitor MMAE (HY-15162) .
|
-
- HY-P99190
-
|
BMS-936557; MDX-1100
|
CXCR
|
Inflammation/Immunology
|
|
Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease .
|
-
- HY-P9919A
-
|
MEDI 4736 (anti-PD-L1)
|
PD-1/PD-L1
|
Cancer
|
|
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity .
|
-
- HY-P9949
-
|
Sch 55700
|
Interleukin Related
|
Inflammation/Immunology
|
|
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively .
|
-
- HY-P99810
-
|
AVTX-002; AEVI 002; SAR 252067; CERC-002; MDGN-002
|
SARS-CoV
|
Cardiovascular Disease
|
|
Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies .
|
-
- HY-P99371
-
|
AK002; Antolimab
|
Apoptosis
|
Inflammation/Immunology
|
|
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
|
-
- HY-P991423
-
|
21H3RK
|
Notch
|
Cancer
|
|
MEDI0639 (21H3RK) is a human monoclonal antibody (mAb) targeting DLL4. MEDI0639 inhibits Notch1 binding to Dll4. MEDI0639 reverses Notch1-mediated growth inhibition of human umbilical vein endothelial cells in vitro. MEDI0639 promotes human angiogenesis and reduces the number of vessels covered by smooth muscle actin-positive mural cells. MEDI0639 can be used in Small cell lung cancer and solid tumors research .
|
-
- HY-P99414
-
|
AMG 557
|
Transmembrane Glycoprotein
Interleukin Related
|
Inflammation/Immunology
|
|
Prezalumab (AMG 557) is a humanized IgG2 monoclonal antibody targeting ICOSL. Prezalumab inhibits T cell activation and related immune responses by binding to ICOSL and blocking the interaction between ICOS and ICOSL. Prezalumab can be used in the research of autoimmune diseases and inflammatory diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) .
|
-
- HY-P99055
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .
|
-
- HY-P99155A
-
|
|
EGFR
|
Cancer
|
|
Zalutumumab (powder) is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab (powder) binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab (powder) binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab (powder) can be used for the research of cancer .
|
-
- HY-P99248
-
|
Risankizumab rzaa; BI 655066
|
Interleukin Related
|
Inflammation/Immunology
|
|
Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis .
|
-
- HY-P991146
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lecankitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A) and interleukin 17F (IL-17F). Lecankitug specifically binds to IL-17A and IL-17F, blocking their signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Lecankitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
|
-
- HY-P99492
-
|
SB-408075; huC242-DM1
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
|
-
- HY-P9984
-
|
rhuMAb Beta7; RG7413; PRO145223
|
Integrin
|
Cancer
|
|
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .
|
-
- HY-P991381
-
|
PPMX-T003
|
Transferrin Receptor
Reactive Oxygen Species (ROS)
Ferroptosis
|
Cancer
|
|
TXB4 (PPMX-T003) is a human monoclonal antibody (mAb) targeting CD71. JST-TfR09 can induce ferroptosis by reducing ferritin levels in ATLL cell lines, increasing the generation of ferrous iron and reactive oxygen species (ROS), and inducing lipid peroxidation via malondialdehyde. JST-TfR09 can be used in leukemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-145644
-
|
C-135-LS; BMS-986414
|
SARS-CoV
|
Infection
Cancer
|
|
Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .
|
-
- HY-P99189
-
|
IMC-A12; NSC742460
|
IGF-1R
|
Cancer
|
|
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer .
|
-
- HY-P99551
-
|
KBSA301; AR-301
|
Antibiotic
|
Infection
|
|
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent .
|
-
- HY-P9961
-
|
|
CD20
|
Cancer
|
|
Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL) .
|
-
- HY-P99361
-
|
PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference antibody (enavatuzumab)
|
TNF Receptor
|
Cancer
|
|
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .
|
-
- HY-P99737
-
|
LY3074828
|
Interleukin Related
|
Inflammation/Immunology
|
|
Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease .
|
-
- HY-P99583
-
|
MEDI4893
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .
|
-
- HY-P991354
-
|
|
PD-1/PD-L1
|
Cancer
|
|
GR-1405 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. GR-1405 enhances cytotoxic T lymphocyte (CTL)-mediated antitumor immune responses against PD-L1-expressing tumor cells. GR-1405 can be used in Lymphoma and Solid tumours research .
|
-
- HY-P99340
-
|
VIR 7831
|
SARS-CoV
|
Infection
Cancer
|
|
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
|
-
- HY-P991353
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Sym-021 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. Sym-021 blocks the binding of PD-L1 and PD-L2 ligands, inducing the secretion of interferon IFN-γ and IL-2 and the proliferation of T cells. Sym-021 has anti-tumor activity in PDX mouse models .
|
-
- HY-P991441
-
|
|
TREM receptor
Apoptosis
|
Neurological Disease
|
|
VGL101 is a human IgG1 monoclonal antibody (mAb) targeting TREM-2. VGL101 is a pSYK agonist (EC50: 0.77 nM). VGL101 restores the survival ability of microglia and monocyte-derived macrophages under ALSP pathological conditions, inhibits apoptosis, and promotes the restoration of cell morphology to a state similar to that of normal activated CSF1R. VGL101 can be used in Leukoencephalopathies research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991424
-
|
|
Interleukin Related
STAT
|
Inflammation/Immunology
|
|
GSK2618960 is a human monoclonal antibody (mAb) targeting IL-7Ra/CD127. GSK2618960 inhibits IL-7-induced STAT5 phosphorylation. GSK2618960 enhances CD4 T cell proliferation response and increases CD83, CD86, and CD209 expression in PBMCs. GSK2618960 can be used in Multiple sclerosis and Sjogren's syndrome research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991245
-
|
|
EGFR
|
Cancer
|
|
Anti-ERBB3/HER3 (SGP1) is a human monoclonal antibody (mAb) targeting ERBB3/HER3. Anti-ERBB3/HER3 (SGP1) inhibits Neuregulin stimulated growth of cultured breast cancer cells. Anti-ERBB3/HER3 (SGP1) can be used in breast cancer research .
|
-
- HY-P99410
-
|
AMG 714; PRV-015
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD) .
|
-
- HY-P99165
-
|
|
IGF-1R
TSH Receptor
|
Endocrinology
|
|
Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research .
|
-
- HY-P99111
-
|
CNTO-148
|
TNF Receptor
Apoptosis
Interleukin Related
Caspase
|
Inflammation/Immunology
Cancer
|
|
Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research .
|
-
- HY-P99613
-
|
MK-4280
|
LAG-3
|
Cancer
|
|
Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research in combination with the PD-L1 inhibitor Pembrolizumab (HY-P9902). Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P99341
-
|
REGN10933
|
SARS-CoV
|
Infection
|
|
Casirivimab (REGN10933) is a human monoclonal antibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms .
|
-
- HY-P991318
-
|
|
Mucin
|
Cancer
|
|
AR20.5 is a human monoclonal antibody (mAb) targeting MUC1. AR20.5 increases the number of activated CD8 T cells, CD3+CD4−CD8−(DN) T cells, and mature dendritic cells in pancreatic tumor-bearing mice. AR20.5 can be used in anti-pancreatic cancer immunity research .
|
-
- HY-P991067
-
|
KP-104
|
Complement System
|
Inflammation/Immunology
|
|
Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonal antibody directed against terminal complement protein C5 fused to the complement factor H 1-5 domain (FH1-5). Vensobafusp alfa shows anti-inflammatory and immunomodulatory activities. The isotype control for Vensobafusp alfa can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) . .
|
-
- HY-P99109
-
|
GLS-010; AB-122; WBP-3055
|
PD-1/PD-L1
|
Cancer
|
|
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .
|
-
- HY-P991364
-
|
BSI-060T
|
Transmembrane Glycoprotein
|
Cancer
|
|
PYX-106 (BSI-060T) is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. PYX-106 reverses Siglec-15-mediated immunosuppression and enhances T-cell proliferation. PYX-106 induces significantly increased levels of IFNγ and TNFα in T cells. PYX-106 can be used in cancer immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990090
-
|
CBP-201
|
Interleukin Related
|
Inflammation/Immunology
|
|
Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research .
|
-
- HY-P991200
-
|
|
Claudin
HCV
|
Infection
|
|
OM-7D3-B3 is a monoclonal antibody targeting human claudin-1 (CLDN1) (Kd = 4 nM). OM-7D3-B3 blocks the process in which CLDN1 is involved in the entry of hepatitis C virus (HCV) into cells. OM-7D3-B3 is promising for research of HCV infection .
|
-
- HY-P991408
-
|
|
TNF Receptor
Interleukin Related
IFNAR
|
Inflammation/Immunology
|
|
DLX-105 is a human monoclonal antibody (mAb) targeting TNFSF2/TNFa. DLX-105 reduces skin epidermal thickness and the expression of K16 and Ki67. DLX-105 down-regulates the mRNA levels of IL-17, TNF-α, IL-23p19, IL-12p40, and IFN-γ. DLX-105 can be used in psoriasis research .
|
-
- HY-P991432
-
|
|
TNF Receptor
NF-κB
c-Myc
|
Cancer
|
|
VTX-0811 is a human IgG4 monoclonal antibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma .
|
-
- HY-P991310
-
|
LT3015; LT-3000
|
LPL Receptor
|
Neurological Disease
Cancer
|
|
Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991328
-
|
|
Notch
|
Cancer
|
|
MAb604.107 is a human monoclonal antibody (mAb) targeting NOTCH1. MAb604.107 inhibits the proliferation and CD34/CD44 expression of primary T-ALL cells. MAb604.107 has anti-tumor activity in four tumor xenograft mouse models: MDA-MB-231, HCC-1806, BT-474, and HCT-116. MAb604.107 can be used in T acute lymphoblastic leukemia research .
|
-
- HY-P991307
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
BND-35 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. BND-35 blocks the interaction of ILT3 with APOE and fibronectin, enhances the pro-inflammatory activity of various myeloid cells, and reverses ILT3-mediated immunosuppression of T cells by various suppressive myeloid cells. BND-35 has anti-tumor activity in the hILT3 transgenic mouse tumor model .
|
-
- HY-P99781
-
|
MLN-1202
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab can also improve synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P9930
-
|
AMG 145
|
NF-κB
Ser/Thr Protease
Toll-like Receptor (TLR)
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .
|
-
- HY-P99620
-
|
CT-P22; CT120
|
Influenza Virus
|
Infection
|
|
Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice .
|
-
- HY-P991223
-
|
|
Transmembrane Glycoprotein
TNF Receptor
|
Cancer
|
|
NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors .
|
-
- HY-P991316
-
|
DX-2400; DX-2410
|
MMP
TGF-β Receptor
TGF-beta/Smad
NO Synthase
|
Cancer
|
|
KD014 (DX-2400) is a human monoclonal antibody (mAb) targeting MMP14 (Ki: 0.9 nM). KD014 inhibits TGFβ and SMAD2/3 activity, increases macrophage numbers and iNOS expression, and shifts macrophage phenotype toward anti-tumor M1-like. KD014 has anti-tumor activity in three different tumor models (MDA-MB-231, MDA-MB-435, and PC3). KD014 can be used in breast cancer research .
|
-
- HY-P9928
-
|
REGN 727; SAR 236553
|
PCSK9
NOD-like Receptor (NLR)
Keap1-Nrf2
HMG Family
NF-κB
CX3CR1
|
Cardiovascular Disease
Cancer
|
|
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation .
|
-
- HY-P99315
-
|
BG 9588; Anti-human CD40L Recombinant antibody; Hu5c8
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99008
-
|
IC14
|
Toll-like Receptor (TLR)
|
Infection
Neurological Disease
Inflammation/Immunology
|
|
Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury .
|
-
- HY-P991358
-
|
LFA-102; X213
|
Estrogen Receptor/ERR
|
Cancer
|
|
XOMA-213 (LFA-102; X213) is a human monoclonal antibody (mAb) targeting PRLR/Prolactin Receptor. XOMA-213 inhibits hPRL-dependent growth of BaF3/hPRLR cells (EC50: 0.5 μg/mL). XOMA-213 inhibits PRLR signaling and tumor growth in the Nb2-11-luc xenograft mouse model and the DMBA-induced rat breast cancer model. XOMA-213 can be used in Breast cancer, Hyperprolactinaemia and Prostate cancer research .
|
-
- HY-P99359
-
|
ABT-555; AE12-1Y-QL; Anti-RGMA Reference antibody (elezanumab)
|
TGF-beta/Smad
|
Metabolic Disease
|
|
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism .
|
-
- HY-P991356
-
|
LAE-005
|
PD-1/PD-L1
|
Cancer
|
|
FAZ-053 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. FAZ-053 inhibits the interaction of PD-L1 with PD-1 and B7-1 on monocytes, dendritic cells, and B cells. FAZ-053 enhances interleukin 2 production. FAZ-053 can be used in advanced alveolar soft tissue sarcoma (ASPS), chordoma, and triple-negative breast cancer research .
|
-
- HY-P991243
-
|
|
EGFR
PI3K
Akt
|
Cancer
|
|
MP-RM-1 is a selective murine monoclonal antibody inhibitor targeting human epidermal growth factor receptor 3 (ErbB-3). MP-RM-1 blocks the activation of ErbB-3 induced by neuregulin 1 (NRG-1β) and promotes the internalization and degradation of ErbB-3, inhibiting downstream signaling pathways such as PI3K-Akt. MP-RM-1 is promising for research of ErbB-3 highly expressed solid tumors such as breast cancer, melanoma, and prostate cancer .
|
-
- HY-P991419
-
|
|
VEGFR
|
Cancer
|
|
MSB-0254 is a human monoclonal antibody (mAb) targeting VEGFR2/KDR/CD309. MSB-0254 inhibits the invasion, migration, and vascular mimetic (VM) formation of U251 and primary glioma cells. MSB-0254 inhibits the growth of U251 and GL261 cell transplanted tumors. MSB-0254 reduces the expression of CD34, VEGFR2, Ki67, MMP2, MMP9, and CD34/PAS. MSB-0254 can be used in advanced solid tumors research .
|
-
- HY-P991198
-
|
|
Tim3
|
Cancer
|
|
M6903 is a humanized monoclonal IgG2 antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) (KD for human TIM-3 is 2.3 nM). M6903 binds to TIM-3, blocking the binding of TIM-3 to phosphatidylserine (PtdSer), carcinoembryonic antigen cell adhesion-related molecule 1 (CEACAM1), and galectin 9 (Gal-9), thus relieving TIM-3-mediated T cell inhibition and exerting the activities of activating antigen-specific T cells and enhancing anti-tumor immunity. M6903 is promising for research of cancers .
|
-
- HY-P990091
-
|
SAR 445088
|
Complement System
|
Inflammation/Immunology
|
|
Riliprubart (SAR 445088) is an anti-C1s humanized IgG4 monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a. Riliprubart can be used to study complement-mediated diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P99152
-
|
Muromanab-CD3
|
CD3
Interleukin Related
IFNAR
|
Inflammation/Immunology
Cancer
|
|
Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonal antibody targeting the CD3 antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate T cells. Muromonab blocks the function of T cell receptors to recognize foreign antigens and inhibits T cell-mediated immune responses, including cell-mediated lymphocyte lysis and T cell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients .
|
-
- HY-P99444
-
|
MSTT 1041A; RG 6149
|
Interleukin Related
MDM-2/p53
NF-κB
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research .
|
-
- HY-P99496
-
|
RPC 4046; ABT 308; CC-93538
|
Interleukin Related
|
Inflammation/Immunology
|
|
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .
|
-
- HY-P99941
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .
|
-
- HY-P99488
-
|
JSP-191; AMG-191
|
c-Kit
|
Inflammation/Immunology
Cancer
|
|
Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonal antibody that binds human CD117 (c-Kit). Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema .
|
-
- HY-P9928A
-
|
REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)
|
PCSK9
NOD-like Receptor (NLR)
Keap1-Nrf2
HMG Family
NF-κB
CX3CR1
|
Cardiovascular Disease
Cancer
|
|
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation .
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P3203A
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
DSTYSLSSTLTLSK TFA is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
|
-
- HY-P3203
-
-
- HY-P4025
-
|
|
HIV
|
Others
|
|
ELDKWA is the highly conserved amino acids on the ecto-domain of gp41. ELDKWA acts as the epitope of a neutralizing monoclonal antibody 2F5 (mAb 2F5) directed against human immunodeficiency virus type 1 .
|
-
- HY-K0213
-
1 Publications Verification
|
|
MCE Protein A Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein A, effectively purifies mammalian monoclonal and polyclonal antibodies, such as human IgG, IgE, IgM.
|
-
- HY-K0214
-
2 Publications Verification
|
|
MCE Protein G Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein G, effectively purifies mammalian monoclonal and polyclonal antibodies, such as human IgG3 and rat IgG2a.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99242
-
-
- HY-P99278
-
|
MT 201; Anti-human EPCAM Recombinant antibody
|
Inhibitory Antibodies
|
Cancer
|
|
Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status .
|
-
- HY-P99246
-
-
- HY-P9938
-
|
|
CGRP Receptor
|
Others
|
|
Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene–related peptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine .
|
-
- HY-P99514
-
|
AGEN1884
|
CTLA-4
|
Cancer
|
|
Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling .
|
-
- HY-P99631
-
|
CSL312
|
Factor Xa
|
Cardiovascular Disease
|
|
Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research .
|
-
- HY-P9916
-
|
Anti-human IL6Rα, human antibody
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Sarilumab (Anti-Human IL6Rα, Human Antibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a interleukin-6 (IL-6) receptor antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6, resulting in reduced inflammation. Sarilumab can be used for the research of Rheumatoid arthritis .
|
-
- HY-P99632
-
|
REGN 2477
|
TGF-β Receptor
|
Inflammation/Immunology
|
|
Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research .
|
-
- HY-P99040
-
|
JNJ-61610588; CI-8993; VSTB112
|
VISTA
|
Cancer
|
|
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab can be used in colorectal cancer research .
|
-
- HY-P99474
-
|
CAT 213; iCo-008
|
CCR
|
Inflammation/Immunology
|
|
Bertilimumab (CAT 213; iCo-008) is a human monoclonal antibody targeting eotaxin-1 (CCL11). Bertilimumab has the potential for allergic disorders research .
|
-
- HY-P9967
-
|
BIIB037
|
Amyloid-β
|
Neurological Disease
|
|
Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research .
|
-
- HY-P99039
-
|
MEDI9447
|
CD73
|
Cancer
|
|
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity .
|
-
- HY-P99424
-
|
RG 7624; RO 5553110; NI-1401
|
Interleukin Related
|
Inflammation/Immunology
|
|
Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities .
|
-
- HY-108810
-
|
Ilaris; ACZ 885
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin .
|
-
- HY-P9974
-
|
OMP-18R5
|
Wnt
|
Cancer
|
|
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .
|
-
- HY-P99041
-
|
ABX-EGF
|
EGFR
|
Cancer
|
|
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer .
|
-
- HY-P99041B
-
|
ABX-EGF (powder)
|
EGFR
|
Cancer
|
|
Panitumumab (ABX-EGF) (powder) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (powder) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (powder) can be used in the research of cancers, such as colon cancer .
|
-
- HY-P99184
-
|
|
Integrin
|
Infection
Inflammation/Immunology
Cancer
|
|
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .
|
-
- HY-P99041A
-
|
|
EGFR
|
Cancer
|
|
Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer .
|
-
- HY-P9957
-
|
ABthrax
|
Bacterial
|
Infection
|
|
Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research .
|
-
- HY-P99232
-
|
5F9 monoclonal antibody
|
Guanylate Cyclase
|
Cancer
|
|
Indusatumab (5F9 Monoclonal antibody) is an anti-human GUCY2C (Guanylate cyclase 2C) monoclonal antibody .
|
-
- HY-P99001
-
-
- HY-P991206
-
-
- HY-P99002
-
-
- HY-P99509
-
-
- HY-P99003
-
-
- HY-P991451
-
|
SGN-ALPV antibody
|
Phosphatase
|
Cancer
|
|
Anti-ALPP Antibody (SGN-ALPV antibody) is a human monoclonal antibody (mAb) targeting ALPP. Anti-ALPP Antibody can be used in solid tumors research .
|
-
- HY-P99324
-
|
Anti-human EGFR Recombinant antibody
|
EGFR
Apoptosis
|
Cancer
|
|
Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonal antibody against EGFR. Tomuzotuximab has anticancer effects .
|
-
- HY-P99271
-
|
Anti-human F3 Recombinant antibody
|
ADC Antibody
|
Cancer
|
|
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab targets tissue factor (TF). Tisotumab can be used for the research of solid tumors .
|
-
- HY-P99526
-
-
- HY-P99447
-
|
|
Bacterial
|
Infection
|
|
Atidortoxumab is a human IgG1κ monoclonal antibody that targets Staph aureus alpha toxin .
|
-
- HY-P9908
-
-
- HY-P991120
-
|
|
TNF Receptor
|
Cancer
|
|
Balertatug is a human IgG1K antibody targeting CD70. The corresponding isotype control is: Human lgG1 kappa, lsotype Control (HY-P99001) .
|
-
- HY-P991486
-
-
- HY-P991207
-
-
- HY-P99304
-
|
Anti-human ERBB3 Recombinant antibody
|
EGFR
|
Cancer
|
|
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody that can be used for the research of cancer .
|
-
- HY-P990727
-
-
- HY-P991379
-
-
- HY-P99457
-
-
- HY-P990096
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Human IgG1 lambda2, Isotype Control is a human monoclonal antibody that is the isotype control of human IgG1κ antibody. Isotype control antibodies can help remove non-specific signals from experimental results and assess the accuracy and reliability of the experiment .
|
-
- HY-P991191
-
-
- HY-P99453
-
|
|
ADC Antibody
|
Cancer
|
|
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .
|
-
- HY-P9909
-
-
- HY-P991299
-
|
|
LAG-3
|
Cancer
|
|
ENUM006 is a human monoclonal antibody (mAb) targeting CD223/LAG3 .
|
-
- HY-P99347
-
-
- HY-P991298
-
|
|
LAG-3
|
Cancer
|
|
DNV-3 is a human monoclonal antibody (mAb) targeting CD223/LAG3 .
|
-
- HY-P99867
-
|
MEDI 573
|
IGF-1R
|
Others
|
|
Dusigitumab (MEDI 573) is a human IgG2λ monoclonal antibody that specifically targets IGF2 and IGF1 .
|
-
- HY-P991360
-
|
MLN2704 antibody
|
PSMA
|
Cancer
|
|
MLN 591 is a human monoclonal antibody (mAb) targeting PSMA. MLN 591 can be used in Prostate cancer research .
|
-
- HY-P991343
-
|
ALD309
|
PCSK9
|
Endocrinology
|
|
ALD306 is a human monoclonal antibody (mAb) targeting PCSK9. ALD306 can be used in Hypercholesterolaemia research .
|
-
- HY-P99211
-
|
ChAglyCD3; TRX 4
|
CD3
|
Metabolic Disease
|
|
Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes .
|
- HY-P99200
-
- HY-108730A
-
- HY-P991204
-
|
ARX517 antibody
|
PSMA
|
Cancer
|
|
Anti-PSMA Antibody is a humanized IgG1 monoclonal antibody that targets PSMA. Anti-PSMA Antibody is the antibody part of the ADC molecule ARX517. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P9981
-
|
XmAb5574; MOR00208; Tafasitamab-cxix; MOR-208
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19 .
|
- HY-P991386
-
- HY-P990753
-
- HY-P991383
-
- HY-P99616
-
|
MOR-202
|
CD38
|
Cancer
|
|
Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research .
|
- HY-P99305
-
- HY-P9964
-
|
|
EGFR
|
Cancer
|
|
Necitumumab is a human IgG monoclonal antibody directed against EGFR. Necitumumab can be used for research of NSCLC, colorectal cancer, etc .
|
- HY-P991325
-
- HY-P990047
-
|
AMG133 antibody
|
GLP Receptor
|
Metabolic Disease
|
|
Maridebart is a human immunoglobulin G1-kappa, anti-GIPR (gastric inhibitory polypeptide receptor) monoclonal antibody .
|
- HY-P99785
-
|
HLX20
|
PD-1/PD-L1
|
Cancer
|
|
Opucolimab is an anti-PD-L1 recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors .
|
- HY-P99604
-
|
AZD-1061; COV2-2130
|
SARS-CoV
|
Infection
|
|
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .
|
- HY-P991177
-
|
|
c-Met/HGFR
|
Cancer
|
|
Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonal antibody that targets c-Met. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991295
-
- HY-P991390
-
- HY-P99408
-
- HY-P99851
-
|
SPECIFID
|
Inhibitory Antibodies
|
Cancer
|
|
Detumomab is a mouse monoclonal antibody targeting human B-cell lymphoma. Detumomab can be used in the research of cancers such as non-Hodgkin's lymphoma (NHL).
|
- HY-P990074
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Enlonstobart is a human immunoglobulin G4-kappa, anti-PDCD1 monoclonal antibody. Enlonstobart is an immunostimulant and antineoplastic .
|
- HY-P991389
-
- HY-P991429
-
|
|
VEGFR
|
Metabolic Disease
|
|
THR-317 is a human monoclonal antibody (mAb) targeting PLGF. THR-317 can be used in Diabetic retinopathy research .
|
- HY-P991312
-
- HY-P991163
-
|
|
CD3
Claudin
|
Cancer
|
|
Tixentamig is a bispecific monoclonal antibody targeting human CD3 ε and CLDN18 (claudin 18). Tixentamig is promising for research of cancers .
|
- HY-P99017
-
- HY-P991371
-
|
PF-06664178 antibody; RN926
|
TROP2
|
Cancer
|
|
PF-06478924 (PF-06664178 antibody; RN926) is a human monoclonal antibody (mAb) targeting TROP2. PF-06478924 can be used in the study of advanced and metastatic solid tumors .
|
- HY-P990772
-
- HY-P991165
-
|
|
Fc Receptor (FcR)
|
Others
|
|
Trovostobart is an anti-VSIR human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990732
-
- HY-P990734
-
- HY-P99195
-
|
|
Trk Receptor
|
Inflammation/Immunology
|
|
Fasinumab (Anti-Human NGF) is a human IgG4 monoclonal antibody to nerve growth factor (NGF). Fasinumab can be used in acute sciatica and knee osteoarthritis (OA) studies .
|
- HY-P990746
-
- HY-P990754
-
|
|
c-Kit
|
Inflammation/Immunology
|
|
Opelkibart is an anti-KIT human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990749
-
- HY-P991405
-
|
|
TNF Receptor
|
Cancer
|
|
EU-102 is a human monoclonal antibody (mAb) targeting TNFSF18. EU-102 can be used in solid tumors research .
|
- HY-P991339
-
- HY-P99356
-
|
BIIB054; Anti-Alpha-synuclein Reference antibody (cinpanemab)
|
α-synuclein
|
Neurological Disease
|
|
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease .
|
- HY-P99533
-
|
SRF-231; SRF231
|
CD47
Interleukin Related
|
Cancer
|
|
Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction .
|
- HY-P99393
-
|
MEDI 0562; Tavolimab
|
TNF Receptor
|
Cancer
|
|
Tavolixizumab (MEDI 0562; Tavolimab) is a human monoclonal antibody to TNFRSF4 (TNF receptor superfamily member 4) for use in cancer immunology research .
|
- HY-P991418
-
|
|
VEGFR
|
Others
|
|
MW02 is a human monoclonal antibody (mAb) targeting VEGFA. MW02 can be used in Wet age-related macular degeneration research .
|
- HY-P991361
-
- HY-P991410
-
|
MEDI0641 antibody
|
Wnt
|
Cancer
|
|
5T4_0108 (MEDI0641 antibody) is a human monoclonal antibody (mAb) targeting TPBG. 5T4_0108 can be used in breast and prostate cancer research .
|
- HY-P991182
-
|
|
CCR
|
Inflammation/Immunology
|
|
Anti-CCR8 Antibody (10A11) is a humanized IgG1 monoclonal antibody that targets CCR8. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99214
-
|
KBPA101
|
Bacterial
|
Infection
|
|
Panobacumab (KBPA101) is a fully human IgM/κ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of P. aeruginosa .
|
- HY-P990100
-
- HY-P99515
-
- HY-P991375
-
|
|
Tau Protein
|
Neurological Disease
|
|
E2814 is a human monoclonal antibody (mAb) targeting MAPT/Tau. E2814 can be used for passive immunity research in Alzheimer's disease (AD) .
|
- HY-P99160
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy .
|
- HY-P991288
-
- HY-P991376
-
|
|
Tau Protein
|
Neurological Disease
|
|
BIIB076 is a human monoclonal antibody (mAb) targeting PHF-tau. BIIB076 can be used for passive immunity research in Alzheimer's disease (AD) .
|
- HY-P99745
-
- HY-P99508
-
|
IBI939
|
Inhibitory Antibodies
|
Cancer
|
|
Tamgiblimab (IBI939) is a fully human monoclonal antibody targeting T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT). Tamgiblimab has anticancer effects .
|
- HY-P991488
-
- HY-P99617
-
|
REGN3767
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity .
|
- HY-P990080
-
|
|
CTLA-4
|
Cancer
|
|
Sovipostobart is an immunoglobulin G1-kappa, anti-CTLA-4 human monoclonal antibody with cleavable prodomain. Sovipostobart is an immunostimulant and antineoplastic .
|
- HY-P991409
-
- HY-P991290
-
- HY-P991435
-
- HY-P991387
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
AGEN1307 is a human monoclonal antibody (mAb) targeting TIGIT. AGEN1307 has an active FcγR binding region and enhances antibody-dependent cellular cytotoxicity (ADCC). AGEN1307 can be used in cancer research .
|
- HY-P991042
-
|
|
IGF-1R
|
Cancer
|
|
Anti-IGFBP2 Antibody (M14) is an human anti-IGFBP2 monoclonal inhibitory antibody, which binds IGFBP2 with high affinity and blocks its binding with IGF1. Anti-IGFBP2 Antibody (M14) inhibits human endothelial cell recruitment, thus blocks the tumor progression of human metastatic cancer .
|
- HY-P990781
-
|
SM03
|
CD22
|
Inflammation/Immunology
|
|
Suciraslimab is an anti-CD22 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990774
-
- HY-P990686
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ispectamab is an anti-TNFRSF17 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990697
-
|
ARX-788
|
EGFR
|
Inflammation/Immunology
|
|
Anvatabart is an anti-ERBB2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990728
-
|
|
CD74
|
Inflammation/Immunology
|
|
Bezetabart is an anti-CD74 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990760
-
- HY-P990729
-
|
|
CD19
|
Inflammation/Immunology
|
|
Budoprutug is an anti-CD19 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990764
-
|
SGN-B6A antibody
|
Integrin
|
Inflammation/Immunology
|
|
Sigvotatug is an anti-ITGB6 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991340
-
|
|
PAI-1
|
Cardiovascular Disease
|
|
CT140 is a human IgG4 monoclonal antibody (mAb) targeting PAI-1. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990747
-
|
|
CD38
|
Inflammation/Immunology
|
|
Lumrotatug is an anti-CD38 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990739
-
|
|
CTLA-4
|
Inflammation/Immunology
|
|
Evalstotug is an anti-CTLA4 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990744
-
- HY-P991166
-
|
|
Mucin
|
Others
|
|
Ubletamig is an anti-MUC16 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
- HY-P991115
-
|
|
Trk Receptor
|
Others
|
|
Amdokitug is an anti-MUSK human IgG1 λ monoclonal antibody. Recommend Isotype Controls: Human IgG1 Lambda2, Isotype Control (HY-P990096) .
|
- HY-P990762
-
- HY-P990767
-
- HY-P990687
-
- HY-P991117
-
|
|
Factor Xa
|
Cardiovascular Disease
|
|
Amrecibart is an anti-coagulation factor 11 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
- HY-P990712
-
|
RZ-358; XOMA 358
|
Insulin Receptor
|
Inflammation/Immunology
|
|
Ersodetug is an anti-INSR (insulin receptor) human IgG2 κ monoclonal antibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P991164
-
|
|
Antifolate
|
Inflammation/Immunology
|
|
Torvutatug is an anti-FOLR1 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990775
-
|
|
CTLA-4
|
Inflammation/Immunology
|
|
Vilastobart is an anti-CTLA4 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99274
-
|
BI 836845; Anti-human IGF1 and IGF2 Recombinant antibody
|
IGF-1R
|
Cancer
|
|
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation .
|
- HY-P991175
-
- HY-P99332
-
|
Anti-human CD3E Recombinant antibody; HuM291
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .
|
- HY-P991480
-
- HY-P99646
-
|
MEDI6570
|
LOX-1
|
Metabolic Disease
|
|
Golocdacimab (MEDI6570) is a fully human anti-LOX-1 monoclonal antibody. Golocdacimab (MEDI6570) has the potential for the research of type 2 diabetes .
|
- HY-P991412
-
- HY-P991437
-
- HY-P9927A
-
- HY-P99199
-
|
NI-0401
|
CD3
|
Inflammation/Immunology
|
|
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .
|
- HY-P991196
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-CD24 Antibody (SWA11) is a human IgG1 monoclonal antibody (mAb) targeting CD24. Anti-CD24 Antibody (SWA11) has anticancer effects, such as lung cancer and ovarian cancer. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991169
-
|
|
Factor Xa
|
Cardiovascular Disease
|
|
Zemocimig is an anti-coagulation factor F9 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
- HY-P990758
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
Reflocibart is an anti-VEGFB human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P990737
-
|
LY-3041658
|
CXCR
|
Inflammation/Immunology
|
|
Eltrekibart is an anti-CXCL human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P990768
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Timcevibart is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99034
-
- HY-P990696
-
- HY-P990725
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Nisfevitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991116
-
- HY-P990705
-
|
REGN-15160
|
SARS-CoV
|
Inflammation/Immunology
|
|
Gorivitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990713
-
- HY-P990773
-
|
LY-3361237
|
CD28
|
Inflammation/Immunology
|
|
Venanprubart is an anti-BTLA human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P99266
-
|
Anti-human CD4 Recombinant antibody
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma .
|
- HY-P991202
-
|
|
TSH Receptor
|
Endocrinology
|
|
Anti-TSHR Antibody (M22) is a humanized IgG1 monoclonal antibody that targets thyrotropin receptor (TSHR). Anti-TSHR Antibody (M22) inhibits the binding of TSH and TSHR. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991185
-
|
|
c-Met/HGFR
|
Cancer
|
|
Anti-MST1R Antibody (MOR07692) is a humanized IgG1 monoclonal antibody that targets MST1R. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99328
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule .
|
- HY-P991197
-
|
|
CD3
|
Cancer
|
|
Anti-GPRC5D Antibody is a humanized IgG1 monoclonal antibody that targets GPRC5D. Anti-GPRC5D Antibody is the antibody part of the ADC molecule LM-305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990068
-
|
SRF617
|
NTPDase
|
Cancer
|
|
Perenostobart is a human immunoglobulin G4-kappa, anti-ENTPD1/CD39 monoclonal antibody. Perenostobart is an immunostimulant and antineoplastic .
|
- HY-P9929
-
|
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
Bezlotoxumab is a human monoclonal antibody directed against C. difficile toxin B. Bezlotoxumab binds to C. difficile toxin B preventing intestinal epithelial damage and colitis .
|
- HY-P9918
-
|
Ticilimumab; CP-675206
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research .
|
- HY-P991398
-
|
|
Toll-like Receptor (TLR)
|
Cancer
|
|
IPH33 is a human monoclonal antibody (mAb) targeting TLR3/CD283. IPH33 can be used in Cancer and Inflammation research .
|
- HY-P991428
-
|
|
HIV
|
Infection
|
|
DIACC-1010 is a human monoclonal antibody (mAb) targeting PLA2G1B. DIACC-1010 can be used in HIV infections research .
|
- HY-P991296
-
- HY-P99642
-
- HY-P991416
-
|
|
VEGFR
|
Others
|
|
BAT5906 is a human monoclonal antibody (mAb) targeting VEGFA. BAT5906 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .
|
- HY-P991498
-
|
|
Influenza Virus
|
Infection
|
|
CAL-203 is a human monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. CAL-203 can be used in respiratory tract infections research.
|
- HY-P99603
-
|
SEA-CD40
|
Inhibitory Antibodies
|
Cancer
|
|
Cifurtilimab (SEA-CD40) is an agonistic nonfucosylated, human IgG1 monoclonal antibody directed against CD40. Cifurtilimab shows antitumor activities .
|
- HY-P991377
-
|
|
Tau Protein
|
Neurological Disease
|
|
TBL-100 is a human monoclonal antibody (mAb) targeting Tau. TBL-100 can be used in Alzheimer's disease (AD) and Progressive supranuclear palsy research .
|
- HY-P99964
-
|
AGS15C; Ha15-10ac12; Ha15-10ac12.1
|
Inhibitory Antibodies
|
Cancer
|
|
Sirtratumab is a human Igγ2 monoclonal antibody against SLIT and NTRK-like family 6 (Slitrk6). Sirtratumab can be used in research of cancer .
|
- HY-P991417
-
|
|
VEGFR
|
Cancer
|
|
LYN00101 is a human monoclonal antibody (mAb) targeting VEGFA. LYN00101 can be used in Cervical cancer, Colorectal cancer, Gastric cancer and Ovarian cancer research .
|
- HY-P991407
-
- HY-P99205
-
|
|
ADC Antibody
|
Cancer
|
|
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .
|
- HY-P99355
-
|
Anti-ACVR2B Reference antibody; BYM338
|
TGF-β Receptor
|
Metabolic Disease
|
|
Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness .
|
- HY-P990684
-
- HY-P991170
-
|
|
SARS-CoV
|
Infection
|
|
Ibramvibart is an anti-SARS-CoV-2 Spike human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990771
-
|
|
CD73
|
Inflammation/Immunology
|
|
Uprevstobart is an anti-NT5E human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990704
-
|
AZD-2936
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Rilvegostomig is an anti-PDCD1/TIGIT human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990769
-
- HY-P990755
-
|
|
EGFR
|
Inflammation/Immunology
|
|
Pamvatamig is an anti-EGFR/MET human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P991171
-
- HY-P991485
-
- HY-P991297
-
|
|
|
Cancer
|
|
AM0003 is a human monoclonal antibody (mAb) targeting CD223/LAG3. AM0003 can be used in the study of advanced solid tumors .
|
- HY-P991331
-
|
|
CD73
|
Cancer
|
|
BC-010 is a human monoclonal antibody (mAb) targeting NT5E/CD73. BC-010 can be used in the study of tumors.
|
- HY-P99318
-
|
LT 1009; Anti-human S1P Recombinant antibody
|
LPL Receptor
|
Cancer
|
|
Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC) .
|
- HY-P991293
-
|
|
c-Kit
|
Metabolic Disease
|
|
NN-2101 is a human monoclonal antibody (mAb) targeting c-Kit/CD117. NN-2101 is used in the research of retinal disorders and diabetic macular edema.
|
- HY-P99357
-
|
REGN1193; Anti-GCGR Reference antibody (crotedumab)
|
GCGR
|
Metabolic Disease
|
|
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes .
|
- HY-P991327
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
PAT-LM1 is a human monoclonal antibody (mAb) targeting NRB54/NONO. PAT-LM1 can be used in haematological malignancies research.
|
- HY-P99398
-
|
BPS 804
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Setrusumab (BPS 804) is a fully human monoclonal antibody targets sclerostin. Setrusumab efftively improves bone strength. Setrusumab can be used for the resesrch of Osteogenesis Imperfecta (OI) and cancer .
|
- HY-P99586
-
|
REGN2222
|
RSV
|
Infection
|
|
Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection .
|
- HY-P991306
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
ATG-032 is a human monoclonal antibody (mAb) targeting LILRB2/ILT4. ATG-032 can be used in haematological malignancies research.
|
- HY-P99286
-
|
PRO 95780; rhuMAb-DR 5; Anti-human DR5 Recombinant antibody
|
Apoptosis
|
Cancer
|
|
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma .
|
- HY-P99703
-
|
17.1.41
|
HBV
|
Infection
|
|
Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .
|
- HY-P99876
-
|
OMP-336B11
|
Inhibitory Antibodies
|
Others
|
|
Efaprimermin alfa (OMP-336B11) is a human monoclonal antibody targeting TNFRSF18. Efaprimermin alfa is a GITR ligand-Fc fusion protein .
|
- HY-108852
-
|
CHI 621
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation .
|
- HY-P99057A
-
|
CDX-1127 (anti-CD27)
|
TNF Receptor
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Varlilumab (CDX-1127) (anti-CD27) is an agonist anti-CD27 monoclonal antibody. Varlilumab (anti-CD27) can promote T cell expansion and activate the immune response. Varlilumab (anti-CD27) has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors .
|
- HY-P99057
-
|
CDX-1127
|
TNF Receptor
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Varlilumab (CDX-1127) is an agonist anti-CD27 monoclonal antibody. Varlilumab can promote T cell expansion and activate the immune response. Varlilumab has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors .
|
- HY-P99254
-
|
1E10
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is an anti-idiotype monoclonal antibody (MAb). Racotumomab reacts to Neu-glycolyl (NeuGc)-containing gangliosides, sulfatides, and other antigens expressed in tumors. Racotumomab is an active anticancer agent for lung cancer .
|
- HY-P991174
-
|
|
TREM receptor
|
Inflammation/Immunology
|
|
Anti-TREM2 Antibody (AL2p-58) is a humanized IgG1 monoclonal antibody that targets TREM2. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991075
-
|
|
NAMPT
|
Inflammation/Immunology
|
|
ALT-100 (Human IgG1) is a humanized IgG1 monoclonal antibody that targets NAMPT. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990726
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Abiprubart is an anti-CD40 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P990743
-
- HY-P990702
-
|
LVGN-3616
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Pradusinstobart is an anti-PDCD1 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P990750
-
|
|
LAG-3
|
Inflammation/Immunology
|
|
Negalstobart is an anti-LAG3 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P99668
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research .
|
- HY-P991453
-
|
|
C-type Lectin-like Receptors (CTLRs)
|
Cancer
|
|
Anti-CD371/CLEC12A Antibody (H6e7) is a human monoclonal antibody (mAb) targeting CD371/CLEC12A. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99335
-
|
Anti-human IL17A Recombinant antibody
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis .
|
- HY-P991072
-
|
MAPP-66
|
HIV
HSV
|
Infection
|
|
MB-66 (MAPP-66) is a fully human IgG1 antibody that targets HSV and HIV. MB-66 is a monoclonal antibody film for vaginal application. The isotype control for MB-66 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-164153
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
ADC Control Human IgG1-vcMMAE is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
|
- HY-P99209
-
|
MEDI-524
|
RSV
|
Infection
|
|
Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research .
|
- HY-P99323
-
|
BTT 1023; Anti-human AOC3 Recombinant antibody
|
VAP-1
|
Inflammation/Immunology
|
|
Timolumab (BTT1023 ), a recombinant fully human monoclonal antibody that specifically binds VAP-1. Timolumab (BTT1023 ) could be used in the study of chronic inflammatory diseases .
|
- HY-P9905
-
Cetuximab
Maximum Cited Publications
39 Publications Verification
C225
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
|
Cancer
|
|
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
|
- HY-P991368
-
- HY-P991291
-
|
|
Insulin Receptor
|
Endocrinology
|
|
XOMA 129 is a human monoclonal antibody targeting INSR. XOMA 129 is an insulin receptor (IR) antagonist that inhibits the drop in blood glucose. XOMA 129 can be used in the study of hypoglycemia .
|
- HY-P99473
-
|
BI-505
|
Integrin
|
Cancer
|
|
Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects .
|
- HY-P991385
-
|
|
Tie
|
Neurological Disease
Metabolic Disease
|
|
UBX2050 is a human monoclonal antibody (mAb) targeting TIE2. UBX2050 can be used in Age-related macular degeneration, Diabetic macular oedema and Diabetic retinopathy research .
|
- HY-P991303
-
|
Sym022; S 95017
|
|
Cancer
|
|
TQB-2223 is a human monoclonal antibody (mAb) targeting CD223/LAG3. TQB-2223 can be used in the study of Hodgkin lymphoma .
|
- HY-P99465
-
- HY-P991494
-
|
|
RSV
|
Infection
|
|
IN-002 is a human monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. IN-002 can be used in respiratory syncytial virus (RSV) infections research.
|
- HY-P99832
-
|
c13C6-FR1
|
Filovirus
|
Infection
|
|
Cosfroviximab (c13C6-FR1) is a mouse/human chimeric monoclonal antibody against Ebola virus glycoprotein (EBOV-GP) .
|
- HY-P990690
-
|
MEDI-5752
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Volrustomig is an anti-CTLA4/PDCD1 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990770
-
- HY-P990761
-
- HY-P99485
-
|
AMG 139; MEDI2070
|
Interleukin Related
|
Inflammation/Immunology
|
|
Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease .
|
- HY-P990700
-
|
RO-7247669; RG-6139
|
PD-1/PD-L1
LAG-3
|
Inflammation/Immunology
|
|
Tobemstomig is an anti-PDCD1/LAG3 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990694
-
|
TG-1801
|
CD19
CD47
|
Inflammation/Immunology
|
|
Zeripatamig is an anti-CD19/CD47 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990701
-
|
RO-7121661
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Lomvastomig is an anti-PDCD1/HAVCR2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99364
-
|
Anti-VEGFR1/FLT1 Reference antibody; IMC-18F1
|
VEGFR
|
Cancer
|
|
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a human Anti-VEGFR-1 IgG1 monoclonal antibody. Icrucumab has the potential for the research of advanced solid tumors .
|
- HY-P991106
-
|
LY-3076226 antibody
|
FGFR
|
Cancer
|
|
IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody against FGFR3. IMC-D11 can be used for the antibody part of LY3076226. IMC-D11 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P9950
-
|
Olizumab; rhuMab-E25
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research .
|
- HY-P99353
-
|
Anti-ACVRL1 / ALK-1 Reference antibody (ascrinvacumab); PF-03446962
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) .
|
- HY-P990756
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Pemivibart is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
- HY-P990777
-
- HY-P990766
-
|
AZD3152
|
SARS-CoV
|
Inflammation/Immunology
|
|
Sipavibart is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
- HY-P990751
-
- HY-P991341
-
|
|
Cadherin
|
Inflammation/Immunology
|
|
FF-21101 is a human IgG1 monoclonal antibody (mAb) targeting CDH3/P-cadherin. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990711
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Canrivitug is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
- HY-P99307
-
|
AMG-203; Anti-human CSF2 Recombinant antibody
|
c-Fms
|
Inflammation/Immunology
|
|
Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis .
|
- HY-P991326
-
|
EDP-10; JHL-1311
|
Interleukin Related
|
Endocrinology
|
|
BL-9020 is a human monoclonal antibody (mAb) targeting NKp46/NCR1. BL-9020 can be used in type 1 diabetes mellitus research.
|
- HY-P991347
-
|
|
PD-1/PD-L1
|
Cancer
|
|
AM0001 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. AM0001 can be used in cancer research .
|
- HY-P991420
-
|
|
VEGFR
|
Cancer
|
|
UB-925 is a human monoclonal antibody (mAb) targeting VEGFR2/KDR/CD309. UB-925 can be used in Gastric cancer research .
|
- HY-P991439
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
BIIB023 is a human monoclonal antibody (mAb) targeting TNFRSF12A/TWEAKR/CD266. BIIB023 can be used in lupus nephritis and rheumatoid arthritis research .
|
- HY-P99760
-
|
BCD-145
|
CTLA-4
|
Cancer
|
|
Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma .
|
- HY-P991499
-
|
|
RSV
|
Infection
|
|
EVO-46120 is a human monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. EVO-46120 can be used in respiratory syncytial virus (RSV) and metapneumovirus infections research.
|
- HY-P99807
-
|
BCD-100
|
PD-1/PD-L1
|
Cancer
|
|
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma .
|
- HY-P99262
-
|
BAX69; Anti-human MIF Recombinant antibody
|
Macrophage migration inhibitory factor (MIF)
|
Cancer
|
|
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer .
|
- HY-P99484
-
|
AGEN 1181
|
CTLA-4
|
Cancer
|
|
Botensilimab (AGEN 1181), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer .
|
- HY-P99320
-
|
OMP 59R5; Anti-human NOTCH2 Recombinant antibody
|
Notch
|
Cancer
|
|
Tarextumab (OMP-59R5) is an anti-Notch2/3 fully human IgG2 monoclonal antibody. Tarextumab shows anti-tumor activity .
|
- HY-P991140
-
|
|
Claudin
|
Cancer
|
|
Garetatug is a humanized monoclonal antibody targeting human CLDN18 (claudin-18). Garetatug specifically binds to CLDN18, interfering with relevant cell signaling pathways and exerting antitumor activity .
|
- HY-P9925
-
|
AMG 827; KHK4827
|
Interleukin Related
|
Inflammation/Immunology
|
|
Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis .
|
- HY-P991414
-
|
|
HIV
|
Infection
Cancer
|
|
FGI-1011A6 is a human monoclonal antibody (mAb) targeting TSG101. FGI-1011A6 can be used in Prostate cancer and Viral infections research .
|
- HY-P991187
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-TM4SF1 Antibody (AGX-A07) is a humanized IgG1 monoclonal antibody that targets TM4SF1. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99014
-
|
ARGX-110
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML) .
|
- HY-P99354
-
|
Anti-human CTLA4xLAG3
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .
|
- HY-P991304
-
|
|
MMP
|
Cancer
|
|
IO-106 is a human IgG1 monoclonal antibody (mAb) targeting LAIR1/CD305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991302
-
|
|
LAG-3
|
Cancer
|
|
KL-A289 is a human monoclonal antibody (mAb) targeting CD223/LAG3. KL-A289 can be used in the study of metastatic GC .
|
- HY-P99337
-
|
Ansuvimab-zyk; mAb114
|
Filovirus
|
Infection
|
|
Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells .
|
- HY-P99695
-
|
CAT-152
|
TGF-beta/Smad
|
Neurological Disease
|
|
Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research .
|
- HY-P99857
-
|
PF-06252616
|
TGF-beta/Smad
|
Metabolic Disease
|
|
Domagrozumab is an anti-myostatin humanized monoclonal antibody with a KD value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD) .
|
- HY-P991309
-
- HY-P99423
-
|
ADG 20
|
SARS-CoV
|
Infection
|
|
Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .
|
- HY-P99168
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research .
|
- HY-P991434
-
|
|
Integrin
|
Inflammation/Immunology
|
|
SAN-300 is a human IgG1 monoclonal antibody (mAb) targeting ITGA1/VLA-1. SAN-300 can be used in Rheumatoid arthritis research .
|
- HY-P99375
-
|
IMC-RON8; LY3012219; Anti-MSPR/RON/CD136 Reference antibody (narnatumab)
|
Tyrosinase
c-Met/HGFR
|
Cancer
|
|
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer .
|
- HY-P9979
-
|
UCB7665
|
TNF Receptor
|
Inflammation/Immunology
|
|
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .
|
- HY-P990876
-
|
PF-06480605; RVT-3101
|
TNF Receptor
|
Inflammation/Immunology
|
|
Afimkibart (PF-06480605) is a human IgG1 monoclonal antibody targeting tumor necrosis factor-like ligand 1A (TL1A). Afimkibart can be used in the research of inflammatory bowel disease .
|
- HY-P99607
-
|
IDEC-151
|
HIV
|
Inflammation/Immunology
|
|
Clenoliximab (IDEC-151) is a macaque-human chimeric monoclonal antibody (immunoglobulin G4) specific for the CD4 molecule on the surface of T lymphocytes. Clenoliximab can be used for the research of rheumatoid arthritis .
|
- HY-P99889
-
|
BRII-198
|
SARS-CoV
|
Infection
|
|
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
|
- HY-P9S0008
-
|
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
|
Cancer
|
|
Cetuximab (PBS) is a human IgG1 monoclonal antibody that can inhibit EGFR. The SPR method measured the Kd value of Cetuximab for EGFR to be 0.201 nM; Cetuximab has a highly effective anti-tumor effect .
|
- HY-P991384
-
|
|
Tie
|
Cancer
|
|
DX-2240 is a human monoclonal antibody (mAb) targeting TIE1. DX-2240 inhibits tumor growth and sensitizes tumor vasculature to anti-angiogenic agents (VEGF pathway inhibitors) .
|
- HY-P9966
-
|
MGA271
|
CD276/B7-H3
|
Cancer
|
|
Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators .
|
- HY-P99366A
-
|
AMG 157 (anti-TSLP); MEDI 19929 (anti-TSLP); Tezepelumab-ekko (anti-TSLP)
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tezepelumab (anti-TSLP) is human monoclonal antibody (IgG2λ) that binds specifically to TSLP, blocking it from interacting with its heterodimeric receptor. Tezepelumab can be used for the research of severe, uncontrolled asthma .
|
- HY-P991082
-
|
SAR-428926 antibody
|
Transmembrane Glycoprotein
|
Cancer
|
|
Anti-LAMP1/CD107a Antibody (SAR-428926 antibody) is an anti-LAMP1 humanized monoclonal antibody. Anti-LAMP1/CD107a Antibody can be used for the antibody part of SAR-428926. Antibody Anti-LAMP1/CD107a Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99276
-
|
Anti-human CA-125 Recombinant antibody
|
Inhibitory Antibodies
|
Cancer
|
|
Abagovomab (Anti-Human CA-125 Recombinant Antibody) is a murine monoclonal anti-idiotypic antibody, against the tumor-associated antigen, CA-125. Abagovomab is generated by a mouse hybridoma, can imitate the human TAA, CA-125. Abagovomab can elicit humoral and cellular immune responses against ovarian cancer (oc) .
|
- HY-P990752
-
|
REGN-5678
|
CD28
|
Inflammation/Immunology
|
|
Nezastomig is an anti-FOLH1/CD28 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P991333
-
- HY-P99900
-
|
MSL-109
|
CMV
|
Infection
|
|
Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL .
|
- HY-P991399
-
- HY-P991392
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
TGTB227 is a human monoclonal antibody (mAb) targeting TIGIT. TGTB227 inhibits the immunosuppressive function of Tregs by reducing the expression of Foxp3 in Tregs. TGTB227 can be used in tumor immunity research .
|
- HY-P99411
-
|
SHP647
|
Integrin
|
Inflammation/Immunology
|
|
Ontamalimab (SHP647) is a fully-human IgG2 monoclonal antibody targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Ontamalimab can be used for the research of Crohn's disease .
|
- HY-P991160
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Suvonstobart is a monoclonal antibody targeting human CD24 (signal transducer CD24). Suvonstobart specifically binds to CD24, activating relevant immune cell signaling pathways and exerting immunostimulatory and antitumor activities .
|
- HY-P99700
-
|
IBI-188
|
Inhibitory Antibodies
|
Cancer
|
|
Letaplimab (IBI-188) is a human IgG4 anti-CD47 monoclonal antibody. CD47 is overexpressed on cancer cells, it is a ligand for SIRPα. Letaplimab enhances tumor cell phagocytosis .
|
- HY-P991126
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy .
|
- HY-P991139
-
|
|
CTLA-4
|
Cancer
|
|
Futermestotug is a humanized immunoglobulin G1-κ monoclonal antibody targeting human cytotoxic T-lymphocyte associated protein 4 (CTLA4). Futermestotug is promising for research of various malignant tumors .
|
- HY-P99207
-
|
KB 003
|
SARS-CoV
|
Cancer
|
|
Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies .
|
- HY-P99461
-
|
ISU-104
|
EGFR
|
Cancer
|
|
Barecetamab (ISU-104) is a fully human anti-ErbB3 monoclonal antibody. Barecetamab can be used for the research of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) .
|
- HY-P9922
-
|
IMC-3G3; LY3012207
|
PDGFR
|
Cancer
|
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .
|
- HY-P991436
-
|
BMS-986415
|
Interleukin Related
IFNAR
|
Cancer
|
|
DF6002 (BMS-986415) is a human monoclonal antibody (mAb) targeting IL-12. DF6002 increases IFN-γ levels. DF6002 can be used in solid tumors research .
|
- HY-P991152
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Oturkibart is a humanized immunoglobulin G4-κ monoclonal antibody targeting the human interleukin 4 receptor (IL4R). Oturkibart is promising for research of inflammatory diseases, such as asthma and atopic dermatitis .
|
- HY-P991184
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Anti-LY6G6D Antibody (1G4) is a humanized IgG1 monoclonal antibody that targets LY6G6D. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-164152
-
|
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
|
Cancer
|
|
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
- HY-164154
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
|
- HY-P990745
-
- HY-P990691
-
- HY-P99909
-
|
PF-06863135
|
TNF Receptor
|
Inflammation/Immunology
|
|
Elranatamab (PF-06863135) is an anti-CD3E/TNFRSF17 human IgG2κ monoclonal antibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990692
-
|
|
CD3
|
Inflammation/Immunology
|
|
Ciduvectamig is an anti-CD3E/TMEFF2 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P99263
-
|
Anti-human selectin P Recombinant antibody
|
P-selectin
|
Cardiovascular Disease
|
|
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion .
|
- HY-P9991
-
|
TST001
|
Gap Junction Protein
|
Cancer
|
|
Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
|
- HY-P991404
-
|
|
TNF Receptor
|
Cancer
|
|
AMG-228 is a human IgG1 monoclonal antibody (mAb) targeting TNFRSF18/GITR/CD357. AMG-228 can be used in advanced solid tumors research .
|
- HY-P990021
-
|
|
Bacterial
|
Others
|
|
Calpurbatug is an immunoglobulin G1 antibody. Calpurbatug has activity with anti-bacterial DNA-binding protein DNABII family and anti-human monoclonal TRL1068 γ1-chain .
|
- HY-P991150
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ompekimig is a humanized immunoglobulin monoclonal antibody targeting human interleukin 4 (IL-4) and interleukin 13 (IL-13). Ompekimig is promising for research of immune-mediated inflammatory diseases, such as asthma and atopic dermatitis .
|
- HY-P991396
-
|
|
Tim3
|
Cancer
|
|
LY-3321367 is a human monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. LY-3321367 can be used in solid tumors research .
|
- HY-P99550
-
|
MEDI-3506
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease .
|
- HY-P99955
-
- HY-P99442
-
|
Hu1D10
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro .
|
- HY-P991313
-
|
|
c-Fms
|
Inflammation/Immunology
|
|
PD-360324 is a human monoclonal antibody (mAb) targeting CSF1/M-CSF. PD-360324 can be used in cutaneous lupus erythematosus, pulmonary sarcoidosis and rheumatoid arthritis research .
|
- HY-P991308
-
- HY-P991349
-
|
|
PD-1/PD-L1
|
Cancer
|
|
GNR-051 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. GNR-051 can be used in Solid tumours research .
|
- HY-P991252
-
|
AIMab-7195
|
Histamine Receptor
|
Inflammation/Immunology
|
|
XmAb-7195 (AIMab-7195) is a human monoclonal antibody (mAb) targeting IGHE. XmAb-7195 can be used in Food hypersensitivity, Allergic asthma, Allergic rhinitis, Atopic dermatitis and Conjunctivitis research .
|
- HY-P991433
-
|
|
TNF Receptor
|
Cancer
|
|
BIIB036 is a human IgG1 monoclonal antibody (mAb) targeting TNFRSF12A/Fn14. BIIB036 inhibits the growth of patient-derived primary colorectal tumors in SCID mice .
|
- HY-P99792
-
|
NM57; rhRIG
|
RABV
|
Infection
|
|
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .
|
- HY-P99895
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .
|
- HY-P991336
-
- HY-P99530
-
|
AGT-181; HIRMAb-IDUA
|
Insulin Receptor
|
Metabolic Disease
|
|
Valanafusp alfa (AGT-181) is a chimeric monoclonal antibody that fuses human α-L-iduronidase (IDUA) and targets the human insulin receptor (HIR). Valanafusp alfa has brain penetrating properties, making it useful for research on mucopolysaccharidosis type I (MPS I) .
|
- HY-P991305
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
AGEN-1571 is a human IgG1 monoclonal antibody (mAb) targeting ILT2. AGEN-1571 promotes adaptive and innate immune responses. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001)
|
- HY-P991314
-
|
|
MDM-2/p53
|
Cancer
|
|
NMC-001 is a human IgG1 monoclonal antibody (mAb) targeting MDM2. NMC-001 can be used in pancreatic cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99234
-
|
|
Interleukin Related
ADC Antibody
|
Cancer
|
|
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .
|
- HY-P991342
-
|
PCA062 antibody
|
Cadherin
|
Cancer
|
|
CQY684 (PCA062 antibody) is a human monoclonal antibody (mAb) targeting CDH3/P-cadherin. CQY684 stabilizes the X-dimer of P-cadherin, promoting its endocytosis and directing it to lysosomal degradation. CQY684 can be used in Breast, esophageal, and head and neck cancers research .
|
- HY-P99013
-
|
GC33; RO5137382
|
Glycoprotein VI
|
Cancer
|
|
Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .
|
- HY-P99279
-
|
Anti-human Phosphatidylserine Recombinant antibody
|
Inhibitory Antibodies
|
Cancer
|
|
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer .
|
- HY-P990558
-
|
BMS-986148 antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
BMS-986021 (BMS-986148 antibody) is a human monoclonal antibody expressed in CHO, targeting Mesothelin. BMS-986021 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.46 kDa. For the isotype control of BMS-986021, refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P99280
-
|
Anti-human IL17A/IL-17F Recombinant antibody
|
Interleukin Related
|
Inflammation/Immunology
|
|
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation .
|
- HY-P991362
-
|
|
TNF Receptor
|
Cancer
|
|
GB-223 is a human monoclonal antibody (mAb) targeting TNFSF11/RANKL/CD254. GB-223 can be used in Giant cell tumour of bone and Postmenopausal osteoporosis research .
|
- HY-P991320
-
|
|
PD-1/PD-L1
|
Cancer
|
|
BAT-1308 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. BAT-1308 can be used in cervical cancer and endometrial cancer research.
|
- HY-P99036
-
- HY-P99877
-
|
AMG592
|
Inhibitory Antibodies
|
Others
|
|
Efavaleukin alfa (AMG592) is a human monoclonal antibody. Efavaleukin alfa is composed of the IGHG1 Fc fragment fused to IL-2. The expression system of Efavaleukin alfa is usually CHO (Chinese Hamster Ovary) cells .
|
- HY-P991135
-
|
|
CCR
|
Cancer
|
|
Enzelkitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the human C-C motif chemokine receptor 8 (CCR8). Enzelkitug is promising for research of various solid tumors and hematological malignancies .
|
- HY-P99365
-
|
ALXN1210
|
Complement System
|
Metabolic Disease
|
|
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .
|
- HY-P99764
-
|
REGN-3471
|
Filovirus
|
Infection
|
|
Odesivimab is a human monoclonal antibody, targeting Ebola virus glycoprotein with a KD value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein. Odesivimab can be used in research of Ebola virus infection .
|
- HY-P9901
-
|
MDX-010; BMS-734016
|
CTLA-4
|
Cancer
|
|
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies .
|
- HY-P991323
-
- HY-P99795
-
|
GSK 3196165; MOR103
|
c-Fms
|
Inflammation/Immunology
|
|
Otilimab (GSK 3196165) is an anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) human monoclonal antibody. Otilimab neutralises the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor .
|
- HY-P991334
-
|
|
Orexin Receptor (OX Receptor)
|
Cancer
|
|
INCAGN1949 is a human IgG1 monoclonal antibody (mAb) targeting TNFRSF4/OX40/CD134. INCAGN1949 selectively deplete intratumoral regulatory T cells .
|
- HY-P99196
-
|
|
c-Met/HGFR
|
Cancer
|
|
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion .
|
- HY-P991162
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tilrekimig is a monoclonal antibody targeting human interleukin 4 (IL-4), interleukin 13 (IL-13), and TSLP (thymic stromal lymphopoietin). Tilrekimig is promising for research of allergic and inflammatory diseases, such as asthma and atopic dermatitis .
|
- HY-P991143
-
|
|
Claudin
|
Cancer
|
|
Ixotatug is a monoclonal antibody targeting human CLDN6 (claudin-6). Ixotatug specifically binds to CLDN6, interfering with relevant signaling pathways in tumor cells and exerting antitumor activity. Ixotatug is promising for research of cancers .
|
- HY-P991195
-
|
|
TNF Receptor
|
Cancer
|
|
SIM-0235 is humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets and inhibits TNFR2, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
|
- HY-P991124
-
|
|
Factor XI
|
Cardiovascular Disease
|
|
Cenvacibart is a monoclonal antibody with anticoagulant activity, targeting human coagulation factor XI (F11). Cenvacibart blocks the role of coagulation factor XI in the coagulation cascade, reducing thrombus formation. Cenvacibart is promising for research of thrombotic diseases .
|
- HY-P9915
-
|
Anti-human CD38, human antibody
|
CD38
ADC Antibody
|
Inflammation/Immunology
Cancer
|
|
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
|
- HY-P991460
-
|
|
TNF Receptor
|
Cancer
|
|
Sym029 is a human IgG monoclonal antibody (mAb) targeting TNFRSF5/CD40. Sym029 can be used in cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991145
-
|
|
SLC39 (Zinc Transporter)
|
Cancer
|
|
Laventatug is a humanized monoclonal antibody targeting human SLC39A6. Laventatug specifically binds to SLC39A6, interfering with the intracellular zinc ion transport process and thus exerting antitumor activity. Laventatug is promising for research of cancers .
|
- HY-P991137
-
|
|
Ser/Thr Protease
|
Metabolic Disease
|
|
Exerenibart is an immunoglobulin G4-κ monoclonal antibody targeting human transmembrane serine protease 6 (TMPRSS6). Exerenibart is promising for research of diseases associated with iron metabolism disorders, such as iron overload or iron deficiency .
|
- HY-P99222
-
|
MGA-031; PRV-031
|
CD3
|
Metabolic Disease
|
|
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .
|
- HY-P99648
-
|
BMS-986168; IPN007; BIIB092
|
Tau Protein
|
Neurological Disease
|
|
Gosuranemab (BMS-986168) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab binds to human N-terminal tau residues 15-22. Gosuranemab has the potential for the research of alzheimer’s disease (AD) .
|
- HY-P991203
-
|
|
Guanylate Cyclase
|
Cancer
|
|
PF-07062119 is humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets and inhibits GUCY2C, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
|
- HY-P991355
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PDL-GEX is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. PDL-GEX can be used in cancer research .
|
- HY-P991348
-
|
|
PD-1/PD-L1
|
Cancer
|
|
BAT-1306 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. BAT-1306 can be used in Colorectal cancer and Solid tumours research .
|
- HY-P99010A
-
|
|
Interleukin Related
FGFR
|
Cancer
|
|
Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa .
|
- HY-P99656
-
|
MCDS0593A
|
ADC Antibody
|
Cancer
|
|
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .
|
- HY-P99813
-
|
HER3-DXd; U3-1402
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .
|
- HY-P991484
-
|
|
Influenza Virus
|
Infection
|
|
ADI-65534 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-65534 can be used in Hantavirus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991450
-
|
ADI-15742; MBP-134 AF
|
Filovirus
|
Infection
|
|
ADI-15878 is a human IgG monoclonal antibody (mAb) targeting Envelope glycoprotein, GP2. ADI-15878 can be used in Ebola virus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991489
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
ENx-108A is a human IgG4 monoclonal antibody (mAb) targeting IL-11. BI-765423 can be used in fibrotic diseases research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
- HY-P991483
-
|
|
Influenza Virus
|
Infection
|
|
ADI-65533 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-65533 can be used in Hantavirus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99971
-
|
|
ADC Antibody
Transmembrane Glycoprotein
|
Cancer
|
|
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P991301
-
|
|
LAG-3
|
Cancer
|
|
IMP-761 is a human IgG4 monoclonal antibody (mAb) targeting CD223/LAG3. IMP-761 binds to D1 of human LAG32. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
- HY-P991335
-
|
|
Orexin Receptor (OX Receptor)
|
Cancer
|
|
BAT6026 is a human monoclonal antibody (mAb) targeting TNFRSF4/OX40/CD134. BAT6026 significantly reduces Treg cells and increased CD8+ T cells in tumor .
|
- HY-P99945
-
- HY-P990014
-
|
IMC-001; STI-3031
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic .
|
- HY-P99007
-
|
BAY 1179470
|
FGFR
|
Cancer
|
|
Aprutumab (BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research .
|
- HY-P99936
-
|
LJM716
|
EGFR
|
Cancer
|
|
Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential .
|
- HY-P99652
-
|
AK 111
|
Interleukin Related
|
Inflammation/Immunology
|
|
Gumokimab (AK 111) is a monoclonal antibody targeting IL-17A, which can be used in the study of psoriasis, ankylosing spondylitis. Gumokimab competitively blocks the binding of human IL-17A to IL-17R.
|
- HY-P991394
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
SEA-TGT is a human monoclonal antibody (mAb) targeting TIGIT. SEA-TGT enhances binding to the activating FcγRIIIA while reducing binding to the inhibitory FcγRIIb. SEA-TGT can be used in advanced solid tumors and Lymphoma research .
|
- HY-P9801
-
|
SARS-CoV-2 (2019-nCoV) Spike RBD antibody
|
SARS-CoV
|
Infection
|
|
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .
|
- HY-P991369
-
|
|
Sialyltransferase
|
Cancer
|
|
EBU-141 is a human monoclonal antibody (mAb) targeting CD75/ST6GAL1. EBU-141 can be used in B-cell lymphoma and multiple myeloma research .
|
- HY-P991300
-
|
|
LAG-3
|
Cancer
|
|
GSK2831781 is a human IgG1 monoclonal antibody (mAb) targeting CD223/LAG3. GSK2831781 can be used in the study of ulcerative colitis Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991282
-
|
|
Interleukin Related
|
Cancer
|
|
KHK2823 is a humanized monoclonal anti-human CD123/IL3RA antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001). KHK2823 can be used in research related to leukemia .
|
- HY-P991446
-
|
|
Influenza Virus
|
|
|
MEDI-8852 is a human IgG1 monoclonal antibody (mAb) targeting influenza A virus hemagglutinin HA. MEDI-8852 can be used in influenza A virus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P9914
-
|
Anti-human C5, humanized antibody
|
Complement System
|
Cardiovascular Disease
Neurological Disease
|
|
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies .
|
- HY-P990043
-
|
|
Ser/Thr Kinase
TREM receptor
|
Inflammation/Immunology
|
|
Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP) .
|
- HY-P99313
-
|
Anti-human IGHE Recombinant antibody
|
Apoptosis
|
Inflammation/Immunology
|
|
Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research .
|
- HY-P99230
-
|
|
Integrin
CD22
|
Cancer
|
|
Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99194
-
|
REGN1500
|
ANGPTL
|
Cardiovascular Disease
Metabolic Disease
|
|
Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia .
|
- HY-P991374
-
|
|
Tau Protein
|
Neurological Disease
|
|
PNT001 is a human IgG1 monoclonal antibody (mAb) targeting cis-pT231 Tau. PNT001 can be used in Neurodegenerative disorders and Traumatic brain injuries research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P9915A
-
|
Anti-human CD38, human antibody (PBS)
|
ADC Antibody
CD38
|
Cancer
|
|
Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
|
- HY-P991442
-
|
TAK-920
|
TREM receptor
|
Neurological Disease
|
|
DNL-919 (TAK-920) is a human IgG1 monoclonal antibody (mAb) targeting TREM-2. DNL-919 can be used in Alzheimer's disease research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99257
-
|
ASKP 1240
|
TNF Receptor
|
Inflammation/Immunology
|
|
Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (Kd: 0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection .
|
- HY-P991278
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
ABM-125 is a human IgG anti-IL-25 monoclonal antibody. The isotype control of ABM-125 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). ABM-125 can be used in research related to viral asthma .
|
- HY-P99178
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
CTX-471 is a fully human monoclonal antibody of CD137. CTX-471 has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with Kd values of 50 nM, 61 nM and 748 nM, respectively. CTX-471 can be used for the research of immunomodulation and cancer .
|
- HY-P991421
-
|
|
VISTA
|
Cancer
|
|
W0180 is a human IgG1 monoclonal antibody (mAb) targeting VISTA/B7-H5. W0180 has the potential to activate T cells. W0180 can be used in solid tumors research .
|
- HY-P991130
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Dalidnetug is a humanized monoclonal antibody targeting human amyloid-beta precursor protein (APP). Dalidnetug specifically binds to APP to reduce the production of amyloid-beta (Aβ), thus exerting the activity of clearing amyloid-beta. Dalidnetug is promising for research of Alzheimer's disease .
|
- HY-P99197
-
|
CP-751871
|
IGF-1R
|
Cancer
|
|
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM .
|
- HY-P99346
-
|
CT-P59
|
SARS-CoV
Angiotensin-converting Enzyme (ACE)
|
Infection
|
|
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .
|
- HY-P99265
-
|
HGS-ETR1; Anti-human TNFRSF10A Recombinant antibody
|
Inhibitory Antibodies
|
Cancer
|
|
Mapatumumab (HGS-ETR1) is a fully human IgG2 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab can be used for the research of cancer .
|
- HY-P99833
-
|
CK-301; TG-1501
|
PD-1/PD-L1
|
Cancer
|
|
Cosibelimab (CK-301) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab exhibits antitumor efficacy .
|
- HY-P991125
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy .
|
- HY-P991337
-
- HY-P991192
-
|
|
TNF Receptor
|
Cancer
|
|
BI-1808 is a human IgG1 monoclonal antibody that targets TNFR2by blocking interaction of TNFR2 with ligand TNF-α, confers FcγR-dependent depletion of Treg and mediates expansion of intratumoral CD8 + T cells .
|
- HY-P991155
-
|
|
CD3
TNF Receptor
|
Cancer
|
|
Ramantamig is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (tumor necrosis factor receptor superfamily member 17)。Ramantamig is promising for research of cancers, especially hematological malignancies such as multiple myeloma .
|
- HY-P9934
-
|
C7E3
|
Integrin
|
Cardiovascular Disease
|
|
Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .
|
- HY-P991156
-
|
|
Ras
|
Inflammation/Immunology
|
|
Rapaprutug is a monoclonal antibody targeting human KARS1 (lysyl-tRNA synthetase 1). Rapaprutug blocks the relevant inflammatory signaling pathways in which KARS1 is involved, reducing the production and release of inflammatory factors. Rapaprutug is promising for research of inflammatory diseases .
|
- HY-P991321
-
|
|
Trk Receptor
|
Inflammation/Immunology
|
|
ABT-110 is a human monoclonal antibody (mAb) targeting NGF/bNGF. ABT-110 reduces established thermal and mechanical hypersensitivity in the CFA rat model. ABT-110 can be used in persistent/chronic inflammatory pain research .
|
- HY-P9807
-
|
SARS-CR3022; SARS-CoV-2 antibody-CR3022
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .
|
- HY-P991127
-
|
|
Complement System
|
Inflammation/Immunology
|
|
Claseprubart is a monoclonal antibody targeting human complement C1s. Claseprubart specifically binds to complement C1s to inhibit the activation of the complement system, exerting immunosuppressive activity. Claseprubart is promising for research of autoimmune diseases and inflammation-related diseases .
|
- HY-P991332
-
|
|
CD73
|
Cancer
|
|
JAB-BX102 is a human monoclonal antibody (mAb) targeting NT5E/CD73. JAB-BX102 can be used in the study of cancers such as breast cancer, pancreatic cancer, and prostate cancer .
|
- HY-P991168
-
|
|
Amyloid-β
CCR
|
Neurological Disease
Inflammation/Immunology
|
|
Velaprumig is a monoclonal antibody targeting human CD99, CCL25, and anti-human Aβ (Aβ-47F). Velaprumig regulates immune cell migration and reduces β-amyloid-related pathological processes, exerting immunomodulatory and potential anti - Alzheimer's disease activities .
|
- HY-P991351
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
RTX-002 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. RTX-002 can be used to study autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis .
|
- HY-P991317
-
|
|
Mucin
|
Cancer
|
|
BTH1704 is a human monoclonal antibody (mAb) targeting MUC1. BTH1704 enables PGG-primed leukocytes to kill iC3b-opsonized tumor cells. BTH1704 can be used in pancreatic and breast cancer research .
|
- HY-P99768
-
|
TTAC-0001
|
VEGFR
|
Cancer
|
|
Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer .
|
- HY-P991147
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Ledostomig is an immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human netrin-5 (NTS5) and programmed death-1 (PD-1). Ledostomig is promising for research of various cancers .
|
- HY-P991254
-
|
|
Integrin
TGF-β Receptor
|
Metabolic Disease
|
|
VPI-2690B is a human monoclonal antibody (mAb) targeting Integrin aVb3. VPI-2690B inhibits TGF-β signaling. VPI-2690B can be used in Diabetic nephropathies research .
|
- HY-P991363
-
|
|
Myosin
|
Inflammation/Immunology
|
|
AX-202 is a human monoclonal antibody (mAb) targeting S100A4. AX-202 has antifibrotic effects in the mouse Tsk-1 model. AX-202 can be used in Plaque psoriasis and Systemic scleroderma research .
|
- HY-P991357
-
|
|
PD-1/PD-L1
|
Cancer
|
|
STT-001 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. STT-001 can be used in Solid tumours research .
|
- HY-P9927
-
|
AIN457
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .
|
- HY-P991411
-
|
ALXN2220
|
Transthyretin (TTR)
|
Cardiovascular Disease
Neurological Disease
|
|
NI-006 (ALXN2220) is a human monoclonal antibody (mAb) targeting Transthyretin/TTR. NI-006 stimulates macrophage-mediated phagocytosis of deposited amyloid fibrils. NI-006 can be used in Cardiomyopathies and Familial amyloid neuropathy research .
|
- HY-P99415
-
|
MAA868
|
Factor Xa
|
Cardiovascular Disease
|
|
Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies .
|
- HY-P991373
-
|
|
Tau Protein
|
Neurological Disease
|
|
APNmAb005 is a human monoclonal antibody (mAb) targeting MAPT/Tau/PHF-tau. APNmAb005 blocks tau seeding in vitro and rescues neuronal loss in rTG4510 mice. APNmAb005 can be used in Alzheimer’s disease (AD) research .
|
- HY-P99770
-
|
514-G3
|
Bacterial
|
Infection
|
|
Omodenbamab is an anti-SpA (Staphylococcal protein A) human monoclonal antibody with a KD value of 0.0467 nM. Omodenbamab circumvents a key S. aureus evasion mechanism by targeting the cell wall moiety Protein A (SpA). Omodenbamab can be used in research of S. aureus bloodstream infection .
|
- HY-P99858
-
|
AB154
|
Transmembrane Glycoprotein
|
Cancer
|
|
Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used for studies of non-small cell lung cancer and esophageal cancer .
|
- HY-P991128
-
|
|
Transthyretin (TTR)
|
Cardiovascular Disease
Neurological Disease
|
|
Cliramitug is a monoclonal antibody targeting human transthyretin (TTR). Cliramitug binds to TTR to inhibit its amyloid-forming process, exerting activity against amyloid protein formation. Cliramitug is promising for research of diseases related to transthyretin amyloidosis, such as certain neurological and cardiovascular diseases .
|
- HY-P99710
-
|
BI 767551; DZIF-10c
|
SARS-CoV
|
Infection
|
|
Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .
|
- HY-P991123
-
|
|
Adenylate Cyclase
|
Inflammation/Immunology
|
|
Bocunebart is a humanized monoclonal antibody targeting human adenylate cyclase-activating polypeptide (ADCYAP1). Bocunebart exerts anti-inflammatory activity by specifically binding to ADCYAP1 and inhibiting related inflammatory signaling pathways. Bocunebart is promising for research of inflammation-related diseases .
|
- HY-P991426
-
|
|
Transmembrane Glycoprotein
IFNAR
TNF Receptor
|
Cancer
|
|
MB-314 is a human IgG1 monoclonal antibody (mAb) targeting Lewis Y. MB-314 induces enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MB-314 increases the release of IFN-γ, TNF-α, MCP-1, and IL-6. MB-314 can be used in cancer research .
|
- HY-P99167
-
|
HCD122
|
TNF Receptor
|
Cancer
|
|
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .
|
- HY-P99622
-
|
IMC-20D7S
|
Tyrosinase
|
Cancer
|
|
Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance .
|
- HY-P991495
-
|
|
RSV
|
Infection
|
|
VIR-8190 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. VIR-8190 can be used in respiratory syncytial virus (RSV) and metapneumovirus infections research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991346
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
CC-90006 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. CC-90006 can be used in psoriasis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99260
-
|
AMG 655; TRAIL-R2 mAb; human Anti-TNFRSF10B Recombinant antibody
|
TNF Receptor
|
Cancer
|
|
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers.
.
|
- HY-P991138
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Firsekibart is an immunoglobulin G4-λ2 monoclonal antibody targeting human interleukin 1β (IL-1β). Firsekibart is promising for research of inflammation-related diseases, such as rheumatoid arthritis and inflammatory bowel disease .
|
- HY-P99056
-
|
PF 05082566
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20 + non-Hodgkin lymphomas .
|
- HY-P99846
-
|
QAX576
|
Interleukin Related
|
Inflammation/Immunology
|
|
Dectrekumab (QAX576) is a human monoclonal antibody that targets IL-13. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research .
|
- HY-P99519
-
|
KPL-716
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) receptor β subunit monoclonal antibody. Vixarelimab inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash .
|
- HY-P991161
-
|
|
Complement System
|
Inflammation/Immunology
|
|
Tanruprubart is a monoclonal antibody targeting human complement C1q. Tanruprubart specifically binds to complement C1q, inhibiting the initiation of the classical complement activation pathway and exerting immunosuppressive activity. Tanruprubart is promising for research of autoimmune diseases and inflammation-related diseases .
|
- HY-P991367
-
|
|
CD47
|
Cancer
|
|
ES004 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a. ES004 enhances macrophage phagocytosis and induces potent T cell responses to promote tumor killing. ES004 can be used in Solid tumours research .
|
- HY-P99399
-
|
RG 6100; RO7105705; MTAU-9937A
|
Tau Protein
|
Neurological Disease
|
|
Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .
|
- HY-P99786
-
|
REGN3918
|
Complement System
|
Metabolic Disease
|
|
Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .
|
- HY-P99322
-
|
LFG316; Anti-human C5 Recombinant antibody
|
Complement System
|
Inflammation/Immunology
|
|
Tesidolumab (LFG316) is a fully-human IgG1/λ anti-C5 monoclonal antibody of 143 kDa (without glycosylation). Tesidolumab (LFG316) blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex .
|
- HY-P99110
-
|
SHP643; DX-2930
|
Kallikrein
|
Inflammation/Immunology
|
|
Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema .
|
- HY-P991141
-
|
|
VEGFR
|
Cancer
|
|
Inlecitug is a chimeric monoclonal antibody targeting human KDR (kinase insert domain receptor). Inlecitug specifically binds to KDR, blocking the binding of vascular endothelial growth factor (VEGF) to KDR and inhibiting angiogenesis, thus exerting antitumor activity. Inlecitug is promising for research of cancers .
|
- HY-P99156
-
|
BMS-986016
|
LAG-3
|
Cancer
|
|
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer .
|
- HY-P99151
-
|
|
ADC Antibody
TNF Receptor
|
Cancer
|
|
Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC50 of 10 nM against human CD30+ cancer cells .
|
- HY-P99275
-
|
human Anti-ERBB3 Recombinant antibody
|
EGFR
Akt
ERK
PARP
Survivin
|
Cancer
|
|
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
|
- HY-P99114
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .
|
- HY-P990764B
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Sigvotatug (Biotinylated) is a biotinylated derivative of Sigvotatug (HY-P990764). Sigvotatug (Biotinylated) is a humanized IgG1 κ monoclonal antibody inhibitor against ITGB6. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991251
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
QX006N is a humanized monoclonal antibody inhibitor targeting human interferon α/β receptor 1 (IFNAR1). QX006N is promising for research of systemic lupus erythematosus (SLE) and other IFNAR1-related autoimmune diseases .
|
- HY-P991136
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Etuptamig is a chimeric monoclonal antibody of immunoglobulin λ-chain-γ1, λ-chain-γ3 targeting human natural killer cell cytotoxicity receptor 1 (NCR1). Etuptamig is promising for research of various cancers .
|
- HY-P991378
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
MORAb-066 is a human monoclonal antibody (mAb) targeting CD142/F3/TF. MORAb-066 can be used in Breast cancer, Colorectal cancer, Non-small cell lung cancer and Pancreatic cancer research .
|
- HY-P99327
-
|
BT-061
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies .
|
- HY-P991134
-
|
|
IGF-1R
|
Inflammation/Immunology
|
|
Elegrobart is an immunoglobulin G1-κ monoclonal antibody targeting the human insulin-like growth factor 1 receptor (IGF1R). Elegrobart is promising for research of diseases associated with abnormal IGF1R signaling, especially thyroid eye disease .
|
- HY-P99450
-
|
IPH 5401; Anti-C5aR1 mAb
|
Complement System
|
Inflammation/Immunology
Cancer
|
|
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .
|
- HY-P991352
-
|
|
PD-1/PD-L1
|
Cancer
|
|
SG-001 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. SG-001 can be used in Cervical cancer, Colorectal cancer, Solid tumours and Biliary cancer research .
|
- HY-P99556
-
|
AZD8895
|
SARS-CoV
|
Infection
|
|
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .
|
- HY-P99376
-
|
OMS 721; Anti-MASP2 Reference antibody (narsoplimab)
|
SARS-CoV
|
Infection
|
|
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 .
|
- HY-P991280
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
BMS-981164 is a human IgG1-kappa anti-IL31 monoclonal antibody. The isotype control of BMS-981164 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). BMS-981164 can be used in research related to atopic dermatitis .
|
- HY-P991482
-
|
|
Influenza Virus
|
Infection
|
|
ADI-42898 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-42898 binds to the Gn/Gc complex and blocks the cell entry of seven HCPS- and HFRS-associated hantaviruses. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99389
-
|
JNJ-64304500; IPH-2301; NN-8555
|
C-type Lectin-like Receptors (CTLRs)
|
Inflammation/Immunology
|
|
Tesnatilimab (JNJ-64304500) is a human IgG4 monoclonal antibody targeting NKG2D. Tesnatilimab can be studied in research for diseases such as Crohn’s disease (CD) and Inflammatory Bowel Disease (IBD). Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P991338
-
|
|
Orexin Receptor (OX Receptor)
|
Cancer
|
|
MEDI-6469 is a human monoclonal antibody (mAb) targeting TNFRSF4/OX40/CD134. MEDI-6469 targets the OX40 receptor on activated T cells to enhance the immune response against cancer cells. .
|
- HY-P99754
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Netakimab is an anti-IL-17 IgG1 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99220
-
|
LY2127399
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .
|
- HY-P99336
-
|
BI-RR 0001; Anti-human IL6 Recombinant antibody
|
Integrin
|
Neurological Disease
Inflammation/Immunology
|
|
Enlimomab (BI-RR 0001), a murine IgG2a monoclonal antibody to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. Enlimomab has anti-inflammatory effects, and can be used for stroke research .
|
- HY-P990033
-
|
CC-95251; BMS-986351
|
CD47
|
Cancer
|
|
Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPα antibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research .
|
- HY-P990031
-
|
M-6223
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function .
|
- HY-P991040
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
hu14.18 (K322A) is a humanized anti-disialoganglioside GD2 monoclonal antibody that contains fully human amino acid sequences for immunoglobulin G1 heavy and kappa light chains. hu14.18 (K322A) has antibody-dependent cellular cytotoxicity (ADCC). hu14.18 (K322A) can be used for the study of high-risk neuroblastoma .
|
- HY-P991393
-
|
|
Transmembrane Glycoprotein
IFNAR
TNF Receptor
|
Cancer
|
|
ASP8374 is a human IgG4 monoclonal antibody (mAb) targeting TIGIT. ASP8374 increases IL-2 production in Jurkat cells and IFN-γ and TNF-α production in human PBMCs. ASP8374 can be used in advanced solid tumors research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
- HY-P991445
-
|
|
SARS-CoV
|
Infection
|
|
REGN3051 is a human IgG1 monoclonal antibody (mAb) targeting MERS CoV. REGN3051 reduces viral titers in the lungs of mice expressing human DPP4. REGN3051 decreases lung disease severity and viral replication in marmosets inoculated with MERS-CoV. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991458
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
hu3S193 is a human IgG monoclonal antibody (mAb) targeting Lewis Y. hu3S193 has excellent immune effector function (complement-dependent cytotoxicity) (IC50: 1.0 μg/ml) and antibody-dependent cellular cytotoxicity (IC50: 5.0 μg/ml). hu3S193 can be used in small cell lung cancer (SCLC) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991255
-
|
|
IGF-1R
|
Inflammation/Immunology
|
|
VRDN-002 is a human monoclonal antibody (mAb) targeting IGF1R/CD221. VRDN-002 reduces inflammation and proptosis in thyroid eye disease (TED). VPI-2690B can be used in Graves ophthalmopathy research .
|
- HY-P99669
-
|
MDX-060
|
TNF Receptor
|
Cancer
|
|
Iratumumab (MDX-060) a human anti-CD30 IgG1κ monoclonal antibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) .
|
- HY-P9919
-
|
MEDI 4736
|
PD-1/PD-L1
|
Cancer
|
|
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
|
- HY-P991391
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
COM902 is a human IgG4 monoclonal antibody (mAb) targeting TIGIT. COM902 enhances anti-tumor immune responses. COM902 can be used in Multiple myeloma, Solid tumours and Colorectal cancer research. Recommended isotype control: IgG4-lambda .
|
- HY-P99541
-
|
anti-hepatitis B; OST 577; SDZ-OST 577
|
HBV
|
Infection
|
|
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research .
|
- HY-P991345
-
|
AMP-514
|
PD-1/PD-L1
|
Cancer
|
|
MEDI-0680 (AMP-514) is a human IgG4 monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. MEDI-0680 can be used in Diffuse Large B-Cell Lymphoma (DLBCL) research .
|
- HY-P991292
-
|
|
ADC Antibody
|
Cancer
|
|
AB-3A4 is a human IgG1 monoclonal antibody (mAb) targeting KAAG1. AB-3A4 can be used in the study of ovarian cancer, triple-negative breast cancer, and prostate cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991448
-
|
|
Glycoprotein VI
|
Cancer
|
|
MDX-1414 is a human IgG1 monoclonal antibody (mAb) targeting GPC3. MDX-1414 has antitumor activity in the HepG2 xenograft model. MDX-1414 can be used in liver cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991422
-
|
DS9231; TS-23; CSL-301
|
PAI-1
|
Cardiovascular Disease
|
|
Stromab (DS9231; TS-23; CSL-301) is a human IgG1 monoclonal antibody (mAb) targeting Serpin F2. Stromab can be used in schaemic stroke, Pulmonary embolism, Myocardial infarction and Thrombosis research. Recommended isotype control: Human IgG1 lambda, Isotype Control (HY-P99992) .
|
- HY-P9920A
-
|
|
VEGFR
|
Cancer
|
|
Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .
|
- HY-P991225
-
|
|
Fc Receptor (FcR)
CD20
|
Inflammation/Immunology
Cancer
|
|
BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) .
|
- HY-P9933
-
|
APN-311
|
Apoptosis
PERK
mTOR
|
Cancer
|
|
Dinutuximab (APN-311) is a chimeric human-mouse anti-GD2 monoclonal antibody. Dinutuximab can bind to GD2 on the cell surface, triggering antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and promoting tumor regression. Dinutuximab can inhibit the growth, invasion, and migration and induce apoptosis of tumor cells. Dinutuximab can be used in the research of tumors such as neuroblastoma and breast cancer .
|
- HY-P99756
-
|
MEDI8897
|
RSV
|
Infection
|
|
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
|
- HY-P99191
-
|
NI-0501
|
IFNAR
|
Inflammation/Immunology
|
|
Emapalumab (NI-0501) is a human monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH) .
|
- HY-P991413
-
|
|
Trk Receptor
|
Neurological Disease
|
|
ZEB85 is a human monoclonal antibody (mAb) targeting TrkB. ZEB85 activates TrkB and its downstream signaling cascades and increases neuronal activity. ZEB85 prevents β-amyloid toxicity in cultured hippocampal neurons. ZEB85 can be used in Alzheimer's disease (AD) research .
|
- HY-P99299
-
|
HGS-ETR 2; ETR2-ST01
|
Apoptosis
|
Cancer
|
|
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .
|
- HY-P991329
-
|
|
Complement System
|
Cancer
|
|
ASP-1948 is a human monoclonal antibody (mAb) targeting NRP1/VEGF165R/CD34. ASP-1948 reverses the suppressive effects of regulatory T cells. ASP-1948 can be used in solid tumors research .
|
- HY-P99486
-
|
ABT-874
|
Interleukin Related
|
Inflammation/Immunology
|
|
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .
|
- HY-P991401
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
GSK2862277 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK2862277 increases neutrophil extracellular trap formation and alveolar macrophage phagocytosis. GSK2862277 can be used in Acute lung injury and Acute Respiratory Distress Syndrome (ARDS) research. Recommended isotype control: VHH-hFc .
|
- HY-P99680
-
|
SB-210396; IDEC CE9.1
|
Interleukin Related
|
Cancer
|
|
Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research .
|
- HY-P991403
-
|
|
TNF Receptor
|
Cancer
|
|
BC011 is a human monoclonal antibody (mAb) targeting TNFRSF1B. BC011 promotes CD8+T cell proliferation and depletes Treg cells, thereby increasing the proportion of effector T cells in the tumor microenvironment. BC011 can be used in tumor Immunity research.
|
- HY-P991330
-
|
|
CD73
|
Cancer
|
|
BMS-986179 is a human monoclonal antibody (mAb) targeting NT5E/CD73. BMS-986179 inhibits CD73 enzymatic activity in tumor vasculature and tumor cells. BMS-986179 can be used in advanced solid tumors research .
|
- HY-P99643
-
|
UCB6114
|
Dan family
|
Cancer
|
|
Ginisortamab (UCB6114) is a fully human IgG4P anti Gremlin-1 monoclonal antibody, with mean IC50 values of 8.2 nM and 9 nM against human and mouse gremlin-1, respectivly. Ginisortamab inhibits gremlin-1 antagonism of BMP signaling pathways. Ginisortamab has the potential for the research of gastrointestinal (GI) tumors .
|
- HY-P991311
-
|
|
LPL Receptor
Wnt
|
Cancer
|
|
GSK3178022 is a human IgG1 monoclonal antibody (mAb) targeting LRP6. GSK3178022 inhibits the expression of WNT target genes SP5 and AXIN2. GSK3178022 has antitumor activity in the RSPO fusion model of colorectal cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991247
-
|
|
MHC
|
Cancer
|
|
Anti-HLA-A2 (Hu8F4) is a human monoclonal antibody (mAb) targeting HLA-A2. Anti-HLA-A2 (Hu8F4) can be used in Acute myeloid leukaemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99294
-
|
AMG 479; human Anti-IGF1R Recombinant antibody
|
IGF-1R
|
Cancer
|
|
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer .
|
- HY-P991144
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lasrekibart is a humanized monoclonal antibody targeting human interleukin 5 (IL-5). Lasrekibart specifically binds to IL-5, blocking the interaction between IL-5 and its receptor, thus exerting immunosuppressive and anti-inflammatory activities. Lasrekibart is promising for research of allergic and inflammatory diseases, such as asthma .
|
- HY-P99162
-
|
CIM331
|
Interleukin Related
|
Inflammation/Immunology
|
|
Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD) .
|
- HY-P991129
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Crusekitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A). Crusekitug specifically binds to IL-17A, blocking its signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Crusekitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
|
- HY-P991397
-
|
|
Tim3
|
Cancer
|
|
Sym023 is a human monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. Sym023 enhances immunostimulatory and anti-tumor activities. Sym023 can be used in Non-small cell lung cancer, Solid tumors and Lymphoma research .
|
- HY-P99688
-
|
AL001
|
Neurotensin Receptor
|
Cancer
|
|
Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research .
|
- HY-P99913
-
|
|
c-Fms
|
Inflammation/Immunology
Cancer
|
|
Eflapegrastim is a human IgG4 monoclonal antibody, is also a granulocyte colony-stimulating factor (G-CSF). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia .
|
- HY-P99252
-
|
Anti-human CD6 Recombinant antibody
|
CD6
|
Infection
Inflammation/Immunology
|
|
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .
|
- HY-P991452
-
|
|
Orexin Receptor (OX Receptor)
|
Cancer
|
|
Anti-CD200R1/OX2R Antibody (I-4P) is a human monoclonal antibody (mAb) targeting CD200R1/OX2R. Anti-CD200R1/OX2R Antibody (I-4P) can be used in solid tumors research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
- HY-P991425
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
AT-1413 is a human monoclonal antibody (mAb) targeting CD43. AT-1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) in melanoma cell lines and acute myeloid leukemia (AML) cells. AT-1413 has antitumor activity in AML mouse models. AT-1413 can be used in Acute myeloid leukaemia, Breast cancer, Malignant melanoma and Myelodysplastic syndromes research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99384
-
|
B-701; MFGR-1877S; RG-7444
|
FGFR
|
Cancer
|
|
Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991142
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
Isuventatug is a monoclonal antibody targeting human MICA (MHC class I chain-related molecule A) and MICB (MHC class I chain-related molecule B). Isuventatug binds to MICA and MICB to regulate the interaction between immune cells and tumor cells, exerting antitumor activity. Isuventatug is promising for research of cancer immunotherapy .
|
- HY-P9803
-
|
SARS-80R; SARS antibody-80R
|
SARS-CoV
|
Infection
|
|
Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells .
|
- HY-P991395
-
|
|
Tim3
|
Cancer
|
|
TQB2618 is a human IgG4 monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. TQB2618 activates immune cell function and induces significant anti-tumor activity when used in combination with anti-PD-1 agents .
|
- HY-P991319
-
|
|
Mucin
|
Cancer
|
|
TAB-004 is a human monoclonal antibody (mAb) targeting MUC1. TAB-004 specifically recognizes tMUC1 in all major subtypes of breast cancer without affecting normal breast epithelial cells. TAB-004 can be used in triple-negative breast cancer (TNBC) research .
|
- HY-P99637
-
|
MHAA4549A; RG7745
|
Influenza Virus
|
Infection
|
|
Gedivumab (MHAA4549A; RG7745) is a human monoclonal antibody that targets influenza A virus (IAV) with high specificity and binds to the highly conserved stem region of the IAV haemagglutinin protein, thereby preventing haemagglutinin maturation and blocking haemagglutinin-mediated membrane fusion in the intranucleosome. Gedivumab can be used in IAV infection disease studies .
|
- HY-P9805
-
|
MERS-3A1; MERS antibody-3A1
|
SARS-CoV
|
Infection
|
|
Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells.
Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor .
|
- HY-P991382
-
|
|
TGF-β Receptor
|
Cancer
|
|
SAR-439459 is a human monoclonal antibody (mAb) targeting TGFB1/TGFβ-1. SAR-439459 blocks TGFβ-mediated pSMAD signaling, and suppression of T cells and NK cells. SAR-439459 has anti-tumor activity .
|
- HY-P991201
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
REGN-7257 is a humanized monoclonal antibody targeting IL2RG that effectively blocks signaling of all γ-c cytokines. REGN-7257 can be used in the study of aplastic anemia. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
- HY-P99342
-
|
REGN10987
|
SARS-CoV
|
Infection
|
|
Imdevimab (REGN10987) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Imdevimab lacks efficacy against COVID-19 variants. Imdevimab can be used in combination with Casirivimab (HY-P99341), it reduces viral load and improves diseases .
|
- HY-P991402
-
|
|
TNF Receptor
|
Cancer
|
|
BI-1910 is a human monoclonal antibody (mAb) targeting TNFRSF1B. BI-1910 enhances T cell activation and induces CD8 T cell-dependent anti-tumor effects. BI-1910 can be used in solid tumors research. Recommended isotype control: Human IgG1 lambda, Isotype Control (HY-P99992) .
|
- HY-P9931
-
|
CNTO 1959
|
Interleukin Related
|
Inflammation/Immunology
|
|
Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research .
|
- HY-P99385
-
|
ALX-0061
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis .
|
- HY-P991114
-
|
|
FLT3
|
Inflammation/Immunology
|
|
Adezkibart is a human monoclonal antibody immunosuppressant targeting the human FMS-like tyrosine kinase 3 ligand (FLT3LG). Adezkibart is found in the Chinese hamster ovary cell line CHO-K1, which binds to FLT3LG to block the relevant signaling pathway, inhibits the immune response, and exerts immunosuppressive activity. Adezkibart is promising for research of immune-related diseases .
|
- HY-P991493
-
|
|
RSV
|
Infection
|
|
AR-201 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. AR-201 has anti-respiratory syncytial virus (RSV) activity. AR-201 can be used in lower respiratory tract illness (LRTI) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P991279
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Mik-Beta-1 is a human IgG1-kappa anti-IL2RB monoclonal antibody. The isotype control of Mik-Beta-1 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). Mik-Beta-1 can be used in research related to the prevention of allograft rejection .
|
- HY-P990094
-
|
CSL311
|
c-Fms
|
Inflammation/Immunology
|
|
Trabikibart (CSL311), a βc (CSF2RB)-specific, fully human monoclonal antibody, binds to a unique epitope that is specific to the cytokine-binding site of the human βc receptor. Trabikibart has picomolar binding affinity for the human βc receptor. Trabikibart is a potent inhibitor of the combined effects of IL-3, GM-CSF and IL-5 on the survival of eosinophils. Trabikibart has the potential for chronic inflammatory diseases research .
|
- HY-P991052
-
|
|
TNF Receptor
|
Cancer
|
|
GSK-3174998 is a humanized IgG1 OX40/TNFRSF4 agonistic monoclonal antibody. GSK-3174998 has the potential for the study of advanced solid tumors. The isotype control for GSK-3174998 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991406
-
|
|
TNF Receptor
|
Cancer
|
|
MK-1248 is a human IgG4 monoclonal antibody (mAb) targeting TNFSF18. MK-1248 enhances the proliferative response of tumor-infiltrating lymphocytes to anti-CD3 stimulation and promotes the production of anti-tumor-associated regulatory cytokines. MK-1248 can be used in solid tumors research .
|
- HY-P99344
-
|
Anti-human SARS-CoV-2
|
SARS-CoV
|
Infection
|
|
Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab .
|
- HY-P99268
-
|
SAR 256212; MM 121; Anti-human ERBB3/ErbB 3 Recombinant antibody
|
EGFR
Apoptosis
|
Cancer
|
|
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .
|
- HY-P991283
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
AMG 317 is a humanized monoclonal anti-CD124/IL4R/IL-4Rα antibody. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002). AMG 317 can be used in research related to asthma .
|
- HY-P991256
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
FB-825 is a human monoclonal antibody (mAb) targeting IGHE. FB-825 targets the CεmX domain of membrane IgE (mIgE), resulting in the downregulation of mIgE-positive B cells and the production of IgE. FB-825 can be used in Allergic asthma, Atopic dermatitis, Job syndrome and Allergic rhinitis research .
|
- HY-P991400
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
GSK1995057 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK1995057 attenuates pulmonary neutrophilia, inflammatory cytokine release and signs of endothelial injury in bronchoalveolar lavage and serum samples. GSK1995057 can be used in Acute lung injury and Adult respiratory distress syndrome research. Recommended isotype control: dAb (VHH-His) .
|
- HY-P991066
-
|
|
nAChR
|
Neurological Disease
|
|
ARGX-119 is a first-in-class humanized agonist monoclonal antibody specific for muscle-specific kinase (MuSK). ARGX-119 can be used for the study of neuromuscular diseases. The isotype control for ARGX-119 can refer to Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
- HY-P99345
-
|
TSR-042
|
PD-1/PD-L1
|
Cancer
|
|
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively .
|
- HY-P99233
-
|
HuMax-TAC
|
ADC Antibody
Transmembrane Glycoprotein
Interleukin Related
|
Cancer
|
|
Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonal antibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991457
-
|
|
IGF-1R
|
Cancer
|
|
AVE1642 is a human IgG monoclonal antibody (mAb) targeting CD221/IGF1R. AVE1642 delays growth of tumour xenografts and prolongs the survival of tumour-bearing nude mice. AVE1642 can be used in advanced solid tumours research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991149
-
|
|
TNF Receptor
|
Cancer
|
|
Nesfrotamig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2) and human tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Nesfrotamig is promising for research of cancers, especially in ERBB2-positive related tumor diseases, such as breast cancer and gastric cancer .
|
- HY-P991492
-
|
|
RSV
|
Infection
|
|
RSM-01 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. RSM-01 has anti-respiratory syncytial virus (RSV) activity. VIR-7229 can be used in lower respiratory tract illness (LRTI) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990015
-
|
VIR-3434
|
HBV
|
Infection
|
|
Tobevibart (VIR-3434) is a human IgG1 lambda monoclonal antibody against hepatitis B virus (HBV) surface antigen (HBsAg). Tobevibart shows potent neutralization against HBsAg from all HBV genotypes in vitro and inhibits viral entry of HBV and hepatitis delta virus (HDV). Recommend Isotype Controls: Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
- HY-P9958
-
|
AMG-162
|
NF-κB
Caspase
Apoptosis
RANKL/RANK
|
Endocrinology
Cancer
|
|
Denosumab is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .
|
- HY-P991370
-
|
|
STAT
|
Cancer
|
|
SBT-100 is a human monoclonal antibody (mAb) targeting STAT3. SBT-100 inhibits IL-6-mediated P-STAT3 nuclear translocation in HEp-2 and PANC-1 cells. SBT-100 has tumor growth inhibitory effects on MDA-MB-231 .
|
- HY-P991151
-
|
|
PD-1/PD-L1
TNF Receptor
|
Cancer
|
|
Opamtistomig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human programmed death ligand 1 (PD-L1), CD274 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Opamtistomig is promising for research of various solid tumors and hematological malignancies .
|
- HY-P990078
-
|
LY3372993
|
Amyloid-β
|
Neurological Disease
|
|
Remternetug is a human immunoglobulin G1-kappa, anti-APP (amyloid beta A4 precursor protein) Aβ42 N3pGlu peptide monoclonal antibody. Remternetug recognizes a pyroglutamated form of Aβ. Remternetug results in rapid and robust amyloid plaque reduction. Remternetug can be used for Alzheimer's disease research .
|
- HY-P99203
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .
|
- HY-P991173
-
|
|
Notch
|
Cancer
|
|
AMG-119 is a humanized IgG1 monoclonal antibody that targets delta-like ligand 3 (DLL3). AMG-119 can be used for the study of relapsed/refractory (R/R) small cell lung cancer (SCLC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99293
-
|
IDEC 114; Anti-human CD80 Recombinant antibody
|
CD28
|
Cancer
|
|
Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen and blocks CD80–CD28 binding. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma .
|
- HY-P991380
-
|
|
Transferrin Receptor
|
Neurological Disease
|
|
TXB4 is a brain-permeable human monoclonal antibody (mAb) targeting CD71. TXB4 prevents 6-OHDA-induced death of TH-positive neurons in the SNc in a 6-OHDA mouse model of Parkinson's disease (PD). TXB4 can be used in neurodegenerative diseases, acute brain and spinal cord injury, and depression research .
|
- HY-P99552
-
|
IBI-306
|
PCSK9
|
Cardiovascular Disease
|
|
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .
|
- HY-P991248
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
TTX-080 is a humanized monoclonal antagonistic antibody targeting human leukocyte antigen G (HLA-G). TTX-080 exerts anti-tumor activity by relieving HLA-G-mediated immune suppression. TTX-080 is promising for research of solid tumors such as metastatic colorectal cancer (mCRC) and head and neck squamous cell carcinoma (mHNSCC) .
|
- HY-P9806
-
|
MERS-D12; MERS antibody-D12
|
SARS-CoV
|
Infection
|
|
Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding .
|
- HY-P991464
-
|
|
TNF Receptor
|
Cancer
|
|
IBI37G5 is a human monoclonal antibody (mAb) targeting TNFRSF18/GITR/CD357. IBI37G5 has anti-tumor activity in MC38 and B16F10 mouse tumor models. IBI37G5 can be used in the study of cancer immunity .
|
- HY-P99493
-
|
IMGN242; huC242-DM4
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (DM4 (HY-12454)). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
|
- HY-P99163
-
|
ABBV-8E12; C2N-8E12
|
Tau Protein
|
Neurological Disease
|
|
Tilavonemab (ABBV-8E12) is a humanized anti-tau monoclonal antibody that binds to amino acids 25-30 near the N-terminus of the tau protein. Tilavonemab can block the ability of human and mouse neurons to uptake tau aggregates. Tilavonemab can be used for research on Alzheimer’s disease and other tauopathies .
|
- HY-P991366
-
|
AL008
|
CD47
|
Cancer
|
|
IBI-397 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a . IBI-397 promotes human monocyte-derived dendritic cell-mediated T cell proliferation and increases the expression of CD86 and HLA-DR. IBI-397 has antitumor activity in the mouse MDA-MB-231 tumor model. IBI-397 can be used in Myeloma research .
|
- HY-P99407
-
|
VX 15/2503
|
Inhibitory Antibodies
|
Neurological Disease
Cancer
|
|
Pepinemab (VX 15/2503) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), also known as CD100, which is a regulator of neuronal development and plays a role in a variety of cellular processes. Pepinemab can be used in the study of various neurodegenerative diseases such as Alzheimer's disease by blocking the activity of SEMA4D .
|
- HY-P990093
-
|
CM310
|
Interleukin Related
|
Inflammation/Immunology
|
|
Stapokibart (CM310) is a humanised monoclonal antibody targeting IL-4Rα and efficiently blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart has the capacity to interact with IL-4Rα in humans, cynomolgus monkeys, and rats .
|
- HY-P99155
-
|
|
EGFR
|
Cancer
|
|
Zalutumumab is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer .
|
- HY-P99962
-
|
BGB-A425
|
Mucin
|
Cancer
|
|
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (KD=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .
|
- HY-P99325
-
|
IDEC-131; Anti-human CD40 ligand Recombinant antibody
|
TNF Receptor
|
Inflammation/Immunology
|
|
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease .
|
- HY-P99020
-
|
GC1008
|
TGF-beta/Smad
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab improves Bleomycin (HY-108345)-induced acute lung injury. Fresolimumab radiolabeled with 89Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease .
|
- HY-P99970
-
|
|
ADC Antibody
|
Cancer
|
|
Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-141600
-
|
BAY 1187982
|
Antibody-Drug Conjugates (ADCs)
FGFR
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer .
|
- HY-P991253
-
|
|
IGF-1R
|
Cancer
|
|
BIIB022 is a human IgG4 monoclonal antibody (mAb) targeting IGF1R/CD221. BIIB022 blocks IGF-1 and IGF-2-induced phosphorylation of IGF-1R and downstream substrates. BIIB022 can be used in lung, pancreatic, and colon cancer research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
|
- HY-P991487
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
LASN01 is a human IgG1 monoclonal antibody (mAb) targeting IL-11RA. LASN01 inhibits IGF-1 and IL-11-induced hyaluronic acid (HA) release and TGFβ-stimulated procollagen in orbital fibroblasts. LASN01 can be used in thyroid eye disease (TED) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991430
-
|
TB-403
|
VEGFR
|
Cancer
|
|
RO5323441 (TB-403) is a human IgG1 monoclonal antibody (mAb) targeting PLGF. RO5323441 inhibits the binding of human PlGF-1 or PlGF-2 to VEGFR-1 (IC50 values are 0.1 and 0.2 nM, respectively). RO5323441 blocks PlGF-induced VEGFR-1 phosphorylation in Flt-1-transfected HEK293 cells. RO5323441 has antitumor activity .
|
- HY-P991443
-
|
|
CD73
|
Cancer
|
|
IPH5301 is a human IgG1 monoclonal antibody (mAb) targeting NT5E/CD73. IPH5301 has a functionally silent Fc domain, specifically inhibits soluble and membrane CD73 enzyme activity, and restores the proliferation of immune T cells. IPH5301 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991491
-
|
|
SARS-CoV
Influenza Virus
|
Infection
|
|
VIR-7229 is a human IgG1 monoclonal antibody (mAb) targeting Receptor-Binding Domain, RBD, Spike glycoprotein. VIR-7229 exerts antiviral activity by competing with ACE2 for binding and inducing S1 protein shedding. VIR-7229 can be used in SARS-CoV-2 infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991455
-
|
|
TNF Receptor
|
Cancer
|
|
PTX-35 is a human IgG monoclonal antibody (mAb) targeting TNFRSF25. PTX-35 reduces the suppressive activity of regulatory T cells and enhances CD4+ T cell effector responses in a mouse melanoma model. PTX-35 can be used in Islet cell transplant rejection and Solid tumours research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991481
-
|
|
CCR
|
Cancer
|
|
S-531011 is a human IgG1 monoclonal antibody (mAb) targeting CCR8. S-531011 reduces tumor-infiltrating CCR8+ Tregs and has anti-tumor activity in CT26.WT and EMT6 tumor-bearing mouse tumor models. S-531011 can be used in the study of cancer immunity. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P9958A
-
|
|
RANKL/RANK
Apoptosis
NF-κB
|
Neurological Disease
Endocrinology
Cancer
|
|
Denosumab (anti-TNFSF11) is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .
|
- HY-P991427
-
|
|
Apoptosis
|
Cancer
|
|
NP137 is a human IgG1 monoclonal antibody (mAb) targeting Netrin-1. NP137 inhibits the binding of netrin-1 to its receptor UNC5H2 (IC50: 0.5 nM). NP137 activates caspase 3 to induce apoptosis. NP137 can be used in solid tumors and hematologic malignancies research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991070
-
|
|
TNF Receptor
|
Cancer
|
|
ADG-106 is a fully human agonistic monoclonal IgG4 antibody against CD137 (4-1BB). ADG-106 has the mechanism to activate CD137 via strong FcγRIIB-mediated crosslinking while antagonizing CD137 ligands. The isotype control for ADG-106 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P991365
-
|
|
Transmembrane Glycoprotein
|
Endocrinology
|
|
DS-1501 is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. DS-1501 inhibits osteoclastogenesis. DS-1501 suppresses the decrease of lumbar spine bone mineral density (BMD) in ovariectomized (OVX) rats. DS-1501 can be used in Osteoporosis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991444
-
|
|
NTPDase
|
Cancer
|
|
IPH5201 is a human IgG1 monoclonal antibody (mAb) targeting ENTPD1/CD39. IPH5201 accumulates immunostimulatory ATP released by tumor cells treated with combination chemotherapy (CT) and reduces immunosuppressive Ado levels in the tumor microenvironment (TME). IPH5201 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99229
-
|
|
ADC Antibody
|
Cancer
|
|
Upifitamab is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC). Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) .
|
- HY-P99190
-
|
BMS-936557; MDX-1100
|
CXCR
|
Inflammation/Immunology
|
|
Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease .
|
- HY-P9919A
-
|
MEDI 4736 (anti-PD-L1)
|
PD-1/PD-L1
|
Cancer
|
|
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity .
|
- HY-P9949
-
|
Sch 55700
|
Interleukin Related
|
Inflammation/Immunology
|
|
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively .
|
- HY-P99810
-
|
AVTX-002; AEVI 002; SAR 252067; CERC-002; MDGN-002
|
SARS-CoV
|
Cardiovascular Disease
|
|
Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies .
|
- HY-P99371
-
|
AK002; Antolimab
|
Apoptosis
|
Inflammation/Immunology
|
|
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
|
- HY-P991423
-
|
21H3RK
|
Notch
|
Cancer
|
|
MEDI0639 (21H3RK) is a human monoclonal antibody (mAb) targeting DLL4. MEDI0639 inhibits Notch1 binding to Dll4. MEDI0639 reverses Notch1-mediated growth inhibition of human umbilical vein endothelial cells in vitro. MEDI0639 promotes human angiogenesis and reduces the number of vessels covered by smooth muscle actin-positive mural cells. MEDI0639 can be used in Small cell lung cancer and solid tumors research .
|
- HY-P99414
-
|
AMG 557
|
Transmembrane Glycoprotein
Interleukin Related
|
Inflammation/Immunology
|
|
Prezalumab (AMG 557) is a humanized IgG2 monoclonal antibody targeting ICOSL. Prezalumab inhibits T cell activation and related immune responses by binding to ICOSL and blocking the interaction between ICOS and ICOSL. Prezalumab can be used in the research of autoimmune diseases and inflammatory diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) .
|
- HY-P99055
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .
|
- HY-P99155A
-
|
|
EGFR
|
Cancer
|
|
Zalutumumab (powder) is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab (powder) binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab (powder) binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab (powder) can be used for the research of cancer .
|
- HY-P99248
-
|
Risankizumab rzaa; BI 655066
|
Interleukin Related
|
Inflammation/Immunology
|
|
Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis .
|
- HY-P991146
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lecankitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A) and interleukin 17F (IL-17F). Lecankitug specifically binds to IL-17A and IL-17F, blocking their signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Lecankitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
|
- HY-P99492
-
|
SB-408075; huC242-DM1
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
|
- HY-P9984
-
|
rhuMAb Beta7; RG7413; PRO145223
|
Integrin
|
Cancer
|
|
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .
|
- HY-P991381
-
|
PPMX-T003
|
Transferrin Receptor
Reactive Oxygen Species (ROS)
Ferroptosis
|
Cancer
|
|
TXB4 (PPMX-T003) is a human monoclonal antibody (mAb) targeting CD71. JST-TfR09 can induce ferroptosis by reducing ferritin levels in ATLL cell lines, increasing the generation of ferrous iron and reactive oxygen species (ROS), and inducing lipid peroxidation via malondialdehyde. JST-TfR09 can be used in leukemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-145644
-
|
C-135-LS; BMS-986414
|
SARS-CoV
|
Infection
Cancer
|
|
Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .
|
- HY-P99189
-
|
IMC-A12; NSC742460
|
IGF-1R
|
Cancer
|
|
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer .
|
- HY-P99551
-
|
KBSA301; AR-301
|
Antibiotic
|
Infection
|
|
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent .
|
- HY-P9961
-
|
|
CD20
|
Cancer
|
|
Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL) .
|
- HY-P99361
-
|
PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference antibody (enavatuzumab)
|
TNF Receptor
|
Cancer
|
|
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .
|
- HY-P99737
-
|
LY3074828
|
Interleukin Related
|
Inflammation/Immunology
|
|
Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease .
|
- HY-P99583
-
|
MEDI4893
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .
|
- HY-P991354
-
|
|
PD-1/PD-L1
|
Cancer
|
|
GR-1405 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. GR-1405 enhances cytotoxic T lymphocyte (CTL)-mediated antitumor immune responses against PD-L1-expressing tumor cells. GR-1405 can be used in Lymphoma and Solid tumours research .
|
- HY-P99340
-
|
VIR 7831
|
SARS-CoV
|
Infection
Cancer
|
|
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
|
- HY-P991353
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Sym-021 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. Sym-021 blocks the binding of PD-L1 and PD-L2 ligands, inducing the secretion of interferon IFN-γ and IL-2 and the proliferation of T cells. Sym-021 has anti-tumor activity in PDX mouse models .
|
- HY-P991441
-
|
|
TREM receptor
Apoptosis
|
Neurological Disease
|
|
VGL101 is a human IgG1 monoclonal antibody (mAb) targeting TREM-2. VGL101 is a pSYK agonist (EC50: 0.77 nM). VGL101 restores the survival ability of microglia and monocyte-derived macrophages under ALSP pathological conditions, inhibits apoptosis, and promotes the restoration of cell morphology to a state similar to that of normal activated CSF1R. VGL101 can be used in Leukoencephalopathies research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991424
-
|
|
Interleukin Related
STAT
|
Inflammation/Immunology
|
|
GSK2618960 is a human monoclonal antibody (mAb) targeting IL-7Ra/CD127. GSK2618960 inhibits IL-7-induced STAT5 phosphorylation. GSK2618960 enhances CD4 T cell proliferation response and increases CD83, CD86, and CD209 expression in PBMCs. GSK2618960 can be used in Multiple sclerosis and Sjogren's syndrome research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991245
-
|
|
EGFR
|
Cancer
|
|
Anti-ERBB3/HER3 (SGP1) is a human monoclonal antibody (mAb) targeting ERBB3/HER3. Anti-ERBB3/HER3 (SGP1) inhibits Neuregulin stimulated growth of cultured breast cancer cells. Anti-ERBB3/HER3 (SGP1) can be used in breast cancer research .
|
- HY-P99410
-
|
AMG 714; PRV-015
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD) .
|
- HY-P99165
-
|
|
IGF-1R
TSH Receptor
|
Endocrinology
|
|
Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research .
|
- HY-P99111
-
|
CNTO-148
|
TNF Receptor
Apoptosis
Interleukin Related
Caspase
|
Inflammation/Immunology
Cancer
|
|
Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research .
|
- HY-P99613
-
|
MK-4280
|
LAG-3
|
Cancer
|
|
Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research in combination with the PD-L1 inhibitor Pembrolizumab (HY-P9902). Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P99341
-
|
REGN10933
|
SARS-CoV
|
Infection
|
|
Casirivimab (REGN10933) is a human monoclonal antibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms .
|
- HY-P991318
-
|
|
Mucin
|
Cancer
|
|
AR20.5 is a human monoclonal antibody (mAb) targeting MUC1. AR20.5 increases the number of activated CD8 T cells, CD3+CD4−CD8−(DN) T cells, and mature dendritic cells in pancreatic tumor-bearing mice. AR20.5 can be used in anti-pancreatic cancer immunity research .
|
- HY-P991067
-
|
KP-104
|
Complement System
|
Inflammation/Immunology
|
|
Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonal antibody directed against terminal complement protein C5 fused to the complement factor H 1-5 domain (FH1-5). Vensobafusp alfa shows anti-inflammatory and immunomodulatory activities. The isotype control for Vensobafusp alfa can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) . .
|
- HY-P99109
-
|
GLS-010; AB-122; WBP-3055
|
PD-1/PD-L1
|
Cancer
|
|
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .
|
- HY-P991364
-
|
BSI-060T
|
Transmembrane Glycoprotein
|
Cancer
|
|
PYX-106 (BSI-060T) is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. PYX-106 reverses Siglec-15-mediated immunosuppression and enhances T-cell proliferation. PYX-106 induces significantly increased levels of IFNγ and TNFα in T cells. PYX-106 can be used in cancer immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990090
-
|
CBP-201
|
Interleukin Related
|
Inflammation/Immunology
|
|
Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research .
|
- HY-P991200
-
|
|
Claudin
HCV
|
Infection
|
|
OM-7D3-B3 is a monoclonal antibody targeting human claudin-1 (CLDN1) (Kd = 4 nM). OM-7D3-B3 blocks the process in which CLDN1 is involved in the entry of hepatitis C virus (HCV) into cells. OM-7D3-B3 is promising for research of HCV infection .
|
- HY-P991408
-
|
|
TNF Receptor
Interleukin Related
IFNAR
|
Inflammation/Immunology
|
|
DLX-105 is a human monoclonal antibody (mAb) targeting TNFSF2/TNFa. DLX-105 reduces skin epidermal thickness and the expression of K16 and Ki67. DLX-105 down-regulates the mRNA levels of IL-17, TNF-α, IL-23p19, IL-12p40, and IFN-γ. DLX-105 can be used in psoriasis research .
|
- HY-P991432
-
|
|
TNF Receptor
NF-κB
c-Myc
|
Cancer
|
|
VTX-0811 is a human IgG4 monoclonal antibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma .
|
- HY-P991310
-
|
LT3015; LT-3000
|
LPL Receptor
|
Neurological Disease
Cancer
|
|
Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991328
-
|
|
Notch
|
Cancer
|
|
MAb604.107 is a human monoclonal antibody (mAb) targeting NOTCH1. MAb604.107 inhibits the proliferation and CD34/CD44 expression of primary T-ALL cells. MAb604.107 has anti-tumor activity in four tumor xenograft mouse models: MDA-MB-231, HCC-1806, BT-474, and HCT-116. MAb604.107 can be used in T acute lymphoblastic leukemia research .
|
- HY-P991307
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
BND-35 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. BND-35 blocks the interaction of ILT3 with APOE and fibronectin, enhances the pro-inflammatory activity of various myeloid cells, and reverses ILT3-mediated immunosuppression of T cells by various suppressive myeloid cells. BND-35 has anti-tumor activity in the hILT3 transgenic mouse tumor model .
|
- HY-P99781
-
|
MLN-1202
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab can also improve synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P9930
-
|
AMG 145
|
NF-κB
Ser/Thr Protease
Toll-like Receptor (TLR)
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .
|
- HY-P99620
-
|
CT-P22; CT120
|
Influenza Virus
|
Infection
|
|
Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice .
|
- HY-P991223
-
|
|
Transmembrane Glycoprotein
TNF Receptor
|
Cancer
|
|
NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors .
|
- HY-P991316
-
|
DX-2400; DX-2410
|
MMP
TGF-β Receptor
TGF-beta/Smad
NO Synthase
|
Cancer
|
|
KD014 (DX-2400) is a human monoclonal antibody (mAb) targeting MMP14 (Ki: 0.9 nM). KD014 inhibits TGFβ and SMAD2/3 activity, increases macrophage numbers and iNOS expression, and shifts macrophage phenotype toward anti-tumor M1-like. KD014 has anti-tumor activity in three different tumor models (MDA-MB-231, MDA-MB-435, and PC3). KD014 can be used in breast cancer research .
|
- HY-P9928
-
|
REGN 727; SAR 236553
|
PCSK9
NOD-like Receptor (NLR)
Keap1-Nrf2
HMG Family
NF-κB
CX3CR1
|
Cardiovascular Disease
Cancer
|
|
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation .
|
- HY-P99315
-
|
BG 9588; Anti-human CD40L Recombinant antibody; Hu5c8
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P99008
-
|
IC14
|
Toll-like Receptor (TLR)
|
Infection
Neurological Disease
Inflammation/Immunology
|
|
Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury .
|
- HY-P99176
-
ATG-031
1 Publications Verification
|
Inhibitory Antibodies
|
Cancer
|
|
ATG-031 is a humanized anti-CD24 monoclonal antibody with high affinity and specificity. ATG-031 interacts with Siglec-10 expressed by tumor-associated macrophages. ATG-031 effectively stimulates macrophage-mediated phagocytosis and induces cancer cell destruction by blocking the anti-phagocytic surface proteins. ATG-031 can be used in the study of haematological malignancies as well as solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P991358
-
|
LFA-102; X213
|
Estrogen Receptor/ERR
|
Cancer
|
|
XOMA-213 (LFA-102; X213) is a human monoclonal antibody (mAb) targeting PRLR/Prolactin Receptor. XOMA-213 inhibits hPRL-dependent growth of BaF3/hPRLR cells (EC50: 0.5 μg/mL). XOMA-213 inhibits PRLR signaling and tumor growth in the Nb2-11-luc xenograft mouse model and the DMBA-induced rat breast cancer model. XOMA-213 can be used in Breast cancer, Hyperprolactinaemia and Prostate cancer research .
|
- HY-P99359
-
|
ABT-555; AE12-1Y-QL; Anti-RGMA Reference antibody (elezanumab)
|
TGF-beta/Smad
|
Metabolic Disease
|
|
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism .
|
- HY-P991356
-
|
LAE-005
|
PD-1/PD-L1
|
Cancer
|
|
FAZ-053 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. FAZ-053 inhibits the interaction of PD-L1 with PD-1 and B7-1 on monocytes, dendritic cells, and B cells. FAZ-053 enhances interleukin 2 production. FAZ-053 can be used in advanced alveolar soft tissue sarcoma (ASPS), chordoma, and triple-negative breast cancer research .
|
- HY-P991243
-
|
|
EGFR
PI3K
Akt
|
Cancer
|
|
MP-RM-1 is a selective murine monoclonal antibody inhibitor targeting human epidermal growth factor receptor 3 (ErbB-3). MP-RM-1 blocks the activation of ErbB-3 induced by neuregulin 1 (NRG-1β) and promotes the internalization and degradation of ErbB-3, inhibiting downstream signaling pathways such as PI3K-Akt. MP-RM-1 is promising for research of ErbB-3 highly expressed solid tumors such as breast cancer, melanoma, and prostate cancer .
|
- HY-P991419
-
|
|
VEGFR
|
Cancer
|
|
MSB-0254 is a human monoclonal antibody (mAb) targeting VEGFR2/KDR/CD309. MSB-0254 inhibits the invasion, migration, and vascular mimetic (VM) formation of U251 and primary glioma cells. MSB-0254 inhibits the growth of U251 and GL261 cell transplanted tumors. MSB-0254 reduces the expression of CD34, VEGFR2, Ki67, MMP2, MMP9, and CD34/PAS. MSB-0254 can be used in advanced solid tumors research .
|
- HY-P991198
-
|
|
Tim3
|
Cancer
|
|
M6903 is a humanized monoclonal IgG2 antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) (KD for human TIM-3 is 2.3 nM). M6903 binds to TIM-3, blocking the binding of TIM-3 to phosphatidylserine (PtdSer), carcinoembryonic antigen cell adhesion-related molecule 1 (CEACAM1), and galectin 9 (Gal-9), thus relieving TIM-3-mediated T cell inhibition and exerting the activities of activating antigen-specific T cells and enhancing anti-tumor immunity. M6903 is promising for research of cancers .
|
- HY-P990091
-
|
SAR 445088
|
Complement System
|
Inflammation/Immunology
|
|
Riliprubart (SAR 445088) is an anti-C1s humanized IgG4 monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a. Riliprubart can be used to study complement-mediated diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P99152
-
|
Muromanab-CD3
|
CD3
Interleukin Related
IFNAR
|
Inflammation/Immunology
Cancer
|
|
Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonal antibody targeting the CD3 antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate T cells. Muromonab blocks the function of T cell receptors to recognize foreign antigens and inhibits T cell-mediated immune responses, including cell-mediated lymphocyte lysis and T cell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients .
|
- HY-P99444
-
|
MSTT 1041A; RG 6149
|
Interleukin Related
MDM-2/p53
NF-κB
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research .
|
- HY-P99496
-
|
RPC 4046; ABT 308; CC-93538
|
Interleukin Related
|
Inflammation/Immunology
|
|
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .
|
- HY-P99941
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .
|
- HY-P99488
-
|
JSP-191; AMG-191
|
c-Kit
|
Inflammation/Immunology
Cancer
|
|
Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonal antibody that binds human CD117 (c-Kit). Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema .
|
- HY-P9928A
-
|
REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)
|
PCSK9
NOD-like Receptor (NLR)
Keap1-Nrf2
HMG Family
NF-κB
CX3CR1
|
Cardiovascular Disease
Cancer
|
|
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation .
|
| Cat. No. |
Compare |
Product Name |
Species |
Source |
Compare Products
|
| Products |
|
| Cat. No. |
|
| Species |
|
| Source |
|
| Tag |
|
| Accession |
|
| Gene ID |
|
| Molecular Weight |
|
| Purity |
|
| Endotoxin Level |
|
| Biological Activity |
|
| Appearance |
|
| Formulation |
|
| Storage & Stability |
|
| Shipping |
|
| Free Sample |
Yes
No
|
| Size |
* This product has been "discontinued".
Optimized version of product available:
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
